VH3 binding polypeptides

By developing Staphylococci protein A-derived polypeptides with high affinity in VH3 region and low binding affinity in the Fc region, the complex problems of impurity co-purification and purification during antibody and fragment separation in the prior art were solved, and efficient and reliable separation effect was achieved and the stability of the peptide.

CN118946577APending Publication Date: 2024-11-12CYTIVA BIOPROCESS R&D AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380027460.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-14
Filing Date
2023-03-14
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the prior art, Staphylococcus protein A-derived ligands have binding affinity for the Fc portion and VH domain of the antibody, resulting in co-purification of product-related impurities such as haplotypes and truncated variants, and the purification process is complex and not gentle, making it difficult. Achieve efficient and reliable antibody and fragment isolation.

Method used

A VH3-binding polypeptide derived from Staphylococcus protein A has developed a high affinity for the VH3 region of the antibody and significantly reduced or eliminated binding affinity for the Fc region, and exhibits alkaline cleaning stability for efficient isolation of antibodies and fragments. .

Benefits of technology

Gentle elution of antibodies and fragments is achieved, co-purification of product-related impurities is reduced, purification process is simplified, separation efficiency is improved, and the stability and affinity of the peptide are maintained.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946577A_ABST
    Figure CN118946577A_ABST
Patent Text Reader

Abstract

The present disclosure relates to a class of engineered polypeptides having binding affinity for the VH3 region of an immunoglobulin and exhibiting desirable alkali wash stability properties. In addition, the polypeptide exhibits significantly reduced binding affinity to the Fc region of the immunoglobulin. The disclosure also relates to a method for separating immunoglobulin or a fragment thereof by using the polypeptide and a related product.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to a class of engineered polypeptides that have binding affinity to the VH3 region of an immunoglobulin and exhibit desirable alkaline wash stability properties. In addition, the polypeptide exhibits significantly reduced binding affinity to the Fc region of an immunoglobulin. The present disclosure also relates to methods for separating immunoglobulins or fragments thereof using the polypeptides and related products. Background Art

[0002] Immunoglobulins represent the most prevalent biopharmaceutical products in manufacture or development worldwide. The high commercial demand and therefore high value of this particular therapeutic market has led pharmaceutical companies to focus on maximizing the productivity of the manufacturing processes for mAbs and / or their fragments, while controlling the associated costs.

[0003] In most cases, affinity chromatography is used as one of the key steps of purifying these immunoglobulin molecules such as monoclonal or polyclonal antibodies or their fragments. An especially interesting affinity reagent of a class is a protein that can specifically bind to the invariable part of an immunoglobulin molecule, and such interaction has nothing to do with the antigen-binding specificity of the antibody. Such reagents can be widely used in affinity chromatography to reclaim immunoglobulins from different samples (such as, but not limited to, the raw materials in serum or plasma preparations or cell culture sources). An example of such protein is staphylococcal protein A (SpA), which contains a domain that can be partially bound to the Fc and Fab of the lgG immunoglobulin from different species. These domains are usually represented as E-, D-, A-, B- and C-domains.

[0004] SpA-based proteins have been widely used in the field of biotechnology due to their high affinity and selectivity, for example as ligands in affinity chromatography to capture and purify antibodies and for detection or quantification. Currently, SpA-based affinity media are probably the most widely used affinity media for the separation of monoclonal antibodies and their fragments from different samples, including industrial cell culture supernatants. Thus, a variety of matrices containing protein A or protein A-derived ligands are commercially available, for example, as the ligands from Cytiva Biosciences, Uppsala, Sweden. TM MabSelect TM SuRe, MabSelect TM SuRe LX, MabSelect TM PrismA and HiScreen Fibro TM The form of PrismA.

[0005] Some protein A and protein A derived ligands have binding affinity for both the Fc portion of the antibody and some VH domains (particularly VH3) of the antibody. Therefore, co-purification of product-related impurities such as half antibodies and truncated variants may occur and require complex and / or less gentle elution schemes. In addition, purification of bispecific antibodies such as emicizumab or fragments thereof requires complex elution schemes to ensure that only correctly paired bispecific antibodies or fragments thereof are obtained, rather than a mixture of correctly and incorrectly paired antibodies and fragments. Therefore, there is an unmet need in the field for simplified and reliable methods for separating antibodies and fragments thereof. Summary of the invention

[0006] It is an object of the present disclosure to provide VH3 binding SpA-derived ligands that exhibit desirable alkaline wash stability properties.Such ligands may, for example, be used in methods for isolating immunoglobulins and / or fragments thereof.

[0007] One object of the present disclosure is to provide VH3 binding SpA-derived ligands that show no affinity or a significantly reduced affinity for the Fc (fragment crystallizable) region of immunoglobulins.

[0008] It is an object of the present disclosure to provide VH3 binding SpA-derived ligands that allow for efficient isolation of immunoglobulins and / or fragments thereof while alleviating the above-mentioned and other disadvantages of the prior art.

[0009] One object was to provide a VH3 binding SpA-derived ligand that enables gentle elution of purified antibodies.

[0010] Yet another object is to provide VH3 binding SpA-derived ligands that will reduce or prevent co-purification of product related impurities such as half antibodies and truncated variants.

[0011] It is an object of the present disclosure to provide an alkaline-wash stable VH3-binding SpA-derived ligand. Such a ligand can, for example, be used repeatedly to separate immunoglobulins and / or fragments thereof.

[0012] One aim was to provide VH3 binding SpA-derived ligands that would avoid competing interactions and thus be useful in a platform solution for the purification of all VH3 containing products.

[0013] One object was to provide VH3 binding SpA-derived ligands that would avoid competition with Fc for binding interactions and thus show an increased binding capacity for VH3 containing products, in other words VH3 binding SpA-derived ligands that are able to bind more VH3 containing products.

[0014] Yet another object is to provide VH3 binding SpA-derived ligands that will avoid competitive interactions, e.g. to allow elution of asymmetric antibodies and / or fragments thereof, such as bispecific or trispecific antibodies and / or fragments thereof.

[0015] These and other objects which will be apparent to the skilled person from this disclosure are met by the different aspects of the present invention as claimed in the accompanying claims and as generally disclosed herein.

[0016] Accordingly, in a first aspect of the present disclosure, there is provided a VH3 binding polypeptide derived from Staphylococcal protein A (SpA) or any domain thereof, wherein the polypeptide has binding affinity for the VH3 region of trastuzumab and has a lower binding affinity for the same Fc region than the binding affinity of SEQ ID NO: 88 for the Fc region of trastuzumab, and wherein the VH3 binding polypeptide is alkaline washing stable.

[0017] As an alternative, the binding affinity of a VH3 binding polypeptide as disclosed herein to the Fc region of trastuzumab may be evaluated in comparison to the affinity of SEQ ID NO: 89 to the Fc region of trastuzumab. Thus, as an alternative, a VH3 binding polypeptide derived from Staphylococcus protein A (SpA) or any domain thereof is provided, wherein the polypeptide has binding affinity to the VH3 region of trastuzumab and has a lower binding affinity to the same Fc region than the binding affinity of SEQ ID NO: 89 to the Fc region of trastuzumab, and wherein the VH3 binding polypeptide is alkaline washing stable. Thus, it will be appreciated that in some embodiments, a VH3 binding polypeptide derived from Staphylococcus protein A (SpA) or any domain thereof as disclosed herein is provided, which has a lower binding affinity to the same Fc region than the binding affinity of SEQ ID NO: 88 and SEQ ID NO: 89 to the Fc region of trastuzumab.

[0018] The skilled person will appreciate that a VH3 binding polypeptide derived from Staphylococcal protein A (SpA) or any domain thereof as disclosed herein may for example be derived from, but not necessarily from, any of domains A (SEQ ID NO: 92), B (SEQ ID NO: 91), C (SEQ ID NO: 90), D (SEQ ID NO: 93) and E (SEQ ID NO: 94) of SpA or a derivative thereof, such as domain Z (SEQ ID NO: 89) or a variant thereof, such as SEQ ID NO: 88. Thus, a VH3 binding polypeptide derived from a SpA domain may be a derivative, mutant, variant or fragment of a SpA domain as defined above.

[0019] Thus, the VH3 binding polypeptides of the present disclosure are characterized in that they retain the inherent ability to bind to the VH3 of antibodies / immunoglobulins, in particular to the VH3 region of the antibody trastuzumab. They may also exhibit reduced or abolished binding affinity to the Fc region of the antibody trastuzumab. The skilled person recognizes that similar effects will be observed for antibodies or fragments thereof containing the same or similar VH3 region as trastuzumab, as illustrated in the accompanying examples.

[0020] As used herein, the term VH3 in the context of binding affinity to VH3 refers to the antibody trastuzumab (trade name Herceptin TM (Roche), Trazimera TM (Pfizer)), which, according to the Kabat numbering system, comprises amino acid residues in the following positions: H15: G; H17: S; H19: R; H57: T; H59: Y; H64: K; H65: G; H66: R; H68: T; H70: S; H81: Q; H82a: N and H82b: S. In order to avoid any doubt, the term "VH3 region of trastuzumab" and the term "VH3" (without any additional description) are used to refer to the VH3 region of the antibody trastuzumab. The same region VH3 region is also present in the following antibodies: avelumab (trade name Bavencio TM ), denosumab (trade name: Xgeva TM ), Dupilumab (trade name Dupixent TM ) and emicizumab (trade name Hemlibra TM ). The VH3 region of trastuzumab is contained in the fragment antigen binding region (Fab region) of trastuzumab, which Fab is defined by SEQ ID NOs: 182 and 183.

[0021] As used herein, the term Fc (fragment crystallizable) in the context of "binding affinity to Fc" refers to the antibody trastuzumab (trade name Herceptin TM (Roche), Trazimera TM The Fc region of trastuzumab corresponds to the Fc region of antibody subclasses IgG1, IgG2 and IgG4. In order to avoid any doubt, the term "Fc region of trastuzumab" and the term "Fc" (without any additional description) are used to refer to the Fc region of the antibody trastuzumab. The Fc region of trastuzumab is defined by SEQ ID NO: 184.

[0022] In addition, the VH3 binding polypeptides according to the present disclosure are characterized in that their ability to bind to VH3 (in other words, their affinity for VH3) is not affected or only slightly affected by exposure to alkaline conditions, such as conditions during washing of a separation matrix comprising the VH3 binding polypeptide. Such conditions may be washing with 0.5 M NaOH or KOH or other suitable washing liquids known in the art. The skilled person is aware of the conditions commonly used for washing separation matrices and separation columns before reuse thereof. As used herein, the term "alkaline wash stable" refers to a property of a VH3 binding polypeptide that is related to its affinity for VH3 after exposure to 0.5 M NaOH. A VH3 binding polypeptide as disclosed herein is considered to be alkaline wash stable if it retains at least 20% of its VH3 binding ability (in other words, affinity for VH3) after 100 washing cycles compared to its VH3 binding ability / affinity for VH3 before the first washing cycle. The assessment of alkaline wash stability may be as described in the attached Example 1.

[0023] In particular, as will be discussed in detail below, the VH3 binding polypeptides as disclosed herein retain a significant portion of their VH3 binding properties even after repeated alkaline washing steps.

[0024] In one embodiment of this aspect, the VH3 binding polypeptide comprises a sequence A consisting of an amino acid sequence selected from i), ii) and iii),

[0025] Where i), ii) and iii) are defined as follows:

[0026] i)X8X9X 10 X 11 AX 13 X 14 X 15 X 16 X 17 X 18 X 19 PNLX 23 X 24 X 25 X 26 RX 28 X 29 FIQSLX 35 X 36 (SEQ ID NO:95)

[0027] Among them, independently of each other,

[0028] X8 is selected from E, D and A;

[0029] X 15 Selected from E and Q;

[0030] X 16 Selected from I and V;

[0031] X 19 Select from L and M;

[0032] X 23 Selected from N and T;

[0033] X 24 is selected from A and E, if it is E;

[0034] X 25 is selected from D and E, if it is E;

[0035] X 35 Selected from K, R and H;

[0036] X 36 Selected from D and H;

[0037] ii) an amino acid sequence having at least 83% identity to the sequence defined in i)

[0038] iii) an amino acid sequence that is at least 70% identical to any sequence selected from residues 8-36 of SEQ ID NO:88, residues 8-36 of SEQ ID NO:89, residues 8-36 of SEQ ID NO:90, residues 8-36 of SEQ ID NO:91, residues 8-36 of SEQ ID NO:92, residues 11-39 of SEQ ID NO:93, and residues 1-29 of SEQ ID NO:94,

[0039] wherein, in addition, in each of i), ii) and iii), independently of one another,

[0040] X9 is selected from Q, Y and A;

[0041] X 10 Selected from Q and Y;

[0042] X 11 Selected from T, E and R;

[0043] X 13 Selected from L, E, R, A and Q;

[0044] X 14 Selected from L, E, R, A, Q and W;

[0045] X 17 Selected from A, H and L;

[0046] X 18 Selected from R, L and H;

[0047] X26 Selected from Q and S;

[0048] X 28 is selected from N and A; and

[0049] X 29 Select from A and G.

[0050] In one embodiment, a VH3 binding polypeptide is provided, wherein the polypeptide has binding affinity for the VH3 region of an antibody and has low binding affinity for the Fc region of an antibody, and wherein the VH3 binding polypeptide is alkaline washing stable.

[0051] The present inventors have surprisingly found that a polypeptide derived from SpA or a domain thereof at least at positions X9, X 10 , X 11 , X 13 and X 14 and optionally at position X 17 , X 18 and X 26 VH3 binding polypeptides having the amino acid residues disclosed herein in the above positions at least retain or exhibit improved alkaline wash stability properties. Their binding affinity to the Fc of trastuzumab is also significantly reduced or eliminated. VH3 binding polypeptides comprising amino acids as defined herein in the above positions lose at least a substantial portion of their affinity to Fc while retaining affinity to the VH3 region.

[0052] In a specific embodiment, the VH3 binding polypeptide has binding affinity for the VH3 region of trastuzumab. In a specific embodiment, the VH3 binding polypeptide has binding affinity for the VH3 region of trastuzumab and has a lower binding affinity for the Fc region of trastuzumab than the binding affinity of SEQ ID NO: 88 and / or SEQ ID NO: 89 for the same region. As described above, the binding affinity of the VH3 binding polypeptide as disclosed herein to the same Fc region can be evaluated in comparison with the affinity of SEQ ID NO: 88 to the Fc region of trastuzumab. Therefore, in one embodiment, a VH3 binding polypeptide is provided, which comprises sequence A, which consists of an amino acid sequence selected from i), ii) and iii) as defined above, and has a lower binding affinity for the Fc region of trastuzumab than the binding affinity of SEQ ID NO: 88 to the same Fc region. As an alternative, a VH3 binding polypeptide is provided, comprising a sequence A consisting of an amino acid sequence selected from i), ii) and iii) as defined above, and having a lower binding affinity to the Fc region of trastuzumab than the binding affinity of SEQ ID NO: 89 to the same Fc region. In some embodiments, a VH3 binding polypeptide as disclosed herein is provided, which has a lower binding affinity to the Fc region of trastuzumab than the binding affinity of SEQ ID NO: 88 and SEQ ID NO: 89 to the same Fc region. Therefore, the skilled person will understand that SEQ ID NO: 88 and / or SEQ ID NO: 89 can be used as a reference to compare the binding affinity of the VH3 binding polypeptide of the present disclosure to the Fc region of trastuzumab.

[0053] The present inventors have surprisingly found that by allowing a VH3 binding polypeptide derived from SpA or a domain thereof to be present at positions X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X30, X31, X32, X33, X34, X35, X36, X37, X38, X39, X40 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26 The amino acid residues in are altered as disclosed herein, resulting in VH3 binding polypeptides having the desired properties. In particular, the binding affinity to the Fc of trastuzumab is significantly reduced or eliminated, while the VH3 binding polypeptide at least retains or exhibits improved alkaline wash stability properties. The VH3 binding polypeptide comprising the amino acids as defined herein in the above positions loses at least a substantial portion of its affinity to Fc, while retaining affinity to the VH3 region.

[0054] In particular, in one embodiment, a VH3 binding polypeptide as disclosed herein is provided, wherein, independently of each other, in sequence i)

[0055] X8 is selected from E, D and A;

[0056] X 15 Selected from E and Q;

[0057] X 16 Selected from I and V;

[0058] X 19 Select from L and M;

[0059] X 24 is E;

[0060] X 25 is E;

[0061] X 23 Selected from N and T;

[0062] X 35 is selected from K, R and H; and

[0063] X 36 Selected from D and H.

[0064] For the sake of clarification, it should be understood that the % identity in ii) and iii) is the same as X9, X 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26 Thus, in the VH3 binding polypeptides encompassed by the definitions according to ii) and iii), positions X9, X 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26 The amino residue in is as defined above.

[0065] The above definition of sequence-related VH3 binding polypeptides is based on the analysis of a number of VH3 binding polypeptide variants, which were selected for at least maintaining the properties of affinity for VH3 and alkaline washing stability, as described in the accompanying examples. Affinity for Fc was also evaluated and VH3 with reduced or abolished affinity for Fc was selected.

[0066] As described herein, the affinity for VH3 and Fc of trastuzumab was evaluated. As described above, trastuzumab can be defined by the amino acid residues in the above positions according to the Kabat numbering system. Trastuzumab can also be defined as having a heavy chain amino acid sequence according to SEQ ID NO: 183 and a light chain amino acid sequence according to SEQ ID NO: 184.

[0067] The VH3 binding polypeptide may comprise an identified sequence A, which corresponds to a region that interacts and binds to the Fc of the parent scaffold. This region constitutes two alpha helices within the three-helix bundle protein domain, namely helix 1 and helix 2. Helix 2 and helix 3 of the three-helix bundle protein constitute a binding surface that interacts with the VH3 region of the antibody.

[0068] As the skilled person will recognize, the function of any polypeptide is dependent on the tertiary structure of the polypeptide. Therefore, minor changes can be made to the amino acid sequence in the polypeptide without affecting its function. Therefore, the present disclosure encompasses modified variants of VH3 binding polypeptides. These modified variants are alkaline-cleaning stable. The modified variants are such that their affinity for the VH3 region is at least retained. The variants are such that their affinity for the Fc region is significantly reduced or eliminated compared to this.

[0069] The modifications of Fc binding affinity identified by the inventors are applicable to VH3 binding polypeptides based on or derived from different triple helical domains of Staphylococcus aureus protein A, such as any of domains A (SEQ ID NO: 92), B (SEQ ID NO: 91), C (SEQ ID NO: 90), D (SEQ ID NO: 93) and E (SEQ ID NO: 94), in particular domain B, and derivatives thereof. In particular, the modifications may be applicable to VH3 binding polypeptides based on or derived from three-helix bundle protein domain Z (SEQ ID NO: 89), which domain Z is derived from domain B of Staphylococcus protein A, or to variant SEQ ID NO: 88.

[0070] Such VH3 binding polypeptides have been described in the following documents: WO2003080655, Eur JBiochem September 1977; 78(2):471-90, WO2008039141, WO2015005859, US10308690, WO2016079033, WO2017194596, US9663558, WO20160 79034, JP2006304633A, WO2007097361, EP1992692A1, WO2012083425, WO2012086660, US20120208234, EP2495254A1, WO201 3109302A2, WO2015034000, WO2015034056, CN105481954A, WO2016152946A1, WO2017009421, WO2017014261, WO2018009006, WO2018029158, WO2018029157, WO2019030156, CN109721645A, WO2019093439, WO2020040307 and WO2020157281, which are incorporated herein by reference.

[0071] Therefore, the inventors contemplate that the position X9, X 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26 All or a subset of the amino acid residues in are introduced into any previously known VH3 binding polypeptide to achieve the effect of significantly reducing or eliminating the binding affinity to Fc while retaining the VH3 binding properties and at least retaining the alkaline washing stability property.

[0072] The present disclosure also encompasses a VH3 binding polypeptide comprising a sequence A having at least 83% identity to a polypeptide as defined in i). In some embodiments, the polypeptide may comprise a sequence that is at least 87%, such as at least 90%, such as at least 93%, such as at least 96% identical to a polypeptide as defined in i). For example, an amino acid residue belonging to a certain functional group of amino acid residues (e.g., hydrophobic, hydrophilic, polar, etc.) may be exchanged for another amino acid residue from the same functional group. In some embodiments, X9, X10, X20, X30, X40, X50, X60, X70, X80, X90, X100, X110, X120, X130, X140, X150, X160, X170, X180, X190, X210, X220, X310, X40, X51, X61, X70, X80, X90, X190, X100, X110, X120, X130, X140, X150, X160, X170, X180, X190, X210, X220, X310, X40, X51 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26In other embodiments, such changes can be made only in non-variable positions (also referred to as scaffold amino acid residues). In such cases, changes are not allowed in variable positions (i.e., positions represented by "X" in sequence i).

[0073] The present disclosure also encompasses a VH3 binding polypeptide comprising a sequence A having at least 70% identity to any sequence selected from residues 8-36 in SEQ ID NO:88, residues 8-36 in SEQ ID NO:89, residues 8-36 in SEQ ID NO:90, residues 8-36 in SEQ ID NO:91, residues 8-36 in SEQ ID NO:92, residues 11-39 in SEQ ID NO:93, and residues 1-29 in SEQ ID NO:94. In some embodiments, the polypeptide may comprise a sequence that is at least 74%, such as at least 77%, such as at least 80%, such as at least 83%, such as at least 87%, such as at least 90%, such as at least 93%, such as at least 96% identical to any sequence selected from the group consisting of residues 8-36 in SEQ ID NO:88, residues 8-36 in SEQ ID NO:89, residues 8-36 in SEQ ID NO:90, residues 8-36 in SEQ ID NO:91, residues 8-36 in SEQ ID NO:92, residues 11-39 in SEQ ID NO:93, and residues 1-29 in SEQ ID NO:94. In a specific embodiment, the sequence is selected from the group consisting of residues 8-36 of SEQ ID NO:88, residues 8-36 of SEQ ID NO:89, residues 8-36 of SEQ ID NO:90, residues 8-36 of SEQ ID NO:91, residues 8-36 of SEQ ID NO:92, residues 11-39 of SEQ ID NO:93, and residues 1-29 of SEQ ID NO:94. In a specific embodiment, the sequence is selected from the group consisting of residues 8-36 of SEQ ID NO:88 and residues 8-36 of SEQ ID NO:89. In one embodiment, the sequence is SEQ ID NO:88. In one embodiment, the sequence is SEQ ID NO:89.

[0074] As used throughout this disclosure, the term "% identity" can be calculated, for example, as follows. The query sequence is aligned with the target sequence using the CLUSTAL W algorithm (Thompson et al., Nucleic Acids Research, 22: 4673-4680 (1994)). Compare on a window corresponding to the shortest sequence in the aligned sequence. In some cases, the shortest sequence in the aligned sequence may be the target sequence. In other cases, the query sequence may constitute the shortest sequence in the aligned sequence. Compare the amino acid residues at each position and report the percentage of positions with the same corresponding relationship in the query sequence and the target sequence as % identity. In one embodiment of a VH3 binding polypeptide as disclosed herein, the sequence A satisfies criteria i) and ii), or criteria i) and iii), or criteria ii) and iii). In one embodiment, the sequence A satisfies all criteria i), ii) and iii).

[0075] The present disclosure also encompasses any VH3 binding polypeptide, such as, but not limited to, a polypeptide derived from Staphylococcus protein A (SpA) or any domain thereof, which has a residue at positions X9, X10, X20, X30, X40, X50, X60, X70, X80, X90, X100, X110, X120, X130, X140, X150, X160, X170, X 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26 The positions of the VH3 binding polypeptides are as defined herein. Thus, any VH3 binding polypeptide comprising an amino acid residue as defined herein in the above positions is contemplated herein, independent of its length and the presence of substitutions, insertion mutations or deletion mutations. The identification of such VH3 binding polypeptides is within the skill of those skilled in the art. Those skilled in the art will be able to identify such VH3 polypeptides by sequence alignment using, for example, any common alignment tool known in the art, such as standard protein blast (blastp). By selecting appropriate algorithm parameters, including general parameters such as thresholds and word lengths; scoring parameters such as alignment matrices, gap costs and composition adjustments; and filters and masks, the skilled person can adjust the nature of the alignment.

[0076] In particular, the present disclosure encompasses positions X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X29, X30, X31, X32, X33, X34, X35, X36, X37, X38 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26Any VH3 binding polypeptide comprising an amino acid residue as defined herein in the position of , such as but not limited to a polypeptide derived from Staphylococcus protein A (SpA) or any domain thereof, and said VH3 binding polypeptide exhibits the following properties: affinity for the VH3 of trastuzumab compared to SEQ ID NO: 88, reduced or eliminated affinity for the Fc of trastuzumab compared to SEQ ID NO: 88, and is alkaline washing stable. As used herein, the term "position corresponding to..." in this context refers to amino acid residues X9, X 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26 In such an alignment, amino acid residues X9, X 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26 The presence or absence of amino acid residues between positions (whose presence or absence does not significantly change the VH3 binding polypeptide encompassing amino acid residues X9, X 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26 The alpha helical tertiary structure in the region of the residue and / or does not change the VH3 binding surface containing the residue) should not be interpreted as that the position does not correspond to those of SEQ ID NO: 88. On the contrary, the present invention also encompasses amino acid residues X9, X10, X20, X30, X40, X50, X60, X70, X80, X90, X100, X110, X120, X130, X140, X150, X160, X170, X180, X190, X210, X310, X410, X510, X610, X70, X80, X90, X100, X110, X120, X130, X140, X150, X160, X170, X180, X190, 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26 any VH3 binding polypeptide comprising one or more deletion or insertion mutations between positions 1 and 2, which mutations do not significantly alter the alpha helical tertiary structure of the region of the VH3 polypeptide comprising said residues and / or the VH3 binding surface comprising said residues.

[0077] Thus, in one embodiment, a VH3 binding polypeptide derived from Staphylococcus protein A (SpA) or any domain thereof is provided, wherein in alignment with SEQ ID NO: 88, the residues corresponding to positions X9, X10, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X30, X40, X50, X60, X70, X80, X90, X100, X110, X120, X130, X140, X150, X160, X170, X180, X190, X200, X300, X400, X51, X61, X70, X80, X90, X100, X110, X120, X130, X140, X150, X160, X170, X180 10 , X11 , X 13 , X 14 , X 17 , X 18 and X 26 The positions are independent of each other as follows:

[0078] X9 is selected from Q, Y and A;

[0079] X 10 Selected from Q and Y;

[0080] X 11 Selected from T, E and R;

[0081] X 13 Selected from L, E, R, A and Q;

[0082] X 14 Selected from L, E, R, A, Q and W;

[0083] X 17 Selected from A, H and L;

[0084] X 18 Selected from R, L and H;

[0085] X 26 Selected from Q and S;

[0086] X 28 is selected from N and A; and

[0087] X 29 Select from A and G.

[0088] The skilled person will appreciate that the alignment can also be performed using SEQ ID NO: 89. Therefore, in another embodiment, a VH3 binding polypeptide derived from Staphylococcus protein A (SpA) or any domain thereof is provided, wherein in the alignment with SEQ ID NO: 89, the positions X9, X10, X20, X30, X40, X50, X60, X70, X80, X90, X100, X110, X120, X130, X140, X150, X160, X170, X180, X190, X210, X310, X40, X51, X60, X70, X80, X90, X100, X110, X120, X130, X140, X150, X160, X170, X180, X190, X210, X310, X4 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26 The positions are independent of each other as follows:

[0089] X9 is selected from Q, Y and A;

[0090] X 10 Selected from Q and Y;

[0091] X 11 Selected from T, E and R;

[0092] X13 Selected from L, E, R, A and Q;

[0093] X 14 Selected from L, E, R, A, Q and W;

[0094] X 17 Selected from A, H and L;

[0095] X 18 Selected from R, L and H;

[0096] X 26 Selected from Q and S;

[0097] X 28 is selected from N and A; and

[0098] X 29 Select from A and G.

[0099] In one embodiment according to the first aspect as disclosed herein, X9 is selected from Q and Y. In another embodiment, X9 is selected from Q and A. In one embodiment, X9 is selected from A and Y. In one embodiment, X9 is A. In one embodiment, X9 is Y. In one embodiment, X9 is Q.

[0100] In one embodiment, X 10 is Q. In one embodiment, X 10 is Y.

[0101] In one embodiment, X 11 In one embodiment, X11 is selected from T and R. In one embodiment, X 11 is selected from R and E. In one embodiment, X 11 is T. In one embodiment, X 11 is E. In one embodiment, X 11 For R.

[0102] In one embodiment, X 13 is selected from L, E, R and A; or is selected from L, E, R and Q; or is selected from L, E, A and Q; or is selected from L, R, A and Q; or is selected from E, R, A and Q; in particular is selected from L, E, R and A; or is selected from L, E, R and Q; or is selected from L, E, A and Q; or is selected from L, R, A and Q. In one embodiment, X 13is selected from L, E and R; or from L, E and A; or from L, E and Q; or from L, R and A; or from L, R and Q; or from L, A and Q; or from E, R and A; or from E, R and Q; or from E, A and Q; or from R, A and Q; in particular, selected from L, E and R; or from L, E and A; or from L, E and Q; or from L, R and A; or from L, R and Q. In one embodiment, X 13 is selected from L and E; or from L and R; or from L and A; or from L and Q; or from E and R; or from E and A; or from E and Q; or from R and A; or from R and Q; or from A and Q; in particular, from L and E; or from L and R; or from L and A; or from L and Q. In one embodiment, X 13 is L. In one embodiment, X 13 is A. In one embodiment, X 13 is E. In one embodiment, X 13 is Q. In one embodiment, X 13 For R.

[0103] In one embodiment, X 14 is selected from A, W, E, L and Q; or is selected from A, W, E, L and R; or is selected from A, W, E, Q and R; or is selected from A, W, L, Q and R; or is selected from A, E, L, Q and R; or is selected from W, E, L, Q and R. In one embodiment, X 14 is selected from A, W, E and L; or is selected from A, W, E and Q; or is selected from A, W, E and R; or is selected from A, W, L and Q; or is selected from A, W, L and R; or is selected from A, W, Q and R; or is selected from A, E, L and Q; or is selected from A, E, L and R; or is selected from A, E, Q and R; or is selected from A, L, Q and R; or is selected from W, E, L and Q; or is selected from W, E, L and R; or is selected from W, E, Q and R; or is selected from W, L, Q and R; or is selected from E, L, Q and R. In one embodiment, X 14 is selected from A, W and E; or selected from A, W and L; or selected from A, W and Q; or selected from A, W and R; or selected from A, E and L; or selected from A, E and Q; or selected from A, E and R; or selected from A, L and Q; or selected from A, L and R; or selected from A, Q and R; or selected from W, E and L; or selected from W, E and Q; or selected from W, E and R; or selected from W, L and Q; or selected from W, L and R; or selected from W, Q and R; or selected from E, L and Q; or selected from E, L and R; or selected from E, Q and R; or selected from L, Q and R. In one embodiment, X 14is selected from A and W; or selected from A and E; or selected from A and L; or selected from A and Q; or selected from A and R; or selected from W and E; or selected from W and L; or selected from W and Q; or selected from W and R; or selected from E and L; or selected from E and Q; or selected from E and R; or selected from L and Q; or selected from L and R; or selected from Q and R. In one embodiment, X 14 is A. In one embodiment, X 14 is W. In one embodiment, X 14 is E. In one embodiment, X 14 is L. In one embodiment, X 14 is Q. In one embodiment, X 14 For R.

[0104] In one embodiment, X 17 is selected from A and H. In one embodiment, X 17 is selected from A and L. In one embodiment, X 17 is selected from H and L. In one embodiment, X 17 is A. In one embodiment, X 17 is H. In one embodiment, X 17 For L.

[0105] In one embodiment, X 18 is selected from R and L. In one embodiment, X 18 is selected from R and H. In one embodiment, X 18 is selected from H and L. In one embodiment, X 18 is R. In one embodiment, X 18 is L. In one embodiment, X 18 For H.

[0106] In one embodiment, X 26 is Q. In one embodiment, X 26 For S.

[0107] In one embodiment, X 28 is N. In one embodiment, X 28 is A.

[0108] In one embodiment, X 29 is A. In one embodiment, X 29 For G.

[0109] In more specific embodiments defining a subclass of VH3 binding polypeptides as disclosed herein, when X 14 When A, then X 10 Y or X9X 10 is AY.14 A and X 10 Specific examples of VH3 binding polypeptides that are Y are SEQ ID NOs: 2, 7, 10, 11, 13, 14, 15, 16, 21, 27, 31, 36, 41, 43, 48, 51, 52, 54, 55, 56, 57, 62, 67, 72, 77, 82, 83, 84, 85, 86 and 87. 14 A and X9X 10 Specific examples of VH3 binding polypeptides that are AY are SEQ ID NOs: 7, 10, 11, 13, 14, 15, 16, 21, 27, 31, 36, 41, 48, 51, 52, 54, 55, 56, 57, 62, 67, 72, 77, 82, 83, 84, 85, 86, and 87. Similarly, by studying the sequences of the VH3 binding polypeptides shown in Figure 5, it is easy to identify which VH3 binding polypeptides are encompassed in each of the embodiments disclosed herein.

[0110] Other embodiments defining subclasses of VH3 binding polypeptides as disclosed herein may be as follows:

[0111] In a specific embodiment defining a subclass of VH3 binding polypeptides as disclosed herein, X9X 10 X 11 Selected from QQT, QYT, YQT, AQE, AQR and AYR; such as selected from QQT, QYT, AQE, AQR and AYR; such as selected from AQE, AQR and AYR; such as selected from AQR and AYR, such as wherein X9X 10 X 11 In another embodiment, X 17 X 18 is selected from AR, HL and LH; such as selected from AR and HL or selected from AR and LH; such as wherein X 17 X 18 In one embodiment, X 24 X 25 In one embodiment, X 28 X 29 is selected from NA, NG, AA and AG; such as selected from NA, NG and AG or selected from NG, AA and AS; such as selected from NG and AG or selected from AG and NA or selected from AG and AA. In one embodiment, X 28 X 29 In one embodiment, X 28 X 29 In one embodiment, X 28 X 29 In one embodiment, X 28 X29 In one embodiment, independently of each other, X9X 10 X 11 Selected from AQE, AQR and AYR and X 13 X 14 is selected from the group consisting of LA, LW, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ and RR; wherein independently of each other, X9X 10 X 11 Selected from AQE, AQR and AYR and X 13 X 14 is selected from the group consisting of LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ and RR; wherein independently of each other, X9X 10 X 11 Selected from AQR and AYR and X 13 X 14 Selected from LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ and RR; such as where X9X 10 X 11 For AYR and X 13 X 14 In one embodiment, X9X 10 X 11 X 13 X 14 selected from QQTLA, QYTLA, YQTLA, AQELA, AQRLA, AYRLA and AYRLW; such as selected from QQTLA, QYTLA, AQELA, AQRLA, AYRLA and AYRLW; such as selected from AQELA, AQRLA, AYRLA and AYRLW; such as selected from AQRLA and AYRLA; such as wherein X9X 10 X 11 X 13 X 14 For AYRLA.

[0112] In one embodiment, independently of each other, X9X 10 X 11 Selected from AQE, AQR and AYR, X13 X 14 Selected from LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ, RR and LW and X 17 X 18 selected from LH and AR; such that independently of each other, X9X 10 X 11 Selected from AQR and AYR, X 13 X 14 Selected from LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ, RR and LW and X 17 X 18 selected from LH and AR; such that independently of each other, X9X 10 X 11 For AYR, X 13 X 14 Selected from LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ, RR and LW and X 17 X 18 selected from LH and AR; such that independently of each other, X9X 10 X 11 For AYR, X 13 X 14 Selected from LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ, RR and LW and X 17 X 18 For AR.

[0113] In one embodiment, X9X 10 X 11 X 13 X 14 X 17 X 18Selected from QQTLALH, QYTLALH, YQTLALH, QQTLAAR, AQELALH, AQRLALH, AYRLALH, AYRLWLH, AYRLWAR, AYRLAAR, AYRLAHL and AYRLWHL; such as selected from QQTLALH, QYTLALH, QQTLAAR, AQELALH, AQRLALH, AYRLALH, AYRLWLH, AYRLWAR, AYRLAAR, AYRLAHL and AYRLWHL; such as selected from AQELALH, AQRLALH, AYRLALH, AYRLWAR, AYRLAAR and AYRLAHL; such as selected from AQRLALH, AYRLALH and AYRLAAR; such as selected from AQRLALH and AYRLAAR; such as wherein X9X 10 X 11 X 13 X 14 X 17 X 18 In one embodiment, X 24 X 25 X 28 X 29 is selected from EENA, EENG, EEAA and EEAG; such as selected from EENA, EENG and EEAG; such as selected from EENG and EEAG; such as wherein X 24 X 25 X 28 X 29 For EEAG.

[0114] In one embodiment, X 26 X 28 X 29 is selected from QNG, QAA, QAG, QNA and SAG; such as selected from QNG, QAG, QNA and SAG; such as selected from QNG, QAG and SAG and / or selected from QNG, QAG, QNA or selected from QNG, QNA and SAG; such as selected from QAG and SAG; such as wherein X 26 X 28 X 29 It is QAG or SAG.

[0115] In one embodiment, X 26 X 28 X 29 is selected from QAG and SAG; such as wherein X 26 X 28 X 29is QAG or SAG. As described in detail in the experimental section below, the selection of VH3 binding polypeptide variants has led to the identification of a number of individual amino acid sequences according to sequence A as defined herein. These sequences constitute individual embodiments of sequence i) according to this aspect. The sequences of the individual amino acid sequences according to sequence A correspond to amino acid positions 8-36 in SEQ ID NO: 1-82 presented in Figure 5.

[0116] Therefore, in one embodiment according to the first aspect as disclosed herein, a VH3 binding polypeptide is provided, wherein sequence i) corresponds to a sequence selected from SEQ ID NO: 1-82, such as selected from SEQ ID NO: 1-40 and 42-81, such as selected from SEQ ID NO: 1-15 and 42-56, from position 8 to position 36. In one embodiment, sequence i) corresponds to a sequence selected from SEQ ID NO: 1-41, such as selected from SEQ ID NO: 1-40, such as selected from SEQ ID NO: 1-15, from position 8 to position 36. In one embodiment, sequence i) corresponds to a sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4-43 and 45-82; such as selected from the group consisting of SEQ ID NOs: 5-7, 9-11, 13-41, 46-48, 50-52 and 54-82; such as selected from the group consisting of SEQ ID NOs: 6-7, 10, 13-41, 47-48, 51 and 54-82; such as selected from the group consisting of SEQ ID NOs: 6-7, 10, 13, 15-41, 47-48, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 6, 10, 13, 15-41, 47, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 13, 15-41, 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 13, 15-40, 54 and 56-81; such as selected from the group consisting of SEQ ID NOs: NO: 13, 15, 54 and 56. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO: 15-41 and 56-82; such as selected from the group consisting of SEQ ID NO: 15-40 and 56-81 or selected from the group consisting of SEQ ID NO: 15, 41, 56 and 82. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO: 14, 15, 55 and 56. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the following: SEQ ID NO: 1, 2, 4-41; such as selected from SEQ ID NO: 5-7, 9-11, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13, 15-41; such as selected from SEQ ID NO: 6, 10, 13, 15-41; such as selected from SEQ ID NO: 13, 15-41; such as selected from SEQ ID NO: 13, 15-40; such as selected from SEQ ID NO: 13 and 15.In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NOs: 15-41; such as selected from SEQ ID NOs: 15-40 or selected from SEQ ID NOs: 15 and 41. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NOs: 14 and 15.

[0117] In one embodiment, sequence i) corresponds to a sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NOs: 42-43 and 45-82; such as selected from the group consisting of SEQ ID NOs: 46-48, 50-52 and 54-82; such as selected from the group consisting of SEQ ID NOs: 47-48, 51 and 54-82; such as selected from the group consisting of SEQ ID NOs: 47-48, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 47, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 54 and 56-81; such as selected from the group consisting of SEQ ID NOs: 54 and 56. In one embodiment, sequence i) corresponds to a sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NOs: 56-82; such as selected from the group consisting of SEQ ID NOs: 56-81 or selected from the group consisting of SEQ ID NOs: 56 and 82. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from SEQ ID NOs: 55 and 56.

[0118] In one embodiment, sequence i) corresponds to the sequence at position 8 to position 36 in SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15. In one embodiment, sequence i) corresponds to the sequence at position 8 to position 36 in SEQ ID NO: 13. In one embodiment, sequence i) corresponds to the sequence at position 8 to position 36 in SEQ ID NO: 14. In one embodiment, sequence i) corresponds to the sequence at position 8 to position 36 in SEQ ID NO: 15. In one embodiment, sequence i) corresponds to the sequence at position 8 to position 36 in SEQ ID NO: 41. In one embodiment, sequence i) corresponds to the sequence at position 8 to position 36 in SEQ ID NO: 54, SEQ ID NO: 55 or SEQ ID NO: 56. In one embodiment, sequence i) corresponds to the sequence at position 8 to position 36 in SEQ ID NO: 54. In one embodiment, sequence i) corresponds to the sequence at position 8 to position 36 in SEQ ID NO: 55. In one embodiment, sequence i) corresponds to the sequence at position 8 to position 36 in SEQ ID NO: 56. In one embodiment, sequence i) corresponds to the sequence from position 8 to position 36 in SEQ ID NO:82.

[0119] In some embodiments of the present disclosure, the VH3 binding polypeptide is based on a variant of the SpA domain into which a mutation according to the present disclosure is introduced. Thus, in a specific embodiment, a VH3 binding polypeptide as disclosed herein is provided, having a sequence selected from the group consisting of: a sequence corresponding to residues 8-36 in SEQ ID NO: 83; a sequence corresponding to residues 8-36 in SEQ ID NO: 84; a sequence corresponding to residues 8-36 in SEQ ID NO: 85; a sequence corresponding to residues 11-39 in SEQ ID NO: 86; and a sequence corresponding to residues 1-29 in SEQ ID NO: 87.

[0120] In some embodiments of the present disclosure, a polypeptide derived from SpA or sequence A as defined above "forms "a part of" a three-helix bundle protein domain. This should be understood to mean that the sequence of the SpA-derived polypeptide or sequence A is "inserted" into or "grafted" onto the sequence of the original three-helix bundle domain, such that the grafted sequence replaces a similar structural motif in the original domain. For example, without wishing to be bound by theory, it is believed that sequence A constitutes two of the three helices of a three-helix bundle and can therefore replace such a two-helix motif within any three-helix bundle. As the skilled person will recognize, the replacement of two helices of a three-helix bundle domain with two sequence A helices must be performed in a manner that does not affect the basic structure of the polypeptide. That is, the overall folding of the Cα backbone of the polypeptide according to this embodiment of the present invention is substantially the same as the overall folding of the three-helix bundle protein domain of which it forms a part, for example having the same secondary structural elements in the same order, etc. Thus, sequence A according to the present disclosure "forms" "part of" a three-helix bundle domain if the polypeptide according to this embodiment has the same fold as the original domain, meaning that basic structural properties are shared, which for example lead to similar CD spectra. Other relevant parameters are clear to the skilled person.

[0121] Thus, in one embodiment, the SpA derived polypeptide or sequence A forms part of a three-helix bundle protein domain. In some embodiments, the sequence A forms or substantially forms part of two helices with interconnected loops within the three-helix bundle protein domain. In particular, the three-helix bundle protein domain can be selected from domains from bacterial receptor proteins, in other words, from bacterial receptor domains. Non-limiting examples of such domains are five different three-helix domains from protein A of Staphylococcus aureus, such as domains A, B, C, D and E, in particular domain B and its derivatives and domain C and its derivatives. An example of a derivative of domain B is domain Z. Another example of a derivative of domain C is domain C with mutation G29A. In one embodiment, the three-helix bundle protein domain is selected from a domain or a derivative thereof from protein A of Staphylococcus aureus. In some embodiments, the three-helix bundle protein domain is a variant of domain Z, which is derived from domain B of staphylococcal protein A. In some embodiments, the three-helix bundle protein domain is domain C comprising mutation G29A.

[0122] The skilled person will appreciate that the third helix of the three-helix bundle may be provided in said VH3 binding polypeptide as defined herein and that the amino acid sequence of the third helix may vary without significantly deviating from its secondary structure or significantly altering the secondary structure of a polypeptide comprising sequence A and the third helix. Thus, in one embodiment, a VH3 binding polypeptide as defined herein is provided, further comprising a sequence B arranged at the C-terminus of said sequence A, the sequence B consisting of an amino acid sequence selected from iv) and v), wherein iv) and v) are defined as follows:

[0123] iv)DPSX 40 SX 42 X 43 X 44 LX 46 EAX 49 X 50 LNX 53 X 54 (SEQ ID NO:96)

[0124] Among them, independently of each other,

[0125] X 40 Select from Q, T and V;

[0126] X 42 Selected from A, K, L and T;

[0127] X 43 Selected from N, E, A and S;

[0128] X 44 Selected from L, I and V;

[0129] X 46 is selected from A, G, S and K, such as selected from A, S and K;

[0130] X 49 is selected from K and Q, if it is K;

[0131] X 50 Selected from K and R;

[0132] X 53 is selected from D, E, and K; and

[0133] X 54 Selected from A and S;

[0134] v) an amino acid sequence that is at least 75% identical to a sequence as defined in iv).

[0135] In some specific embodiments, sequence B consists of an amino acid sequence selected from iv) and v), and wherein in iv), independently of each other,

[0136] X40 Select from Q, T and V;

[0137] X 42 Selected from A, K, L and T;

[0138] X 43 Selected from N, E, A and S;

[0139] X 44 Selected from L, I and V;

[0140] X 46 Selected from A, S and K;

[0141] X 49 is K;

[0142] X 50 Selected from K and R;

[0143] X 53 is selected from D, E, and K; and

[0144] X 54 Select from A and S.

[0145] Thus, in yet another embodiment, a VH3 binding polypeptide as defined herein is provided, comprising a binding module sequence C comprising or consisting of sequence A as defined herein and sequence B as defined herein, in the order from N-terminus to C-terminus as follows

[0146] [Sequence A]-[Sequence B]

[0147] or an amino acid sequence having at least 70% identity with any sequence selected from the group consisting of residues 8-54 of SEQ ID NO: 88, residues 8-54 of SEQ ID NO: 89, residues 8-54 of SEQ ID NO: 90, residues 8-54 of SEQ ID NO: 91, residues 8-54 of SEQ ID NO: 92, residues 11-57 of SEQ ID NO: 93, and residues 1-47 of SEQ ID NO: 94. Thus, in one embodiment, the sequence C is selected from the group consisting of amino acid sequences having at least 70% identity with any sequence selected from the group consisting of residues 8-54 of SEQ ID NO: 88, residues 8-54 of SEQ ID NO: 89, residues 8-54 of SEQ ID NO: 90, residues 8-54 of SEQ ID NO: 91, residues 8-54 of SEQ ID NO: 92, residues 11-57 of SEQ ID NO: 93, and residues 1-47 of SEQ ID NO: 94. In one embodiment, the sequence C is selected from residues 8-54 of SEQ ID NO:88, residues 8-54 of SEQ ID NO:89, residues 8-54 of SEQ ID NO:90, residues 8-54 of SEQ ID NO:91, residues 8-54 of SEQ ID NO:92, residues 11-57 of SEQ ID NO:93, and residues 1-47 of SEQ ID NO:94; wherein independently of each other,

[0148] X9 is selected from Q, Y and A;

[0149] X 10 Selected from Q and Y;

[0150] X 11 Selected from T, E and R;

[0151] X 13 Selected from L, E, R, A and Q;

[0152] X 14 Selected from L, E, R, A, Q and W;

[0153] X 17 Selected from A, H and L;

[0154] X 18 Selected from R, L and H;

[0155] X 26 Selected from Q and S;

[0156] X 28 is selected from N and A; and

[0157] X29 Selected from A and G;

[0158] The numbers of the amino acid residues correspond to their positions in SEQ ID NO:88.

[0159] In one embodiment, the sequence C has at least 70% identity to any sequence selected from the group consisting of residues 8-54 of SEQ ID NO:88, residues 8-54 of SEQ ID NO:89, residues 8-54 of SEQ ID NO:90, residues 8-54 of SEQ ID NO:91, residues 8-54 of SEQ ID NO:92, residues 11-57 of SEQ ID NO:93, and residues 1-47 of SEQ ID NO:94, and has at least 72%, such as at least 74%, such as at least 76%, such as at least 78%, such as at least 80%, such as at least 82%, such as at least 85%, such as at least 87%, such as at least 89%, such as at least 91%, such as at least 93%, such as at least 85%, such as at least 97% identity to any sequence selected from the group consisting of residues 8-54 of SEQ ID NO:88, residues 8-54 of SEQ ID NO:89, residues 8-54 of SEQ ID NO:90, residues 8-54 of SEQ ID NO:91, residues 8-54 of SEQ ID NO:92, residues 11-57 of SEQ ID NO:93, and residues 1-47 of SEQ ID NO:94. 8-54 in SEQ ID NO:91, 8-54 in SEQ ID NO:92, 11-57 in SEQ ID NO:93, and 1-47 in SEQ ID NO:94. As previously noted, % identity does not apply to positions X9, X 10 , X 11 , X 13 , X 14 , X 17 , X 18 , X 26 , X 28 and X 29 The amino acid residue in the position is as defined above.

[0160] As discussed above, in some embodiments in which the VH3 binding polypeptides as disclosed herein form part of a three-helix bundle protein domain, they substantially form part of at least three helices and the interconnected loop between helix 1 (H1) and helix 2 (H2), referred to as loop 1 (L1) and the interconnected loop between helix 2 (H2) and helix 3 (H3), referred to as loop 1 (L2). Herein, the binding module sequence C substantially forms part of at least three helices and the interconnected loop between helix 1 and helix 2, referred to as loop 1 (L1) and the interconnected loop between helix 2 and helix 3, referred to as loop 2 (L2). It will be appreciated that the length of L1 and L2 may be varied, for example by adding or removing one or more further amino acid residues, provided that such variation does not significantly alter the three-dimensional structure of the polypeptide comprising the binding module sequence C.

[0161] As described above, sequence B comprises L2 and H3. The skilled person will appreciate that the amino acid sequences of L2 and H3 can be combined independently while maintaining the three-dimensional structure of the VH3 binding polypeptide. Thus, in one embodiment, a VH3 binding polypeptide as defined herein is provided, comprising a binding module sequence C, the sequence C consisting of the sequences [sequence A], [L2] and [H3], in the following order from N-terminus to C-terminus: [sequence A] - [L2] - [H3],

[0162] wherein [Sequence A] is as defined herein, and wherein, independently of each other, [L2] is selected from:

[0163] DPSV (SEQ ID NO:97);

[0164] DPSQ (SEQ ID NO: 98);

[0165] EPSQ (SEQ ID NO: 99);

[0166] DPST (SEQ ID NO: 100);

[0167] EPSV (SEQ ID NO: 101); and

[0168] DPSL (SEQ ID NO: 102);

[0169] and [H3] is selected from:

[0170] SANLLAEAKKLNDA(SEQ ID NO:103);

[0171] SKEILAEAKKLNDA(SEQ ID NO:104);

[0172] SKAILAEAKKLNDA(SEQ ID NO:105);

[0173] SANLLAEAKKLNDA(SEQ ID NO:106);

[0174] SANLLAEAKKLNES(SEQ ID NO:107);

[0175] STNVLGEAKKLNES(SEQ ID NO:108);

[0176] SANVLGEAQKLNDS(SEQ ID NO:109);

[0177] SLEILCEAKKLNDA(SEQ ID NO:110);

[0178] SLEILAEAKKLNDA (SEQ ID NO: 111); and

[0179] SKKILKEAKKLNKA (SEQ ID NO: 112).

[0180] In one embodiment, [L2] is selected from the group consisting of: DPSV (SEQ ID NO: 97); DPSQ (SEQ ID NO: 98); DPST (SEQ ID NO: 100); and DPSL (SEQ ID NO: 102). In one embodiment, [L2] is selected from the group consisting of: DPSV (SEQ ID NO: 97); DPSQ (SEQ ID NO: 98); and DPSL (SEQ ID NO: 102). In one embodiment, [L2] is selected from the group consisting of: DPSV (SEQ ID NO: 97) and DPSL (SEQ ID NO: 102).

[0181] In one embodiment, [L2] comprises or consists of DPSV (SEQ ID NO: 97). In one embodiment, [L2] comprises or consists of DPSQ (SEQ ID NO: 98). In one embodiment, [L2] comprises or consists of DPSL (SEQ ID NO: 102).

[0182] In a specific embodiment, [H3] is selected from SANLLAEAKKLNDA (SEQ ID NO: 103); SKEILAEAKKLNDA (SEQ ID NO: 104); SKAILAEAKKLNDA (SEQ ID NO: 105); SANLLAEAKKLNDA (SEQ ID NO: 106); SANLLAEAKKLNES (SEQ ID NO: 107); STNVLGEAKKLNES (SEQ ID NO: 108) and SANVLGEAQKLNDS (SEQ ID NO: 109). In one embodiment, [H3] is selected from SANLLAEAKKLNDA (SEQ ID NO: 103), SKEILAEAKKLNDA (SEQ ID NO: 104) and SKAILAEAKKLNDA (SEQ ID NO: 105), such as selected from SKEILAEAKKLNDA (SEQ ID NO: 104) and SKAILAEAKKLNDA (SEQ ID NO: 105), or selected from SANLLAEAKKLNDA (SEQ ID NO: 103) and SKAILAEAKKLNDA (SEQ ID NO: 105), or selected from SANLLAEAKKLNDA (SEQ ID NO: 103) and SKEILAEAKKLNDA (SEQ ID NO: 104).

[0183] In one embodiment, [H3] comprises or consists of SANLLAEAKKLNDA (SEQ ID NO: 103). In one embodiment, [H3] comprises or consists of SKEILAEAKKLNDA (SEQ ID NO: 104). In one embodiment, [H3] comprises or consists of SKAILAEAKKLNDA (SEQ ID NO: 105).

[0184] In one embodiment, a VH3 binding polypeptide as disclosed herein is provided, comprising a binding module sequence C selected from the group consisting of:

[0185] [Sequence A]-DPSQSANLLAEAKKLNDA (SEQ ID NO: 113);

[0186] [Sequence A]-DPSVSKEILAEAKKLNDA (SEQ ID NO: 114);

[0187] [Sequence A]-DPSVSKAILAEAKKLNDA (SEQ ID NO: 115);

[0188] [Sequence A]-DPSQSANLLAEAKKLNES (SEQ ID NO: 116);

[0189] [Sequence A]-DPSVSLEILGEAKKLNDA (SEQ ID NO: 117);

[0190] [Sequence A]-DPSVSLEILCEAKKLNDA (SEQ ID NO: 118);

[0191] [Sequence A]-DPSVSLEILAEAKKLNDA (SEQ ID NO: 119);

[0192] [Sequence A]-DPSVSLALLAEAKKLNDA (SEQ ID NO: 120);

[0193] [Sequence A]-DPSQSANLLSEAKKLNES (SEQ ID NO: 121);

[0194] [Sequence A] -DPSQSTNVLGEAKKLNES (SEQ ID NO: 122); and

[0195] [Sequence A]-DPSQSANVLGEAQKLNDS (SEQ ID NO: 123);

[0196] wherein [sequence A] is as defined herein. In a specific embodiment, a VH3 binding polypeptide as disclosed herein is provided, comprising a binding module sequence C selected from the group consisting of:

[0197] [Sequence A]-DPSQSANLLAEAKKLNDA (SEQ ID NO: 113);

[0198] [Sequence A]-DPSVSKEILAEAKKLNDA (SEQ ID NO: 114);

[0199] [Sequence A]-DPSVSKAILAEAKKLNDA (SEQ ID NO: 115);

[0200] [Sequence A]-DPSQSANLLAEAKKLNES (SEQ ID NO: 116);

[0201] [Sequence A]-DPSVSLEILGEAKKLNDA (SEQ ID NO: 117);

[0202] [Sequence A]-DPSVSLEILCEAKKLNDA (SEQ ID NO: 118);

[0203] [Sequence A]-DPSVSLEILAEAKKLNDA (SEQ ID NO: 119);

[0204] [Sequence A]-DPSVSLALLAEAKKLNDA (SEQ ID NO: 120); and

[0205] [Sequence A]-DPSQSANLLSEAKKLNES (SEQ ID NO: 121);

[0206] If selected from:

[0207] [Sequence A]-DPSQSANLLAEAKKLNDA (SEQ ID NO: 113);

[0208] [Sequence A]-DPSVSKEILAEAKKLNDA (SEQ ID NO: 114);

[0209] [Sequence A]-DPSVSKAILAEAKKLNDA (SEQ ID NO: 115);

[0210] [Sequence A]-DPSQSANLLAEAKKLNES (SEQ ID NO: 116);

[0211] [Sequence A]-DPSVSLEILGEAKKLNDA (SEQ ID NO: 117);

[0212] [Sequence A]-DPSVSLEILCEAKKLNDA (SEQ ID NO: 118);

[0213] [Sequence A] -DPSVSLEILAEAKKLNDA (SEQ ID NO: 119); and

[0214] [Sequence A]-DPSVSLALLAEAKKLNDA (SEQ ID NO: 120);

[0215] If selected from:

[0216] [Sequence A]-DPSQSANLLAEAKKLNDA (SEQ ID NO: 113);

[0217] [Sequence A]-DPSVSKEILAEAKKLNDA (SEQ ID NO: 114);

[0218] [Sequence A]-DPSVSKAILAEAKKLNDA (SEQ ID NO: 115); and

[0219] [Sequence A]-DPSQSANLLAEAKKLNES (SEQ ID NO: 116);

[0220] If selected from:

[0221] [Sequence A]-DPSQSANLLAEAKKLNDA (SEQ ID NO: 113);

[0222] [Sequence A]-DPSVSKEILAEAKKLNDA (SEQ ID NO: 114); and

[0223] [Sequence A]-DPSVSKAILAEAKKLNDA (SEQ ID NO: 115);

[0224] If selected from:

[0225] [Sequence A] -DPSQSANLLAEAKKLNDA (SEQ ID NO: 113); and

[0226] [Sequence A]-DPSVSKAILAEAKKLNDA (SEQ ID NO: 115).

[0227] In a specific embodiment, the binding module sequence C comprises [sequence A]-DPSQSANLLAEAKKLNDA (SEQ ID NO: 113) or consists of [sequence A]-DPSQSANLLAEAKKLNDA (SEQ ID NO: 113). In a specific embodiment, the binding module sequence C comprises [sequence A]-DPSVSKAILAEAKKLNDA (SEQ ID NO: 115) or consists of [sequence A]-DPSVSKAILAEAKKLNDA (SEQ ID NO: 115).

[0228] In another embodiment, a VH3 binding polypeptide is provided, comprising or consisting of a binding module sequence C selected from the following:

[0229] vi) [Sequence A]-DPSQSANLLAEAKKLNDA (SEQ ID NO: 113);

[0230] wherein [Sequence A] is as defined herein; and

[0231] vii) an amino acid sequence that is at least 85% identical to the sequence defined in vi).

[0232] As discussed above, polypeptides comprising minor changes compared to the above amino acid sequences without significant effects on their tertiary structure and function also fall within the scope of the present disclosure. Thus, in some embodiments, a VH3 binding polypeptide comprising a binding module sequence C as defined above may, for example, have a sequence that is at least 87%, such as at least 89%, such as at least 91%, such as at least 93%, such as at least 95%, such as at least 97% identical to the sequence defined in vi).

[0233] In another embodiment, a VH3 binding polypeptide is provided, comprising or consisting of a binding module sequence C selected from the following:

[0234] viii) [Sequence A]-DPSVSKAILAEAKKLNDA (SEQ ID NO: 115)

[0235] wherein [Sequence A] is as defined herein; and

[0236] ix) an amino acid sequence that is at least 85% identical to a sequence as defined in viii).

[0237] In another embodiment, a VH3 binding polypeptide is provided, comprising or consisting of a binding module sequence C selected from the following:

[0238] x) [Sequence A]-DPSVSKEILAEAKKLNDA (SEQ ID NO: 114)

[0239] wherein [Sequence A] is as defined herein, and

[0240] xi) an amino acid sequence that is at least 85% identical to the sequence defined in x).

[0241] As discussed above, polypeptides containing minor changes compared to the above amino acid sequences without significant effects on their tertiary structure and function also fall within the scope of the present disclosure. Thus, in some embodiments, a VH3 binding polypeptide comprising a binding module sequence C as defined above may, for example, have a sequence at least 87%, such as at least 89%, such as at least 91%, such as at least 93%, such as at least 95%, such as at least 97% identical to a sequence defined in any one of viii) and x).

[0242] As described in detail in the experimental part below, the selection of VH3 binding polypeptide variants has led to the identification of a number of individual amino acid sequences, and said sequences are also referred to herein as binding module sequences C, which constitute individual embodiments of any of sequences vi and viii), corresponding to the sequence from position 8 to position 54 in a sequence selected from SEQ ID NOs: 1-82, such as selected from SEQ ID NOs: 1-40 and 42-81, such as selected from SEQ ID NOs: 1-15 and 42-56 as presented in Figure 5. Thus, the sequence according to the individual amino acid sequence of sequence C corresponds to amino acid position 8 to position 54 in a sequence selected from SEQ ID NOs: 1-82 as presented in Figure 5.

[0243] Therefore, in one embodiment according to the first aspect as disclosed herein, a VH3 binding polypeptide is provided, wherein sequence vi) or viii) corresponds to a sequence selected from SEQ ID NO: 1-82, such as selected from SEQ ID NO: 1-40 and 42-81, such as selected from SEQ ID NO: 1-15 and 42-56, from position 8 to position 54. In one embodiment, a VH3 binding polypeptide is provided, wherein sequence viii) corresponds to a sequence selected from SEQ ID NO: 1-41, such as selected from SEQ ID NO: 1-40, such as selected from SEQ ID NO: 1-15, from position 8 to position 54. In one embodiment, a VH3 binding polypeptide is provided, wherein sequence vi) or viii) corresponds to a sequence from position 8 to position 54 in a sequence selected from the group consisting of: SEQ ID NOs: 1, 2, 4-43 and 45-82; such as selected from the group consisting of: SEQ ID NOs: 5-7, 9-11, 13-41, 46-48, 50-52 and 54-82; such as selected from the group consisting of: SEQ ID NOs: 6-7, 10, 13-41, 47-48, 51 and 54-82; such as selected from the group consisting of: SEQ ID NOs: 6-7, 10, 13, 15-41, 47-48, 51, 54 and 56-82; such as selected from the group consisting of: SEQ ID NOs: 6, 10, 13, 15-41, 47, 51, 54 and 56-82; such as selected from the group consisting of: SEQ ID NOs: 13, 15-41, 54 and 56-82; NO:13, 15-40, 54 and 56-81; such as selected from SEQ ID NO:13, 15, 54 and 56. In one embodiment, a VH3 binding polypeptide is provided, wherein sequence vi) or viii) corresponds to the sequence from position 8 to position 54 in a sequence selected from the group consisting of SEQ ID NO:15-41 and 56-82; such as selected from SEQ ID NO:15-40 and 56-81 or selected from SEQ ID NO:15, 41, 56 and 82. In one embodiment, a VH3 binding polypeptide is provided, wherein sequence vi) or viii) corresponds to the sequence from position 8 to position 54 in a sequence selected from the group consisting of SEQ ID NO:14, 15, 55 and 56.In one embodiment, a VH3 binding polypeptide is provided, wherein sequence viii) corresponds to a sequence from position 8 to position 54 in a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4-41; such as selected from the group consisting of SEQ ID NOs: 5-7, 9-11, 13-41; such as selected from the group consisting of SEQ ID NOs: 6-7, 10, 13-41; such as selected from the group consisting of SEQ ID NOs: 6-7, 10, 13, 15-41; such as selected from the group consisting of SEQ ID NOs: 6, 10, 13, 15-41; such as selected from the group consisting of SEQ ID NOs: 13, 15-41; such as selected from the group consisting of SEQ ID NOs: 13, 15-40; such as selected from the group consisting of SEQ ID NOs: 13 and 15. In one embodiment, a VH3 binding polypeptide is provided, wherein sequence viii) corresponds to a sequence from position 8 to position 54 in a sequence selected from the group consisting of SEQ ID NOs: 15-41, such as selected from the group consisting of SEQ ID NOs: 15-40 or selected from the group consisting of SEQ ID NOs: 15 and 41. In one embodiment, a VH3 binding polypeptide is provided, wherein sequence viii) corresponds to a sequence from position 8 to position 54 in a sequence selected from SEQ ID NO: 14 and SEQ ID NO: 15. In one embodiment, a VH3 binding polypeptide is provided, wherein sequence vii) corresponds to a sequence from position 8 to position 54 in a sequence selected from the group consisting of SEQ ID NO: 42-43 and 45-82; such as selected from the group consisting of SEQ ID NO: 46-48, 50-52 and 54-82; such as selected from the group consisting of SEQ ID NO: 47-48, 51 and 54-82; such as selected from the group consisting of SEQ ID NO: 47-48, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NO: 47, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NO: 54 and 56-82; such as selected from the group consisting of SEQ ID NO: 54 and 56-81; such as selected from the group consisting of SEQ ID NO: 54 and 56. In one embodiment, a VH3 binding polypeptide is provided, wherein sequence vi) corresponds to the sequence from position 8 to position 54 in a sequence selected from SEQ ID NO: 56-82, such as selected from SEQ ID NO 56-81 or selected from SEQ ID NO: 56 and 82. In one embodiment, a VH3 binding polypeptide is provided, wherein sequence vi) corresponds to the sequence from position 8 to position 54 in a sequence selected from SEQ ID NO: 55 and SEQ ID NO: 56. In one embodiment, a VH3 binding polypeptide is provided, wherein sequence viii) corresponds to the sequence from position 8 to position 54 in SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15.In one embodiment, a VH3 binding polypeptide is provided, wherein sequence vi) corresponds to the sequence from position 8 to position 54 in SEQ ID NO:54, SEQ ID NO:55 or SEQ ID NO:56.

[0244] In addition, the present disclosure also encompasses the VH3 binding polypeptides listed as SEQ ID NOs: 83-87 in Figure 5. Thus, in one embodiment, a VH3 binding polypeptide is provided, comprising a sequence selected from the group consisting of: a sequence corresponding to residues 8-54 in SEQ ID NO: 83; a sequence corresponding to residues 8-54 in SEQ ID NO: 84; a sequence corresponding to residues 8-54 in SEQ ID NO: 85; a sequence corresponding to residues 11-57 in SEQ ID NO: 86 and a sequence corresponding to residues 1-47 in SEQ ID NO: 87.

[0245] In some embodiments, the binding module sequence C may form part of a polypeptide comprising an amino acid sequence further comprising sequence 1 [S1] and / or sequence 2 [S2]. In one embodiment, a VH3 binding polypeptide as defined herein is provided, comprising sequence 1 [S1], [binding module sequence C] and sequence 2 [S2], the order from N-terminus to C-terminus being as follows:

[0246] [S1]-[binding module sequence C]-[S2],

[0247] wherein [S1] or [S2] may be present or absent, [Binding Module Sequence C] is as defined herein, and

[0248] Among them, independently of each other,

[0249] [S1] selected from: ADNKFNK (SEQ ID NO:124); VDAKFDK (SEQ ID NO:125); VDNKFNK (SEQ ID NO:126); ADAQQNKFNK (SEQ ID NO:127); IAAKHDK (SEQ ID NO:128); IAAQHDK (SEQ ID NO:129); ADNNFNK (SEQ ID NO:130); IAAKFDE (SEQ ID NO:131); PAAKHDK (SEQ ID NO:132); ADNAFNT (SEQ ID NO:133); FNK; ADNRFNE (SEQ ID NO:134); IDSKFDE (SEQ ID NO:135); ADNRFNR (SEQ ID NO:136); ADNKHNK (SEQ ID NO:137); ADSKFDE (SEQ ID NO:138); IDAKHDE (SEQ ID NO:139); QQNKFNK (SEQ ID NO:140); ADNKFHK (SEQ ID NO:141); KFNK (SEQ ID NO:142); ADNNFNR (SEQ ID NO:143); AAAKHDK (SEQ ID NO:144); IDNKFNK (SEQ ID NO:145); IDAKFDE (SEQ ID NO:146); DNNFNK (SEQ ID NO:147); ADNKFNE (SEQ ID NO:148); AAAQHDK (SEQ ID NO:149); and AAAKFDE (SEQ ID NO:150);

[0250] and [S2] selected from QAPK (SEQ ID NO:151); QAPP (SEQ ID NO:152); QAP; QAPR (SEQ ID NO:153); QAPE (SEQ ID NO:154); APK; QAPG (SEQ ID NO:155); QAIK (SEQ ID NO:156); and QA.

[0251] In one embodiment, S1 is selected from ADNKFNK; VDAKFDK; VDNKFNK; IAAKHDK; IAAQHDK; ADNNFNK; IAAKFDE; PAAKHDK; ADNAFNT; FNK; ADNRFNE; and IDSKFDE, such as selected from ADNKFNK; VDAKFDK; VDNKFNK; IAAKHDK; IAAQHDK; ADNNFNK; IAAKFDE; and PAAKHDK, such as selected from ADNKFNK; VDAKFDK; VDNKFNK; IAAKHDK; IAAQHDK; and ADNNFNK, such as selected from ADNKFNK; VDAKFDK; VDNKFNK; IAAKHDK; and IAAQHDK, such as selected from ADNKFNK; VDAKFDK; VDNKFNK; and IAAKHDK, such as selected from ADNKFNK; VDAKFDK; and VDNKFNK. In one embodiment, S1 comprises VDNKFNK (SEQ ID NO: 158) or consists of VDNKFNK (SEQ ID NO: 158). In one embodiment, S1 comprises VDAKFDK (SEQ ID NO: 160) or consists of VDAKFDK (SEQ ID NO: 160). In one embodiment, S1 comprises ADNKFNK (SEQ ID NO: 159) or consists of ADNKFNK (SEQ ID NO: 159).

[0252] In one embodiment, S2 is selected from QAPK; QAPP; QAP; QAPR; and QAPE, such as selected from QAPK; QAPP; QAP; and QAPE, such as selected from QAPK; QAPP; QAP; and QAPR, such as selected from QAPK; QAPP and QAP; such as selected from QAPK; and QAPP. In one embodiment, S2 comprises QAPK (SEQ ID NO: 151) or consists of QAPK (SEQ ID NO: 151). In one embodiment, S2 comprises QAPP (SEQ ID NO: 152) or consists of QAPP (SEQ ID NO: 152). In one embodiment, S2 comprises QAP or consists of QAP.

[0253] In some embodiments, the VH3 binding polypeptide may be selected from polypeptides of which sequence A forms a part according to the following. The VH3 binding polypeptide may comprise an amino acid sequence selected from the group consisting of:

[0254] ADNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 157);

[0255] VDNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK(SEQ ID NO:158);

[0256] ADNKFNK-[Sequence A]-DPSVSKEILAEAKKLNDAQAPK(SEQ ID NO:159);

[0257] VDAKFDK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK(SEQ ID NO:160);

[0258] VDNKFNK-[Sequence A]-DPSVSKEILAEAKKLNDAQAPK(SEQ ID NO:161);

[0259] VDAKFDK-[Sequence A]-DPSVSKAILAEAKKLNDAQAPK(SEQ ID NO:162);

[0260] ADNNFNK-[Sequence A]-DPSQSANLLAEAKKLNESQAPK(SEQ ID NO:163);

[0261] ADNKHNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK(SEQ ID NO:164);

[0262] ADNKFNK-[Sequence A]-DPSQSANLLAEAAPK(SEQ ID NO:165);

[0263] IAAQHDK-[Sequence A]-DPSVSLEILAEAKKLNDAQAPK(SEQ ID NO:166);

[0264] ADNKFHK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK(SEQ ID NO:167);

[0265] FNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK(SEQ ID NO:168);

[0266] IAAQHDK-[Sequence A]-DPSVSLEILCEAKKLNDAQAPK(SEQ ID NO:169);

[0267] IDAKFDE-[Sequence A]-DPSVSLALLAEAKKLNDAQAPP(SEQ ID NO:170);

[0268] DNNFNK-[Sequence A]-DPSQSANLLAEAKKLNESQAPK (SEQ ID NO: 171);

[0269] VDAKFDK-[Sequence A]-DPSQSANLLAEAKKLNDAQAIK (SEQ ID NO: 172);

[0270] ADNRFNE-[sequence A]-DPSVSKEILAEAKKLNDAQAPE (SEQ ID NO: 173); and

[0271] IDAKFDE-[Sequence A]-DPSVSLSLLAEAKKLNDAQAPP (SEQ ID NO: 174);

[0272] wherein [Sequence A] is as defined herein.

[0273] In a particular embodiment, the VH3 binding polypeptide comprises an amino acid sequence selected from the group consisting of:

[0274] ADNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 157);

[0275] VDNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 158);

[0276] ADNKFNK-[Sequence A]-DPSVSKEILAEAKKLNDAQAPK (SEQ ID NO: 159);

[0277] VDAKFDK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 160);

[0278] VDNKFNK-[Sequence A]-DPSVSKEILAEAKKLNDAQAPK (SEQ ID NO: 161);

[0279] VDAKFDK-[sequence A]-DPSVSKAILAEAKKLNDAQAPK (SEQ ID NO: 162);

[0280] ADNNFNK-[Sequence A]-DPSQSANLLAEAKKLNESQAPK (SEQ ID NO: 163);

[0281] ADNKHNK-[sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 164); and

[0282] ADNKFNK-[Sequence A]-DPSQSANLLAEAAPK (SEQ ID NO: 165);

[0283] If selected

[0284] ADNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 157);

[0285] VDNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 158);

[0286] ADNKFNK-[Sequence A]-DPSVSKEILAEAKKLNDAQAPK (SEQ ID NO: 159);

[0287] VDAKFDK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 160);

[0288] VDNKFNK-[Sequence A]-DPSVSKEILAEAKKLNDAQAPK (SEQ ID NO: 161); and

[0289] VDAKFDK-[sequence A]-DPSVSKAILAEAKKLNDAQAPK (SEQ ID NO: 162);

[0290] If selected

[0291] ADNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 157);

[0292] VDNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 158);

[0293] ADNKFNK-[sequence A]-DPSVSKEILAEAKKLNDAQAPK (SEQ ID NO: 159); and

[0294] VDAKFDK-[sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 160); and

[0295] VDAKFDK-[sequence A]-DPSVSKAILAEAKKLNDAQAPK (SEQ ID NO: 162);

[0296] If selected

[0297] VDNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 158);

[0298] VDAKFDK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 160);

[0299] VDNKFNK-[Sequence A]-DPSVSKEILAEAKKLNDAQAPK (SEQ ID NO: 161); and

[0300] VDAKFDK-[sequence A]-DPSVSKAILAEAKKLNDAQAPK (SEQ ID NO: 162);

[0301] If selected

[0302] VDNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 158); and

[0303] VDAKFDK-[sequence A]-DPSVSKAILAEAKKLNDAQAPK (SEQ ID NO: 162);

[0304] In one embodiment, the VH3 binding polypeptide comprises or consists of VDNKFNK-[sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 158). In one embodiment, the VH3 binding polypeptide comprises or consists of VDAKFDK-[sequence A]-DPSVSKAILAEAKKLNDAQAPK (SEQ ID NO: 162).

[0305] In one embodiment, the VH3 binding polypeptide comprises an amino acid sequence selected from the group consisting of:

[0306] xii) VDNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 158)

[0307] wherein [Sequence A] is as defined herein;

[0308] xiii) an amino acid sequence that is at least 86% identical to the sequence defined in xii). In one embodiment, the VH3 binding polypeptide comprises an amino acid sequence selected from the group consisting of:

[0309] xiv) VDAKFDK-[Sequence A]-DPSVSKAILAEAKKLNDAQAPK (SEQ ID NO: 162)

[0310] wherein [Sequence A] is as defined herein; and

[0311] xv) An amino acid sequence that is at least 86% identical to a sequence as defined in xiv).

[0312] Likewise, polypeptides comprising minor changes compared to the amino acid sequences xii) or xiv) above without significant effects on their tertiary structure and function are also within the scope of the present disclosure. Thus, in some embodiments, a VH3 binding polypeptide as defined above may, for example, have a sequence that is at least 87%, such as at least 89%, such as at least 91%, such as at least 93%, such as at least 94%, such as at least 96%, such as at least 98% identical to the sequence defined in xii) or xiv).

[0313] The sequence xiv) in such a polypeptide may be selected from SEQ ID NO: 1-41, such as SEQ ID NO: 1-40. The sequence xii) in such a polypeptide may be selected from SEQ ID NO: 42-82, such as SEQ ID NO: 42-81. Thus, in one embodiment, sequence xii) or xiv) corresponds to a sequence selected from the group consisting of SEQ ID NO: 1-82, such as selected from the group consisting of SEQ ID NO: 1-40 and 42-81, such as selected from the group consisting of SEQ ID NO: 1-15 and 42-56. In one embodiment, sequence xiv) corresponds to a sequence selected from the group consisting of SEQ ID NO: 1-41, such as selected from the group consisting of SEQ ID NO: 1-40, such as selected from the group consisting of SEQ ID NO: 1-15. In one embodiment, the sequence xii) or xiv) corresponds to a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4-43 and 45-82; such as selected from the group consisting of SEQ ID NOs: 5-7, 9-11, 13-41, 46-48, 50-52 and 54-82; such as selected from the group consisting of SEQ ID NOs: 6-7, 10, 13-41, 47-48, 51 and 54-82; such as selected from the group consisting of SEQ ID NOs: 6-7, 10, 13, 15-41, 47-48, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 6, 10, 13, 15-41, 47, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 13, 15-41, 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 13, 15-40, 54 and 56-81; such as selected from the group consisting of SEQ ID NOs: NO: 13, 15, 54 and 56. In another embodiment, sequence xii) or xiv) corresponds to a sequence selected from the group consisting of SEQ ID NO: 15-41 and 56-82; such as selected from the group consisting of SEQ ID NO: 15-40 and 56-81 or selected from the group consisting of SEQ ID NO: 15, 41, 56 and 82. In one embodiment, sequence xii) or xiv) corresponds to a sequence selected from the group consisting of SEQ ID NO: 14, 15, 55 and 56. In one embodiment, sequence xiv) corresponds to a sequence selected from the following: SEQ ID NO: 1, 2, 4-41; such as selected from SEQ ID NO: 5-7, 9-11, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13, 15-41; such as selected from SEQ ID NO: 6, 10, 13, 15-41; such as selected from SEQ ID NO: 13, 15-41; such as selected from SEQ ID NO: 13, 15-40; such as selected from SEQ ID NO: 13 and 15.In one embodiment, sequence xiv) corresponds to a sequence selected from the group consisting of SEQ ID NOs: 15-41; such as selected from SEQ ID NOs: 15-40 or selected from SEQ ID NOs: 15 and 41. In another embodiment, sequence xiv) corresponds to a sequence selected from the group consisting of SEQ ID NOs: 14 and 15. In yet another embodiment, sequence xii) corresponds to a sequence selected from the group consisting of SEQ ID NOs: 42-43 and 45-82; such as selected from the group consisting of SEQ ID NOs: 46-48, 50-52 and 54-82; such as selected from the group consisting of SEQ ID NOs: 47-48, 51 and 54-82; such as selected from the group consisting of SEQ ID NOs: 47-48, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 47, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 54 and 56-81; such as selected from the group consisting of SEQ ID NOs: 54 and 56. In one embodiment, sequence xii) corresponds to a sequence selected from the group consisting of SEQ ID NOs: 56-82; such as selected from SEQ ID NOs: 56-81 or selected from SEQ ID NOs: 56 and 82. In one embodiment, sequence xii) corresponds to a sequence selected from the group consisting of SEQ ID NOs: 55 and 56. In one embodiment, sequence xiv) corresponds to SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15. In another embodiment, sequence xii) corresponds to a sequence in SEQ ID NO: 54, SEQ ID NO: 55 or SEQ ID NO: 56.

[0314] The VH3 binding polypeptide may also be selected from the sequence according to any one of SEQ ID NOs: 83 to 87. Thus, in one embodiment, the VH3 binding polypeptide as disclosed herein comprises a sequence selected from the group consisting of: a sequence corresponding to residues 1-58 in SEQ ID NO: 83; a sequence corresponding to residues 1-58 in SEQ ID NO: 84; a sequence corresponding to residues 1-58 in SEQ ID NO: 85; a sequence corresponding to residues 3-60 in SEQ ID NO: 86; and a sequence corresponding to residues 1-51 in SEQ ID NO: 87, or a sequence corresponding to residues 1-58 in SEQ ID NO: 83; a sequence corresponding to residues 1-58 in SEQ ID NO: 84; a sequence corresponding to residues 1-58 in SEQ ID NO: 85; a sequence corresponding to residues 1-63 in SEQ ID NO: 86 and a sequence corresponding to residues 1-51 in SEQ ID NO: 87.

[0315] Additional polypeptide domains having the same functionality may be linked to a VH3 binding polypeptide as defined herein, e.g., any VH3 binding polypeptide as defined in any one of i) to xv), thereby obtaining a VH3 binding polypeptide multimer. In particular, such a multimer can be used to improve the efficiency of binding to the VH3 region, e.g., to ensure that more polypeptides containing the VH3 region are bound to the VH3 binding polypeptide multimer compared to its monomeric variant (in other words, VH3 binding polypeptide). Therefore, in a second aspect of the present disclosure, a VH3 binding polypeptide multimer is provided. The multimer is understood to comprise at least two VH3 binding polypeptides as disclosed herein as monomeric units, the amino acid sequences of which may be identical or different. Therefore, in one embodiment, a VH3 binding polypeptide multimer is provided, wherein each monomer of the multimer comprises a VH3 binding polypeptide, which is independently selected from any VH3 binding polypeptide defined herein. In another embodiment, a VH3 binding polypeptide multimer is provided, wherein each monomer of the multimer comprises a sequence A, which is independently selected from any sequence A defined herein.

[0316] The multimeric form of the polypeptide may comprise a suitable number of domains, each domain having VH3 binding activity, and each domain forming a monomer within the multimer. In one embodiment, the multimer is selected from dimers, trimers, tetramers, pentamers, hexamers, heptamers, octamers, nonamers and decamers, such as selected from dimers, tetramers, pentamers, hexamers, heptamers and octamers; such as selected from dimers, tetramers and hexamers. In a specific embodiment, the multimer is a hexamer. In a specific embodiment, the multimer is a tetramer. In one embodiment, the multimer is a linear multimer comprising monomers arranged in sequence. In one embodiment, the multimer is a linear polypeptide comprising monomers arranged in sequence. In one embodiment, each monomer is arranged so that its C-terminus is adjacent to the N-terminus of the monomer that follows it. In one embodiment, at least one monomer is arranged so that its C-terminus is adjacent to the C-terminus of the monomer that follows it.

[0317] The monomers within a multimer may have the same amino acid sequence, but alternatively, they may have different amino acid sequences. Thus, the monomers may have any amino acid sequence of a VH3 binding polypeptide as defined herein, for example, all monomers within a multimer may have different sequences, or only a subset of monomers in a multimer may have different amino acid sequences while the other monomers have the same sequence. In other words, the VH3 binding polypeptides of the present invention may form homopolymers or heteropolymers, such as homodimers or heterodimers. In one embodiment, a VH3 binding polypeptide multimer is provided, wherein the multimer is a homopolymer. In another embodiment, a VH3 binding polypeptide multimer is provided, wherein the multimer is a heteropolymer. The heteropolymer may comprise at least two or at least three different sequences A, wherein each sequence A is as defined herein. In one embodiment, the multimer is a heteropolymer comprising at least two or at least three different VH3 binding polypeptides, each as defined herein. In one embodiment, the multimer is a homopolymer comprising four VH3 binding polypeptides as defined herein. In another embodiment, the multimer is a homopolymer comprising six VH3 binding polypeptides as defined herein. In a specific embodiment, the multimer is a homopolymer or heteropolymer comprising at least three, such as at least four, such as at least five, such as at least six, such as at least seven, such as at least eight monomers selected from SEQ ID NO: 1-82, such as selected from SEQ ID NO: 1-40 and 42-81, such as selected from SEQ ID NO: 1-15 and 42-56; such as selected from SEQ ID NO: 1-41, such as selected from SEQ ID NO: 1-40, such as selected from SEQ ID NO: 1-15.In a specific embodiment, the multimer is a homopolymer or heteropolymer comprising at least three, such as at least four, such as at least five, such as at least six, such as at least seven, such as at least eight monomers, the monomers being selected from SEQ ID NOs: 1, 2, 4-43 and 45-82; such as selected from SEQ ID NOs: 5-7, 9-11, 13-41, 46-48, 50-52 and 54-82; such as selected from SEQ ID NOs: 6-7, 10, 13-41, 47-48, 51 and 54-82; such as selected from SEQ ID NOs: 6-7, 10, 13, 15-41, 47-48, 51, 54 and 56-82; such as selected from SEQ ID NOs: 6, 10, 13, 15-41, 47, 51, 54 and 56-82; such as selected from SEQ ID NOs: 13, 15-41, 54 and 56-82; such as selected from SEQ ID NOs: NO:13, 15-40, 54 and 56-81; such as selected from SEQ ID NO:13, 15, 54 and 56; or selected from SEQ ID NO:15-41 and 56-82; such as selected from SEQ ID NO:15-40 and 56-81 or selected from SEQ ID NO:15, 41, 56 and 82; or selected from SEQ ID NO:14, 15, 55 and 56. In a specific embodiment, the multimer is a homopolymer or heteropolymer comprising at least three, such as at least four, such as at least five, such as at least six, such as at least seven, such as at least eight monomers, and the monomers are selected from SEQ ID NO: 1, 2, 4-41; such as selected from SEQ ID NO: 5-7, 9-11, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13, 15-41; such as selected from SEQ ID NO: 6, 10, 13, 15-41; such as selected from SEQ ID NO: 13, 15-41; such as selected from SEQ ID NO: 13, 15-40; such as selected from SEQ ID NO: 13 and 15; or selected from SEQ ID NO: 15-41; such as selected from SEQ ID NO: 15-40 or selected from SEQ ID NO: 15 and 41; or selected from SEQ ID NO: 14 and 15.In one embodiment, the multimer is a homopolymer or heteropolymer comprising at least three, such as at least four, such as at least five, such as at least six, such as at least seven, such as at least eight monomers, and the monomers are selected from SEQ ID NOs: 42-43 and 45-82; such as selected from SEQ ID NOs: 46-48, 50-52 and 54-82; such as selected from SEQ ID NOs: 47-48, 51 and 54-82; such as selected from SEQ ID NOs: 47-48, 51, 54 and 56-82; such as selected from SEQ ID NOs: 47, 51, 54 and 56-82; such as selected from SEQ ID NOs: 54 and 56-82; such as selected from SEQ ID NOs: 54 and 56-81; such as selected from SEQ ID NOs: 54 and 56; or selected from SEQ ID NOs: 56-82; such as selected from SEQ ID NOs 56-81 or selected from SEQ ID NOs: 56 and 82; or selected from SEQ ID NOs: 55 and 56. In one embodiment, the multimer is a homopolymer or heteropolymer comprising at least three, such as at least four, such as at least five, such as at least six, such as at least seven, such as at least eight monomers, the monomers being selected from SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15; or selected from SEQ ID NO: 54, SEQ ID NO: 55 or SEQ ID NO: 56. In one embodiment, the multimer comprises the sequence SEQ ID NO: 13. In one embodiment, the multimer comprises the sequence SEQ ID NO: 14. In one embodiment, the multimer comprises the sequence SEQ ID NO: 15. In the accompanying examples, multimers of each of SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 are described. The multimer exhibits desirable properties in terms of VH3 affinity and stability when exposed to alkaline washing. In addition, the multimer has low affinity or no affinity for the Fc region of trastuzumab. Specific examples of such multimers are those according to SEQ ID NO: 175, 176 and 177. SEQ ID NO: 175 comprises four SEQ ID NO: 13 and is thus a tetramer. SEQ ID NO: 175 comprises four SEQ ID NO: 15 and is thus a tetramer. SEQ ID NO: 177 comprises four SEQ ID NO: 15 and is thus a hexamer.

[0318] It will be appreciated that the multimer may comprise any one of SEQ ID NOs 83 to 87. In one embodiment, the multimer is a homopolymer or heteropolymer comprising at least three, such as at least four, such as at least five, such as at least six, such as at least seven, such as at least eight monomers selected from: a sequence corresponding to residues 1-58 in SEQ ID NO: 83; a sequence corresponding to residues 1-58 in SEQ ID NO: 84; a sequence corresponding to residues 1-58 in SEQ ID NO: 85; a sequence corresponding to residues 3-60 in SEQ ID NO: 86 and a sequence corresponding to residues 1-51 in SEQ ID NO: 87, or a sequence corresponding to residues 1-58 in SEQ ID NO: 83; a sequence corresponding to residues 1-58 in SEQ ID NO: 84; a sequence corresponding to residues 1-58 in SEQ ID NO: 85; a sequence corresponding to residues 1-63 in SEQ ID NO: 86 and a sequence corresponding to residues 1-51 in SEQ ID NO: 87.

[0319] It will be appreciated that the monomers in the multimers discussed herein (the multimers comprising sequence A or comprising a VH3 binding polypeptide as disclosed herein) may be directly coupled to each other or separated by a linker sequence. The skilled person will appreciate that the presence or absence of a linker sequence may differ between different monomeric parts in a multimer, and that if a linker is present, the sequence of each individual linker may be the same or different. Thus, in one embodiment, the VH3 binding polypeptide multimer comprises at least one linker.

[0320] As the skilled person will appreciate, the construction of a multimer (e.g., as a fusion protein) generally involves the use of a linker between the monomeric parts to be fused. The skilled person is aware of different types of linkers with different properties, such as flexible amino acid linkers, rigid amino acid linkers, and cleavable amino acid linkers. Linkers can be used, for example, to increase the stability of the fusion protein or to improve the folding of the fusion protein, to increase expression or to improve activity, affinity, and / or binding capacity. Therefore, in one embodiment, the VH3 binding polypeptide multimer as defined herein further comprises at least one linker. In one embodiment, there is a linker between each monomer in the multimer. The linker can, for example, be selected from a flexible amino acid linker, a rigid amino acid linker, and a cleavable amino acid linker. Alternatively, the linker can be a non-peptide linker. Therefore, the VH3 binding polypeptide disclosed herein can be directly connected to each other by a peptide bond between the C-terminus and the N-terminus of the polypeptide. Alternatively, two or more monomers (in other words, monomeric units or parts) in a multimer can be connected by an element comprising an oligomer or polymer species, such as an element comprising up to 15 or 30 amino acids, such as 1-5, 1-10, or 5-10 amino acids. In one embodiment, the linker comprises up to 15 amino acid residues. The properties of such a connection should preferably not destabilize the spatial conformation of the protein unit, that is, not destabilize the spatial conformation of the VH3 binding polypeptide monomer within the multimer. This can be achieved, for example, by avoiding the presence of proline in the linker. In addition, the linker should preferably be sufficiently stable in an alkaline environment without damaging the properties of the protein unit. For this reason, it would be advantageous if the linker does not contain asparagine. In addition, it would be advantageous if the linker does not contain glutamine. The multimer may also contain multiple amino acid residues at the N-terminus that are derived from the cloning process or are composed of residues from the cleaved signal transduction sequence. The number of additional amino acid residues may be, for example, 15 or less, such as 10 or less or 5 or less.

[0321] The skilled artisan will appreciate that various modifications and / or additions may be made to the VH3 binding polypeptide or VH3 binding polypeptide multimer according to any aspect disclosed herein to tailor the polypeptide or multimer for a particular application without departing from the scope of the present disclosure.

[0322] For example, in one embodiment, a VH3 binding polypeptide or VH3 binding polypeptide multimer as described herein is provided, which has been extended by additional amino acids at the C-terminus and / or N-terminus and / or comprises additional amino acids at the C-terminus and / or N-terminus. Such a polypeptide or multimer is understood to be a polypeptide or multimer having one or more additional amino acid residues at the first and / or last position of the polypeptide chain (i.e. at the N-terminus and / or C-terminus of the polypeptide or multimer). For example, the additional amino acid residues may be at the N-terminus and / or C-terminus of any of the sequence A according to i), ii) or iii), the binding module sequence C according to vi), vii), viiii), ix), x), xi), or the sequence xii), xiii), xiv) or xv). Thus, the VH3 binding polypeptide as defined herein may comprise any suitable number of additional amino acid residues, such as one, two, three, four, five, six, seven, eight, nine, ten or more additional amino acid residues. Said amino acid residues may individually or collectively improve the production, purification, in vitro stabilization or coupling of the polypeptide to a substrate of interest, for example to a solid support such as described in connection with the separation matrix aspect.

[0323] The additional amino residue may be coupled to the VH3 binding polypeptide or multimer by means of chemical conjugation (using known organic chemistry methods) or by any other means, such as expressing the VH3 binding polypeptide or multimer as a fusion protein or in any other way directly or via a linker (e.g., an amino acid linker as described above).

[0324] In some embodiments, the VH3 binding polypeptide and / or polymer disclosed above also comprises one or more coupling elements at the C-terminus or N-terminus, which are selected from cysteine ​​residues, multiple lysine residues and multiple histidine residues. The coupling element may be, for example, a single cysteine ​​at the C-terminus. The coupling element may be directly connected to the C-terminus or the N-terminus, or it / they may be connected via a joint comprising up to 15 amino acids (such as 1-5, 1-10 or 5-10 amino acids). The segment should preferably be sufficiently stable in an alkaline environment without compromising the properties of the protein. For this reason, it would be advantageous if the segment did not contain asparagine. In addition, it would be advantageous if the segment did not contain glutamine. An advantage of having a C-terminal cysteine ​​is that the end-point coupling of the protein can be achieved by the reaction of cysteine ​​thiol with the electrophilic group on the carrier. This provides excellent fluidity of the coupled protein, which is important for binding capacity.

[0325] The skilled person will appreciate that there are many ways to produce polypeptides. Thus, in one embodiment, a VH3 binding polypeptide multimer as disclosed herein is provided, wherein the VH3 binding polypeptide monomers are expressed as fusion proteins. In another embodiment, a VH3 binding polypeptide multimer as disclosed herein is provided, wherein the VH3 binding polypeptide monomer units are covalently coupled together.

[0326] As used in this disclosure, the terms "VH3 binding" and "binding affinity for VH3" refer to a property of a polypeptide that can be tested, for example, by ELISA or using surface plasmon resonance (SPR) technology.

[0327] VH3 binding affinity can be tested in an experiment in which a polypeptide containing VH3 or a fragment thereof (hereinafter also referred to as a sample) is immobilized on a sensor chip of a surface plasmon resonance (SPR) instrument and the sample containing the polypeptide to be tested is passed over the chip. Alternatively, the polypeptide to be tested is immobilized on a sensor chip of the instrument and a sample containing VH3 or a fragment thereof is passed over the chip. The skilled person can then interpret the results obtained by such an experiment to establish at least a qualitative measure of the binding affinity of the polypeptide for VH3. If a quantitative measurement is required, for example to determine the K of the interaction, the binding affinity of the polypeptide to VH3 can be determined by measuring the binding affinity of the polypeptide to VH3. D If the value is not known, surface plasmon resonance methods can also be used. For example, in Biacore TM (Cytiva TM ) or ProteOn TM XPR 36 (Bio-Rad TM ) instrument. The polypeptide containing VH3 or its fragment is appropriately immobilized on the sensor chip of the instrument, and samples of the polypeptide whose affinity is to be determined are prepared by serial dilution and injected in random order. Fab containing VH3 can be used as a target for evaluating VH3 binding affinity, and K can then be calculated from the results using, for example, the 1:1 Langmuir binding model of BIAevaluation 4.1 software or other suitable software provided by the instrument manufacturer. D The skilled person will appreciate that the VH3-containing Fab may be passed through the chip or may be immobilized on a sensor chip in an experimental setup as described above.

[0328] As described above, the VH3 binding polypeptides and VH3 binding polypeptide multimers disclosed herein are capable of binding to the VH3 region of trastuzumab. Therefore, in one embodiment, a VH3 binding polypeptide or VH3 binding polypeptide multimer as disclosed herein is provided, which is capable of binding to VH3 such that the K D Value is at most 1x 10 -6 M, such as up to 1x 10 -7 M, such as up to 1x10 -8M, such as up to 1x 10 -9 M, such as up to 1x 10 -10 M, such as up to 1x 10 -11 M. For example, K D Values ​​may be calculated based on the interaction of a VH3 binding polypeptide or VH3 binding polypeptide multimer as disclosed herein with a VH3 containing Fab.

[0329] It is understood that the VH3 binding polypeptide and / or VH3 binding polypeptide multimer exhibits a K for interaction with VH3 similar to SEQ ID NO: 88 and / or SEQ ID NO: 89. D In particular, the K of the interaction of a VH3 binding polypeptide or VH3 binding polypeptide multimer with VH3 as disclosed herein is D The value may be related to the K of the interaction between SEQ ID NO:88 and / or SEQ ID NO:89 and VH3 D For example, if the K of the interaction of SEQ ID NO:88 and / or SEQ ID NO:89 with a particular VH3 is D The value in one assay is 9 x 10 -10 M, then the K of the interaction between the VH3 binding polypeptide or VH3 binding polypeptide multimer and VH3 D The values ​​in this assay can be between 9x 10 -9 M to 9x 10 -11 The skilled person will recognize that comparing K obtained using the same assay D Values ​​may be useful, and although there may be some variation between different assays, intra-assay comparisons generally show the same trends regardless of the assay used. For example, the assay may differ depending on whether a VH3-containing polypeptide or a VH3-binding polypeptide is immobilized on the chip. In one embodiment, the K for interaction with VH3 is measured in an assay in which a VH3-binding polypeptide is immobilized on the chip. D In a different embodiment, the K value of the interaction with VH3 is measured in an assay in which a polypeptide containing VH3 is immobilized on a chip. D In one embodiment, the VH3-containing polypeptide is a VH3-containing Fab.

[0330] In another embodiment, a VH3 binding polypeptide or VH3 binding polypeptide multimer as disclosed herein is provided, which is capable of binding to VH3 such that the K D The value is the K of the interaction between SEQ ID NO:88 and VH3 DThe value of the VH3 binding polypeptide or VH3 binding polypeptide multimer is at least 25%, such as at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80%, such as at least 90%. In one embodiment, the VH3 binding polypeptide or VH3 binding polypeptide multimer is capable of binding to VH3 such that the K of the interaction is D The value is the K of the interaction between SEQ ID NO:89 and VH3 D The value of the VH3 binding polypeptide or VH3 binding polypeptide multimer is at least 25%, such as at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80%, such as at least 90%. In one embodiment, the VH3 binding polypeptide or VH3 binding polypeptide multimer is capable of binding to VH3 such that the K of the interaction is D The K values ​​are for the interaction of SEQ ID NO:88 and SEQ ID NO:89 with VH3. D The K value of the interaction with VH3 is at least 25%, such as at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80%, such as at least 90%. D The value can be tested, for example, using a Fab comprising VH3 or using a full-length antibody. For example, the measurement can be performed using the conditions described in Example 1, 2 or 3. The skilled person recognizes that other VH3-containing polypeptides can be used where appropriate.

[0331] Similarly, as used in this disclosure, the terms "Fc binding" and "binding affinity to Fc" refer to properties of a polypeptide that can be tested, for example, by ELISA or using surface plasmon resonance (SPR) technology. Fc binding affinity can be tested in an experiment in which Fc or a fragment thereof is immobilized on a sensor chip of a surface plasmon resonance (SPR) instrument and a sample containing the polypeptide to be tested is passed over the chip. Alternatively, the polypeptide to be tested (in this case a VH3 binding polypeptide) can be immobilized on a sensor chip of the instrument and a sample containing Fc or a fragment thereof is passed over the chip. The skilled person will understand that if binding to Fc is eliminated or significantly reduced, substantial absence of binding should be detected. The skilled person can then interpret the results obtained by such an experiment to establish at least a qualitative measure of the binding affinity of the polypeptide to Fc. If a quantitative measurement is required, for example to determine the K of the interaction, the binding affinity of the polypeptide to Fc can be determined by measuring the binding affinity of the polypeptide to Fc. D If the binding value is 0, surface plasmon resonance methods can also be used in a similar manner as explained above for VH3 binding.

[0332] As explained in relation to the first aspect of the present disclosure, the VH3 binding polypeptides and VH3 binding polypeptide multimers as defined herein may have a significantly reduced or eliminated binding affinity to the Fc of trastuzumab. The skilled person will appreciate that the VH3 binding polypeptides and VH3 binding polypeptide multimers of the present invention do not significantly interact with Fc, and therefore, their ability to bind to Fc is low.

[0333] In one embodiment, a VH3 binding polypeptide or VH3 binding polypeptide multimer as disclosed herein is provided, which is not capable of being cleaved at a rate of less than 1 x 10 -4 M, if less than 1x 10 -3 The interaction K of M D Value is bound to Fc.

[0334] In addition, the VH3 binding polypeptides and multimers thereof disclosed herein show improved alkaline cleaning stability. In embodiments where the VH3 binding polypeptides or multimers are used to separate or isolate, for example, antibodies / immunoglobulins having a VH3 region, high alkaline stability will allow the use of highly alkaline conditions during cleaning, which is critical for long-term repeated use in bioprocess separation environments.

[0335] In one embodiment, a VH3 binding polypeptide or VH3 binding polypeptide multimer as disclosed herein is provided, which retains at least 19%, such as at least 20%, such as at least 21%, such as at least 23%, such as at least 25%, such as at least 27%, such as at least 29%, such as at least 31%, such as at least 33%, such as at least 35%, such as at least 37%, such as at least 39%, such as at least 41%, such as at least 43%, such as at least 45%, such as at least 47%, such as at least 48%, such as at least 50% of its original VH3 binding capacity after at least one washing step with 0.5M NaOH. In one embodiment, the washing step comprises exposure to 0.5M NaOH, such as incubation with 0.5M NaOH, for a period of about 2-15 minutes, such as 5-15 minutes, such as about 5 minutes or about 10 minutes or about 15 minutes. For example, the incubation time with 0.5M NaOH can be 5±0.5 minutes, 6±0.5 minutes, 7±0.5 minutes, or 8±0.5 minutes, 9±0.5 minutes, 10±0.5 minutes, 11±0.5 minutes, 13±0.5 minutes, 14±0.5 minutes, 14±0.5 minutes, or 15±0.5 minutes. The incubation time can also be longer, such as about 20 minutes or about 30 minutes or even 60 minutes or longer. The skilled person is familiar with the appropriate time range for washing the affinity column with NaOH. In one embodiment, the VH3 binding polypeptide or VH3 binding polypeptide multimer as disclosed herein retains at least 19%, such as at least 20%, such as at least 21%, such as at least 23%, such as at least 25%, such as at least 27%, such as at least 29%, such as at least 31%, such as at least 33%, such as at least 35%, such as at least 37%, such as at least 39%, such as at least 41%, such as at least 43%, such as at least 45%, such as at least 47%, such as at least 48%, such as at least 50% of its original VH3 binding capacity after at least 10, 20, 40, 50, 75 or 100 washing steps using 0.5M NaOH. For example, each washing step can be 10 minutes, so if the washing step is performed 100 times, the exposure time (and therefore the incubation time) of the VH3 binding polypeptide or VH3 binding polypeptide multimer as disclosed herein to NaOH will be 1000 minutes.

[0336] In one embodiment, a VH3 binding polypeptide or VH3 binding polypeptide multimer as disclosed herein is provided, which retains at least 19%, such as at least 20%, such as at least 21%, such as at least 23%, such as at least 25%, such as at least 27%, such as at least 29%, such as at least 31%, such as at least 33%, such as at least 35%, such as at least 37%, such as at least 39%, such as at least 41%, such as at least 43%, such as at least 45%, such as at least 47%, such as at least 48%, such as at least 50% of its original VH3 binding capacity after 100 repeated binding cycles followed by washing with 0.5M NaOH. It should be understood that a washing step is performed after each binding cycle. The washing step can be, for example, incubation in contact with 0.5M NaOH for about 5-15 minutes, such as about 5 minutes or 10 minutes or 15 minutes. For example, the incubation time in contact with 0.5 M NaOH can be 5±0.5 minutes, 6±0.5 minutes, 7±0.5 minutes, or 8±0.5 minutes, 9±0.5 minutes, 10±0.5 minutes, 11±0.5 minutes, 13±0.5 minutes, 14±0.5 minutes, 14±0.5 minutes or 15±0.5 minutes.

[0337] In one embodiment, a VH3 binding polypeptide or VH3 binding polypeptide multimer as disclosed herein is provided, which exhibits an alkaline stability of at least 35%, such as at least 40%, such as at least 40%, such as at least 45%, such as at least 50%, such as at least 55%, such as at least 60%, such as at least 65%, such as at least 70%, such as at least 75%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95% of the alkaline stability of SEQ ID NO: 88 or SEQ ID NO: 89 after incubation in 0.5 M NaOH, such as after repeated incubation with 0.5 M NaOH. In one embodiment, after incubation in 0.5 M NaOH, the VH3 binding polypeptide or VH3 binding polypeptide multimer has an alkaline stability of at least 60%, such as at least 70%, such as at least 80%, such as at least 85%, such as at least 89%, such as at least 90%, such as at least 95%, such as at least 98%, such as at least 99% of the alkaline stability of SEQ ID NO: 88. In one embodiment, after incubation in 0.5 M NaOH, the VH3 binding polypeptide or VH3 binding polypeptide multimer has an alkaline stability of at least 60%, such as at least 70%, such as at least 80%, such as at least 85%, such as at least 89%, such as at least 90%, such as at least 95%, such as at least 98%, such as at least 99% of the alkaline stability of SEQ ID NO: 89. In one embodiment, after incubation in 0.5 M NaOH, the VH3 binding polypeptide or VH3 binding polypeptide multimer has an alkaline stability of at least 60%, such as at least 70%, such as at least 80%, such as at least 85%, such as at least 89%, such as at least 90%, such as at least 95%, such as at least 98%, such as at least 99% of the alkaline stability of SEQ ID NO: 88 and SEQ ID NO: 89. The skilled person will understand that the alkaline cleaning stability of the polypeptides disclosed herein can be tested and compared with the alkaline cleaning stability of SEQ ID NO: 88 or 89, for example as described in the accompanying examples.

[0338] In one embodiment, a VH3 binding polypeptide or VH3 binding polypeptide multimer as disclosed herein is provided, which retains at least 19%, such as at least 20%, such as at least 21%, such as at least 23%, such as at least 25%, such as at least 27%, such as at least 29%, such as at least 31%, such as at least 33%, such as at least 35%, such as at least 37%, such as at least 39%, such as at least 41%, such as at least 43%, such as at least 45%, such as at least 47%, such as at least 48%, such as at least 50% of its original VH3 binding capacity after incubation in 0.5M NaOH. In one embodiment, the incubation lasts for at least 12 hours, such as at least 24 hours, such as at least 36 hours, such as at least 48 hours, such as at least 72 hours, such as at least 96 hours or more. The incubation can be carried out, for example, at 22+ / -2°C. Thus, the extent of VH3 binding ability can be assessed, for example, after incubation of the VH3 binding polypeptide or multimer thereof in 0.5 M NaOH at 22°C for 24 hours.

[0339] In a third aspect of the present disclosure, provided are a polynucleotide encoding a VH3-binding polypeptide or a VH3-binding polypeptide multimer as described herein; an expression vector comprising the polynucleotide; and a host cell comprising the expression vector.

[0340] The present disclosure also encompasses a method of producing a VH3 binding polypeptide or a VH3 binding polypeptide multimer as described herein, comprising culturing the host cell under conditions that allow expression of the polypeptide or multimer from its expression vector, and isolating the polypeptide or multimer.

[0341] Alternatively, the VH3 binding polypeptides or multimers as disclosed herein can be produced by non-biological peptide synthesis using amino acids and / or amino acid derivatives with protected reactive side chains, the non-biological peptide synthesis comprising

[0342] - stepwise coupling of amino acids and / or amino acid derivatives to form a polypeptide according to the first aspect or a multimer according to the second aspect having protected reactive side chains,

[0343] - removing protecting groups from reactive side chains of the polypeptide or polymer, and

[0344] -Folding of polypeptides or polymers in aqueous solution.

[0345] In another aspect, the present invention discloses a separation matrix comprising a VH3 binding polypeptide according to any embodiment disclosed above coupled to a solid support. Such a matrix can be used to separate immunoglobulins or other VH3-containing proteins from, for example, a sample. Since the VH3 binding polypeptide or its multimer as disclosed herein has binding affinity for VH3 and has low or no binding affinity for Fc, the separation matrix can allow efficient separation of VH3-containing proteins from any Fc-containing proteins or impurities. As described above, the VH3 binding polypeptide exhibits improved alkaline stability, which will allow the use of highly alkaline conditions during cleaning of the separation matrix, which is essential for long-term repeated use in a bioprocess separation environment. The alkaline stability of the matrix can be assessed by measuring the immunoglobulin binding capacity or VH3 binding capacity before and after incubation in an alkaline solution at a specified temperature, such as 22+ / -2°C. Incubation may be carried out, for example, in 0.5 M or 1.0 M NaOH for a number of 5, 10 or 15 minute cycles, such as 50, 100, 200 or 300 cycles, corresponding to a total incubation time of 12.5, 25, 50 or 75 hours.

[0346] The VH3 binding capacity of the matrix after 96-100 15 minute incubation cycles or a total incubation time of 24 or 25 hours at 22+ / -2°C in 0.5M NaOH can be at least 80%, such as at least 85%, at least 90% or at least 95% of the VH3 capacity before incubation. The capacity of the matrix after a total incubation time of 24 hours at 22+ / -2°C in 1.0M NaOH can be at least 70%, such as at least 80% or at least 90% of the VH3 capacity before incubation. The VH3 binding capacity of the separation matrix can be measured as dynamic binding capacity (DBC). Therefore, the dynamic binding capacity of the separation matrix after 96-100 15 minute incubation cycles or a total incubation time of 24 or 25 hours at 22+ / -2°C can be at least 80%, such as at least 85%, at least 90% or at least 95% of its DBC before incubation. The DBC of the separation matrix after a total incubation time of 24 hours in 1.0 M NaOH at 22 + / - 2°C may be at least 70%, such as at least 80% or at least 90% of the DBC before incubation.

[0347] In one embodiment, the separation matrix comprises a VH3 binding polypeptide multimer, wherein each monomer comprises a VH3 binding polypeptide as defined herein. The multimer, which is a homopolymer or a heteropolymer, may be a dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer, nonamer or decamer. For example, the separation matrix may comprise a hexamer of a VH3 binding polypeptide coupled to a solid support. For example, the separation matrix may comprise a tetramer of a VH3 binding polypeptide coupled to a solid support. Each monomer of the VH3 binding polypeptide multimer may comprise a sequence A independently selected from any sequence A defined herein. In particular, the separation matrix may comprise a sequence selected from the following: SEQ ID NO: 1-82, such as selected from SEQ ID NO: 1-40 and 42-81, such as selected from SEQ ID NO: 1-15 and 42-56; such as selected from SEQ ID NO: 1-41, such as selected from SEQ ID NO: 1-40, such as selected from SEQ ID NO: 1-15. In one embodiment, the separation matrix comprises a sequence selected from the group consisting of: SEQ ID NO: 1, 2, 4-43 and 45-82; such as selected from the group consisting of: SEQ ID NO: 5-7, 9-11, 13-41, 46-48, 50-52 and 54-82; such as selected from the group consisting of: SEQ ID NO: 6-7, 10, 13-41, 47-48, 51 and 54-82; such as selected from the group consisting of: SEQ ID NO: 6-7, 10, 13, 15-41, 47-48, 51, 54 and 56-82; such as selected from the group consisting of: SEQ ID NO: 6, 10, 13, 15-41, 47, 51, 54 and 56-82; such as selected from the group consisting of: SEQ ID NO: 13, 15-41, 54 and 56-82; such as selected from the group consisting of: SEQ ID NO: 13, 15-40, 54 and 56-81; such as selected from the group consisting of: NO:13, 15, 54 and 56; or selected from SEQ ID NO:15-41 and 56-82; such as selected from SEQ ID NO:15-40 and 56-81 or selected from SEQ ID NO:15, 41, 56 and 82; or selected from SEQ ID NO:14, 15, 55 and 56.In one embodiment, the separation matrix comprises a sequence selected from the following: SEQ ID NO: 1, 2, 4-41; such as selected from SEQ ID NO: 5-7, 9-11, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13, 15-41; such as selected from SEQ ID NO: 6, 10, 13, 15-41; such as selected from SEQ ID NO: 13, 15-41; such as selected from SEQ ID NO: 13, 15-40; such as selected from SEQ ID NO: 13 and 15; or selected from SEQ ID NO: 15-41; such as selected from SEQ ID NO: 15-40 or selected from SEQ ID NO: 15 and 41; or selected from SEQ ID NO: 14 and 15. In one embodiment, the separation matrix comprises a sequence selected from the group consisting of SEQ ID NOs: 42-43 and 45-82; such as selected from the group consisting of SEQ ID NOs: 46-48, 50-52 and 54-82; such as selected from the group consisting of SEQ ID NOs: 47-48, 51 and 54-82; such as selected from the group consisting of SEQ ID NOs: 47-48, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 47, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 54 and 56-82; such as selected from the group consisting of SEQ ID NOs: 54 and 56-81; such as selected from the group consisting of SEQ ID NOs: 54 and 56; or selected from the group consisting of SEQ ID NOs: 56-82; such as selected from the group consisting of SEQ ID NOs 56-81 or selected from the group consisting of SEQ ID NOs: 56 and 82; or selected from the group consisting of SEQ ID NOs: 55 and 56. In one embodiment, the separation matrix comprises a sequence selected from SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or selected from SEQ ID NO: 54, SEQ ID NO: 55 or SEQ ID NO: 56. In one embodiment, the separation matrix comprises the sequence SEQ ID NO: 13. In one embodiment, the separation matrix comprises the sequence SEQ ID NO: 14. In one embodiment, the separation matrix comprises a VH3 binding polypeptide multimer, optionally a hexamer or a tetramer, wherein each monomer of the multimer comprises a sequence corresponding to SEQ ID NO: 15.

[0348] The separation matrix may comprise a sequence selected from the group consisting of SEQ ID NOs: 83-87. In one embodiment, the separation matrix comprises a VH3 binding polypeptide multimer, optionally a hexamer or a tetramer, wherein each monomer of the multimer comprises a sequence corresponding to any one of the above-mentioned sequences. In one embodiment, the separation matrix comprises a VH3 binding polypeptide multimer, optionally a hexamer or a tetramer, wherein each monomer of the multimer comprises a sequence corresponding to SEQ ID NO: 13. In one embodiment, the separation matrix comprises a VH3 binding polypeptide multimer, optionally a hexamer or a tetramer, wherein each monomer of the multimer comprises a sequence corresponding to SEQ ID NO: 14. In one embodiment, the separation matrix comprises a VH3 binding polypeptide multimer, optionally a hexamer or a tetramer, wherein each monomer of the multimer comprises a sequence corresponding to SEQ ID NO: 15. The separation matrix may comprise a sequence selected from the group consisting of SEQ ID NOs: 175-177, such as selected from the group consisting of SEQ ID NOs: 176 and 177. In one embodiment, the separation matrix comprises SEQ ID NO: 175. In one embodiment, the separation matrix comprises SEQ ID NO: 176. In one embodiment, the separation matrix comprises SEQ ID NO: 177. The skilled person will appreciate that the expressed VH3 binding polypeptide in monomeric or multimeric form should be purified to an appropriate degree before being affixed to a support. Such purification methods are well known in the art and are readily implemented using standard methods for affixing protein-based ligands to a support. Suitable methods and supports are discussed in more detail below and are disclosed, for example, in WO16079033, which is incorporated herein by reference.

[0349] The solid support of matrix according to the present invention can be any suitable well-known kind.As a non-limiting example, conventional affinity separation matrix usually has organic properties and is based on exposing the polymer of hydrophilic surface to the aqueous medium used, i.e., exposing hydroxyl (-OH), carboxyl (-COOH), carboxamido (-CONH2, possibly in N-substituted form), amino (-NH2, possibly in substituted form), few or polyethylene oxide groups on its external surface and (if present) internal surface.Solid support can be porous suitably.Porosity can be expressed as Kav or Kd value (the fraction of pore volume that can be utilized by probe molecules of specific size), measured by reversed-phase size exclusion chromatography, for example, according to Gel Filtration Principles and Methods, Pharmacia LKB Biotechnology 1991, the method described in pp 6-13.According to definition, Kd and Kav values ​​are all in the scope 0-1 all the time. The Kav value may advantageously be 0.6-0.95, for example 0.7-0.90 or 0.6-0.8, as measured using a dextran of Mw 110 kDa as a probe molecule. This has the advantage that the carrier has a large portion of pores that can accommodate the polypeptide / polymer of the invention and the immunoglobulin bound to the polypeptide / polymer and provide mass transfer of the immunoglobulin to and from the binding site.

[0350] The polypeptide or polymer can be attached to the carrier via conventional coupling techniques, for example, utilizing thiol, amino and / or carboxyl groups present in the ligand. Bisepoxides, epichlorohydrin, CNBr, N-hydroxysuccinimide (NHS), etc. are well-known coupling agents. A molecule called a spacer can be introduced between the carrier and the polypeptide / polymer, which will improve the availability of the polypeptide / polymer and promote the chemical coupling of the polypeptide / polymer to the carrier. Depending on the properties of the polypeptide / polymer and the coupling conditions, the coupling can be multi-point coupling (e.g., via multiple lysines) or single-point coupling (e.g., via a single cysteine).

[0351] Alternatively, the polypeptide / polymer may be attached to the support by non-covalent bonding, such as physical adsorption or biospecific adsorption.

[0352] In some embodiments, the matrix comprises 5-25, such as 5-20mg / ml, 5-15mg / ml, 5-11mg / ml or 6-11mg / ml polypeptide or polymer coupled to the carrier. The amount of the coupled polypeptide / polymer can be controlled by the concentration of the polypeptide / polymer used in the coupling process, by used activation and coupling conditions and / or by the pore structure of the carrier used. Generally speaking, the absolute binding capacity of the matrix increases with the amount of the coupled polypeptide / polymer, at least until the point at which the pore is significantly shrunk because of the coupled polypeptide / polymer. The relative binding capacity of every mg of coupled polypeptide / polymer will reduce under high coupling levels, resulting in achieving optimal cost-effectiveness within the scope specified above.

[0353] In certain embodiments, polypeptide or polymer is coupled to carrier via thioether bond.The method for carrying out such coupling is well known in the art, and those skilled in the art can easily carry out using standard techniques and equipment.Thioether bond is flexible and stable, and is generally suitable for affinity chromatography.Especially, when thioether bond is via the terminal or near-terminal cysteine ​​residue on polypeptide or polymer, the mobility of coupled polypeptide / polymer will be enhanced, thereby providing improved binding capacity and binding kinetics.In some embodiments, polypeptide / polymer is coupled via the C-terminal cysteine ​​provided on protein as described above.This allows the efficient coupling of cysteine ​​thiol and electrophilic group (for example, epoxy group, halohydrin group etc.) on carrier, thereby produces thioether bridge coupling.

[0354] In certain embodiments, the solid carrier comprises a polyhydroxy polymer, such as a polysaccharide. Examples of polysaccharides include, for example, dextran, starch, cellulose, pullulan, agar, agarose, etc. Polysaccharides are inherently hydrophilic, have a low degree of nonspecific interactions, they provide a high content of reactive (activatable) hydroxyl groups and they are generally stable to alkaline cleaning solutions used in bioprocessing. In some embodiments, the carrier comprises agar or agarose. The carrier used in the present invention can be easily prepared according to standard methods, such as reversed suspension gelation (S Hjerten: Biochim Biophys Acta 79 (2), 393-398 (1964)). Alternatively, the base matrix is ​​a commercially available product, such as SEPHAROSE®. TM FF(Cytiva TM ). In one embodiment that is particularly advantageous for large-scale separations, the support is modified using the methods described in US6602990 or US7396467 (these documents are hereby incorporated by reference in their entirety) to increase its rigidity and thus make the matrix more suitable for high flow rates.

[0355] In certain embodiments, the carrier (such as a polysaccharide or agarose carrier) is cross-linked, such as with hydroxyalkyl ether cross-links. The cross-linking reagent that produces such cross-links can be, for example, an epihalohydrin such as epichlorohydrin, a diepoxide such as butanediol diglycidyl ether, an allylation reagent such as an allyl halide or allyl glycidyl ether. Cross-linking is beneficial to the rigidity of the carrier and improves chemical stability. Hydroxyalkyl ether cross-links are alkali-stable and do not cause significant nonspecific adsorption.

[0356] Alternatively, the solid support is based on a synthetic polymer such as polyvinyl alcohol, polyhydroxyalkyl acrylate, polyhydroxyalkyl methacrylate, polyacrylamide, polymethacrylamide, etc. In the case of hydrophobic polymers, such as in the case of divinyl and monovinyl substituted benzene matrices, the surface of the matrix is ​​often hydrophilized to expose the hydrophilic groups as defined above to the surrounding aqueous liquid. Such polymers are easily prepared according to standard methods, see for example "Styrenebased polymer supports developed by suspension polymerization" (R Arshady:Chimica e L'Industria 70 (9), 70-75 (1988)). As an alternative, commercially available products such as SOURCE TM (Cytiva TM ). Alternatively, the solid support according to the present invention includes a support of inorganic nature, such as silicon dioxide, zirconium oxide, etc.

[0357] In one embodiment, the solid support has the form of a porous monolith. In an alternative embodiment, the support is in a beaded or granular form, which can be porous or non-porous. The solid support in beaded or granular form can be used as a packed bed or in a suspended form. Suspended forms include those that are referred to as expanded beds and pure suspensions, in which particles or beads move freely. In the case of monoliths, packed beds and expanded beds, separation procedures are usually followed by conventional chromatography with a concentration gradient. In the case of pure suspensions, batch mode will be used.

[0358] In one embodiment, the separation matrix is ​​a convection-based chromatography matrix. Such a convection-based chromatography matrix may include a porous polymer membrane, a fiber support or a fiber substrate. Examples of porous polymer membranes include Mustang from Pall TM Membranes and Sartobind from Sartorius TMThe fiber carrier may be based on electrospun polymer fibers or cellulose fibers, optionally nonwoven fibers. Thus, the fiber carrier may be a fibrous nonwoven polymer matrix. The fibers contained in the fiber carrier have a cross-sectional diameter of 10-1000 nm, such as 200-800 nm, 200-400 nm or 300-400 nm. Such fiber carriers can be found in HiTrap Fibro TM Unit (Cytiva TM ). Alternative fiber carriers are disclosed in, for example, WO2019 / 137869 and WO2018 / 011600.

[0359] In yet another embodiment, the solid support is in another form, such as a surface, a chip, a capillary, or a filter (eg, a membrane or a depth filter matrix).

[0360] In another aspect, the invention provides a method for separating immunoglobulins or fragments thereof, wherein a separation matrix as disclosed above is used. In some embodiments, the method comprises a) contacting a liquid sample containing immunoglobulins or fragments thereof with a separation matrix as disclosed above. The method may also comprise b) washing the separation matrix with a washing solution, c) eluting immunoglobulins from the separation matrix with an eluent, and optionally d) washing the separation matrix with a washing solution. The washing solution may alternatively be referred to as a cleaning in place (CIP) liquid. The contact (incubation) time may be at least 10 minutes.

[0361] The method may also include the following steps: before step a), an affinity separation matrix according to any of the above embodiments is provided and a solution comprising an immunoglobulin or a fragment thereof and at least one other substance is provided as a liquid sample, and after step c), the eluate is recovered and optionally subjected to a further separation step, such as by anion or cation exchange chromatography, multimodal chromatography and / or hydrophobic interaction chromatography. The suitable composition of the liquid sample, washing liquid and eluate and the general conditions for separation are well known in the field of affinity chromatography, particularly in the field of protein A chromatography. The liquid sample comprising a protein containing VH3 and at least one other substance may comprise a host cell protein (HCP), such as CHO cells, Escherichia coli or yeast protein. The content of CHO cells and Escherichia coli proteins can be conveniently determined by immunoassays for these proteins, such as CHO HCP or Escherichia coli HCP ELISA kits from Cygnus Technologies. Host cell proteins or CHO cells / Escherichia coli proteins can be desorbed during step b). Elution can be performed by using any suitable solution for eluting from the protein A medium. This can be, for example, a solution or buffer having a pH of 5 or less, such as pH 2.5-5 or 3-5. In some cases, it can also be a solution or buffer having a pH of 11 or more, such as pH 11-14 or pH 11-13. In some embodiments, the elution buffer or elution buffer gradient comprises at least one monofunctional, difunctional or trifunctional carboxylic acid or a salt of such a carboxylic acid. In certain embodiments, the elution buffer or elution buffer gradient comprises at least one anionic species selected from acetate, citrate, aminoacetate, succinate, phosphate and formate.

[0362] In some embodiments, the cleaning solution is alkaline, such as having a pH of 13 to 14. Such a solution provides effective cleaning of the substrate, particularly at the upper end of the interval.

[0363] In certain embodiments, the cleaning solution comprises 0.1-2.0 M NaOH or KOH, such as 0.5-2.0 or 0.5-1.0 M NaOH or KOH. These are highly effective cleaning solutions, particularly when the NaOH or KOH concentration is above 0.1 M or is at least 0.5 M. The high stability of the polypeptides of the invention enables the use of such strongly alkaline solutions.

[0364] The method may further comprise the step of sterilizing the substrate with a sterilizing solution, which may for example comprise a peroxide, such as hydrogen peroxide and / or a peracid, such as peracetic acid or performic acid.

[0365] In some embodiments, steps a)-d) are repeated at least 10 times, such as at least 50 times, 50-200 times, 50-300 times or 50-500 times. This is very important for process economy because the substrate can be reused many times. Steps a)-c) can also be repeated at least 10 times, such as at least 50 times, 50-200 times, 50-300 times or 50-500 times, and step d) is carried out after multiple steps c) so that step d) is carried out at least 10 times, such as at least 50 times. For example, step d) can be carried out every two to twenty steps c).

[0366] The method of separating immunoglobulins or fragments as disclosed herein can be used to separate fragments comprising at least one VH3 domain. Non-limiting examples of such fragments include Fab fragments, Fab' fragments, F(ab')2, scFab fragments, Fv fragments, scFv fragments, diabodies, triabodies and minibodies. The skilled person is familiar with other fragments that can be separated by this method. Therefore, in one embodiment of the method, the fragment is selected from Fab fragments, Fab' fragments, F(ab')2, scFab fragments, Fv fragments, scFv fragments, diabodies, triabodies and minibodies.

[0367] In particular, the present method may be suitable for separating immunoglobulins or fragments thereof, which are asymmetric immunoglobulins or fragments thereof. As used herein, the term "asymmetric immunoglobulin or fragment thereof" refers to such an immunoglobulin or fragment in which two different heavy chains or heavy chain fragments are paired. Such an immunoglobulin or fragment may be bispecific. An illustrative example of an asymmetric immunoglobulin is the asymmetric bispecific antibody Emicizumab (Chugai Pharmaceutical Co., Ltd.) for the treatment of hemophilia A. Emicizumab has two heavy chains, one of which is a VH3 class and one of which is a VH1 class. The present method allows for the efficient separation of correctly paired variants (VH3-VH1) by using the VH3 interactions of one of the heavy chains. In this way, homodimers (unwanted VH3-VH3 and VH1-VH1) and heterodimers (required VH3-VH1) variants can already be separated in the capture step, thereby simplifying the downstream process. Without being bound by theory, the separation principle is envisioned as follows: homodimers (VH1-VH1) do not bind and therefore enter the flow-through (FT); homodimers (VH3-VH3) bind with two interactions, thereby generating an avidity effect and therefore bind more tightly (stringent) than the correctly paired heterodimers VH1-VH3. Therefore, it is expected that the correctly paired heterodimers are eluted at milder elution conditions than the VH3-VH3 dimers, such as a milder pH. Therefore, by eluting with one or two gradients using step elutions with different pH, separation between VH1-VH3 and VH3-VH3 is achieved. This is illustrated in the attached Example 6. In particular, the ability of the low or eliminated VH3 binding polypeptides and multimers thereof to bind to the Fc region of trastuzumab as disclosed herein advantageously improves the purity of the isolated fractions because there is no or very low any promiscuous Fc interaction.

[0368] Thus, in one embodiment of the method, the immunoglobulin or fragment thereof is an asymmetric immunoglobulin or fragment thereof. In particular, the asymmetric immunoglobulin or fragment thereof comprises a VH3 region. In one embodiment, the asymmetric immunoglobulin or fragment thereof is a multispecific immunoglobulin or fragment thereof, such as at least a bispecific or trispecific immunoglobulin or fragment thereof.

[0369] As will be appreciated by the skilled person, the conditions to which the immunoglobulin and / or fragment thereof is subjected during the separation process may affect its target binding ability. Therefore, it may be beneficial to carry out the elution step c) under mild conditions, such as the mild pH conditions illustrated in the attached Example 4. Thus, in one embodiment of the method, the separation matrix comprises a VH3 binding polypeptide according to SEQ ID NO: 14 or a multimer comprising SEQ ID NO: 14, and the pH level at the time of elution is above 4, such as approximately in the range of 4.10-4.20, such as approximately 4.15. In another embodiment, the separation matrix comprises a VH3 binding polypeptide according to SEQ ID NO: 15 or a multimer comprising SEQ ID NO: 15, and the pH level at the time of elution is below 4, such as approximately in the range of 3.7-3.80, such as approximately 3.75.

[0370] In one embodiment of the methods described herein, wherein the method involves separation of an asymmetric immunoglobulin or fragment thereof, it is envisaged that the elution of the immunoglobulin or fragment thereof from the separation matrix is ​​performed in a pH gradient or by stepwise elution with at least two different pH levels. It should be understood that the method may involve elution of both or one of a symmetric immunoglobulin or fragment thereof and an asymmetric immunoglobulin or fragment thereof. Thus, in one embodiment, a method for separating an asymmetric immunoglobulin or fragment thereof is provided, comprising the steps of:

[0371] a) providing a liquid sample comprising a mixture of at least one symmetric immunoglobulin or a fragment thereof and at least one asymmetric immunoglobulin or a fragment thereof;

[0372] b) contacting the liquid sample with a separation matrix to which the symmetric immunoglobulin or fragment thereof and the asymmetric immunoglobulin or fragment thereof bind with different affinities, wherein the separation matrix is ​​as defined in claim 14;

[0373] c) eluting the immunoglobulin or fragment thereof from a separation matrix, whereby the symmetric immunoglobulin or fragment thereof and the asymmetric immunoglobulin or fragment thereof are at least partially eluted separately from each other, and optionally

[0374] d) washing the separation matrix with a washing solution.

[0375] It is envisaged that the elution of the immunoglobulin or fragment thereof from the separation matrix, whereby the symmetric immunoglobulin or fragment thereof and the asymmetric immunoglobulin or fragment thereof are at least partially separated from each other, can be performed based on pH, ionic strength or a combination of both properties. The skilled person is familiar with different elution techniques. For example, the elution can be performed using a gradient or by stepwise changing the eluent.

[0376] In one embodiment, a method is provided wherein step c) involves:

[0377] c) eluting the immunoglobulin or fragment thereof from the separation matrix with a pH gradient or a step elution with at least two different pH levels, whereby the symmetric immunoglobulin or fragment thereof and the asymmetric immunoglobulin or fragment thereof are at least partially eluted at different pH levels.

[0378] In one embodiment, the asymmetric immunoglobulin or fragment thereof comprises one VH3 domain. In one embodiment, the symmetric immunoglobulin or fragment thereof comprises at least two VH3 domains. In one embodiment, the symmetric immunoglobulin or fragment thereof comprises at least two VH3 domains or no VH3 domain. It should be understood that the VH3 domain is the VH3 domain of trastuzumab.

[0379] As mentioned above, the washing liquid can be NaOH or KOH, such as 0.5NaOH, or other suitable washing liquids known in the art and as discussed above for washing the separation matrix. It should be understood that the embodiments discussed above, such as those involving the elution buffer or gradient, the washing liquid, the optional step of disinfecting the matrix, and the number of times steps a)-c) or a)-d) are repeated, are equally important for the method of separating asymmetric immunoglobulins or fragments thereof as for the method of separating immunoglobulins or fragments thereof, and are not repeated here for the sake of brevity only.

[0380] It will be appreciated that step c) may comprise eluting one of the symmetric immunoglobulin or fragment thereof and the asymmetric immunoglobulin or fragment thereof but not the other. Thus, in one embodiment of the method as described herein, a method is provided comprising step c), step c) comprising eluting at least one of the symmetric immunoglobulin or fragment thereof and the asymmetric immunoglobulin or fragment thereof from a separation matrix at a pH level suitable for eluting one of the symmetric immunoglobulin or fragment thereof and the asymmetric immunoglobulin or fragment thereof but not the other, whereby the symmetric immunoglobulin or fragment thereof and the asymmetric immunoglobulin or fragment thereof are at least partially eluted at different pH levels.

[0381] In one embodiment of the method for separating asymmetric immunoglobulin or its fragment, the separation matrix is ​​as defined herein. As mentioned above, the method allows the efficient separation of immunoglobulin or its fragment that is paired in an undesirable manner (such as homopolymer pairing (also referred to as symmetry)) and immunoglobulin or its fragment that is paired in a desired manner (such as heteropolymer pairing, also referred to as asymmetry).

[0382] It should be understood that the properties of the resin used may affect the separation efficiency of the immunoglobulin or its fragment. For example, a solid carrier (e.g., agarose beads) characterized by smaller particles or beads can be used to improve resolution. Therefore, in one embodiment, the separation matrix comprises a solid carrier having a particle or bead size of at most 75 μm, such as at most 60 μm, such as at most 50 μm or less. In one embodiment, the particle or bead size is the diameter of the particle or bead. In one embodiment, the bead is agarose beads.

[0383] In a specific embodiment, a method for separating asymmetric immunoglobulins or fragments thereof as disclosed herein is provided, wherein no more than 25%, such as no more than 20%, such as no more than 15%, such as no more than 10% of the asymmetric immunoglobulins or fragments thereof are present in the same eluate as the symmetric immunoglobulins or fragments thereof. In a specific embodiment, a method for separating asymmetric immunoglobulins or fragments thereof as disclosed herein is provided, wherein no more than 25%, such as no more than 20%, such as no more than 15%, such as no more than 10%, such as no more than 5%, such as no more than 3% or less of the eluate contains both symmetric and asymmetric immunoglobulins or fragments thereof. For the sake of clarification, in this context, the eluate should be interpreted as the fraction containing the bulk of the protein that binds to the separation matrix after the protein sample is contacted with the separation matrix as disclosed herein. The other fractions are considered to be the flow-through.

[0384] In one embodiment, a method for isolating an asymmetric immunoglobulin or a fragment thereof is provided, wherein the asymmetric immunoglobulin or a fragment thereof is a multispecific immunoglobulin or a fragment thereof, such as at least a bispecific or trispecific immunoglobulin or a fragment thereof.

[0385] The terms "VH3 binding polypeptide" and "VH3 binding protein" refer to a polypeptide or protein, respectively, that is capable of binding to VH3 of an antibody, and include, for example, protein A, or any fragment or fusion protein thereof that retains the binding property.

[0386] The term "linker" refers herein to an element in a multimer that connects two polypeptide units, monomers or domains to each other.

[0387] The term "spacer" herein refers to an element that connects a polypeptide or polypeptide multimer to a carrier.

[0388] In the context of protein purification, the term "dynamic binding capacity (DBC)" of a chromatography column describes the maximum amount of target protein that can be loaded onto the column without unnecessary losses, measured under realistic experimental conditions (default flow rate, real protein sample).

[0389] Although the present invention has been described with reference to various exemplary aspects and embodiments, it will be appreciated by those skilled in the art that various changes may be made and that equivalents may be substituted for its elements without departing from the scope of the present invention. In addition, many modifications may be made to adapt specific situations or molecules to the teachings of the present invention without departing from its basic scope. Therefore, it is intended that the present invention is not limited to any particular embodiment contemplated, but will include all embodiments falling within the scope of the appended claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0390] Figure 1A Biacore analysis of VH3 binding polypeptides of the invention (SEQ ID NOs: 1 to 4) using 5000 nM trastuzumab Fc fragment as analyte is shown, compared to an alkaline wash stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab and a control that does not bind Fc (SEQ ID NO: 180). For clarity of presentation, the results of the Biacore analysis are shown in Figure 1A The data are shown in two figures, one figure including data corresponding to SEQ ID NO:88 and the other figure not including data corresponding to SEQ ID NO:88.

[0391] Figure 1B Shown is a Biacore analysis of VH3 binding polypeptides of the invention (SEQ ID NOs: 1 to 4) using 5000 nM trastuzumab Fab fragment as analyte, compared to a non-Fc binding control (SEQ ID NO: 180).

[0392] Figure 1C To use Biacore TM An exemplary graph of the alkaline wash stability evaluation of the tested alkaline wash stable VH3 binding polypeptides of the invention (SEQ ID NOs: 1 to 4) compared to an alkaline wash stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab and an alkaline wash unstable control that does not bind Fc (negative CTRL).

[0393] Figure 2A Biacore analysis of the VH3 binding polypeptides of the invention (SEQ ID NOs: 5 to 12) using 5000 nM trastuzumab Fc fragment as analyte is shown, compared to an alkaline wash stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab. For clarity of presentation, the results of the Biacore analysis are shown in Figure 2AThe data are shown in two figures, one figure including data corresponding to SEQ ID NO:88 and the other figure not including data corresponding to SEQ ID NO:88.

[0394] Figure 2B Biacore analysis of the VH3 binding polypeptides of the invention (SEQ ID NOs: 5 to 12) using 625 nM trastuzumab as analyte is shown, compared to an alkaline wash stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab. For clarity of presentation, the results of the Biacore analysis are shown in Figure 2B The data are shown in two figures, one figure including data corresponding to SEQ ID NO:88 and the other figure not including data corresponding to SEQ ID NO:88.

[0395] Figure 2C To use Biacore TM Exemplary graphs evaluating the tested alkaline wash stable VH3 binding polypeptides of the invention (SEQ ID NOs: 5 to 12) compared to an alkaline wash stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab and an alkaline wash unstable control that does not bind Fc (negative CTRL).

[0396] Figure 3A Biacore analysis of the VH3 binding polypeptides of the invention (SEQ ID NOs: 13 to 15) using 5000 nM trastuzumab Fc fragment as analyte is shown, compared to an alkaline wash stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab. For clarity of presentation, the results of the Biacore analysis are shown in Figure 3A The data are shown in two figures, one figure including data corresponding to SEQ ID NO:88 and the other figure not including data corresponding to SEQ ID NO:88.

[0397] Figure 3B Shown is Biacore analysis of VH3 binding polypeptides of the invention (SEQ ID NO: 10 and SEQ ID NOs: 13 to 15) using 2500 nM trastuzumab Fab fragment as analyte, compared to an alkaline wash stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab and an alkaline wash unstable control that does not bind Fc (negative CTRL).

[0398] Figure 3CShown is Biacore analysis of VH3 binding polypeptides of the invention (SEQ ID NO: 10 and SEQ ID NOs: 13 to 15) using 625 nM trastuzumab as analyte, compared to an alkaline wash stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab and an alkaline wash unstable control that does not bind Fc (negative CTRL).

[0399] Figure 3D To use Biacore TM An exemplary graph of the alkaline wash stability evaluation of the tested alkaline wash stable VH3 binding polypeptides of the invention (SEQ ID NO: 10 and SEQ ID NOs: 13 to 15) was compared to an alkaline wash stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab and an alkaline wash unstable control that does not bind Fc (negative CTRL).

[0400] Figure 4A Shown is the elution profile of an emicizumab feed comprising a VH1 / VH3 bispecific antibody and in addition a VH3 / VH3 mismatched homodimer using a pH gradient and a reference resin (SEQ ID NO: 181).

[0401] Figure 4B Shown is the elution profile of an emicizumab feed comprising a VH1 / VH3 bispecific antibody and furthermore a VH3 / VH3 mismatched homodimer using a pH gradient and a resin according to the invention wherein SEQ ID NO: 177 is coupled to a 60 μm agarose base matrix.

[0402] Figure 4C Shown is the elution profile of an emicizumab feed comprising a VH1 / VH3 bispecific antibody and furthermore a VH3 / VH3 mismatched homodimer using a pH gradient and a resin according to the invention wherein SEQ ID NO: 177 is coupled to a 50 μm agarose base matrix.

[0403] Figure 5 is a list of amino acid sequences of examples of VH3 binding polypeptides of the present disclosure (SEQ ID NOs: 1-82) and derivatives of domains A, B, C, D and E of Staphylococcus protein A (SEQ ID NOs: 83-87). In the VH3 binding polypeptides of the present disclosure, the deduced sequence A extends from residue 8 to residue 36 in each of SEQ ID NOs: 1-82. The amino acid sequence sequence B extends from residue 37 to residue 54, and the binding module sequence C predicted to constitute the complete three-helix bundle in each of these VH3 binding polypeptides extends from residue 8 to residue 54 of the 58-mer. Example

[0404] Summary of Examples 1-10

[0405] The following examples disclose the surprising identification of novel VH3 binding SpA derived polypeptides which exhibit no or significantly reduced affinity for the Fc region of immunoglobulins and which are alkaline washing stable.

[0406] A class of alkaline wash stable VH3 binding polypeptides was identified that showed abolished trastuzumab Fc binding (SEQ ID NOs: 1-4). The VH3 binding polypeptides (Fr1-4; SEQ ID NOs: 1-4) were evaluated for trastuzumab Fc binding, trastuzumab Fab binding, and alkaline wash stability ( Example 1 ).

[0407] Additional alkaline wash stable VH3 binding polypeptides were identified that showed no binding to the Fc fragment of trastuzumab (Fr5-12; SEQ ID NOs: 5-12). The VH3 binding polypeptides (Fr5-12, SEQ ID NOs: 5 to 12) were evaluated for trastuzumab Fc binding, trastuzumab binding, and alkaline wash stability ( Example 2 ).

[0408] Based on the VH3 binding polypeptide with improved alkaline washing stability (SEQ ID NO: 10), another group of alkaline washing stable VH3 binding polypeptides were identified that did not exhibit trastuzumab Fc binding and showed enhanced binding affinity to trastuzumab and to the Fab fragment of trastuzumab (Fr31-33; SEQ ID NO: 13-15). The VH3 binding polypeptides SEQ ID NO: 13-15 were evaluated in terms of trastuzumab Fc binding, trastuzumab Fab binding, trastuzumab binding and alkaline washing stability ( Example 3 ).

[0409] A subset of alkaline wash stable VH3 binding polypeptides with abolished Fc binding (Fr32 and Fr33; SEQ ID NOs: 14 and 15) were selected for further studies on the column. The further studies included multimerization of the polypeptides into tetramers and hexamers and expression of the multimers in E. coli. Preliminary characterization of these multimeric VH3 binding polypeptides (Fr32-4, Fr33-4 and Fr33-6; SEQ ID NOs: 175-177) was performed, wherein the dynamic binding capacity (DBC), pH elution and alkaline wash stability (DBC) of the multimers of the alkaline wash stable VH3 binding polypeptides were evaluated. Example 4 ).

[0410] A VH3 binding polypeptide multimer variant (Fr33-6; SEQ ID NO: 177) was selected for further study to evaluate the binding specificity to different VH1 and VH3 class target molecules ( Examples 5 and 6 ) and evaluate the binding specificity of VH1 / VH3 asymmetric bispecific antibodies ( Examples 6 and 7 ).

[0411] The effects of mutations in positions 9, 10, 11, 13, 14, 17, 18, 28 and 29 in different scaffolds (SEQ ID NOs: 89-94) were evaluated on trastuzumab Fc binding, trastuzumab Fab binding, trastuzumab binding and alkaline wash stability ( Examples 8 and 9 ).

[0412] Based on the sequence of Fr33 (SEQ ID NOs: 15 and 56), another novel class of VH3 binding polypeptides (SEQ ID NOs: 16-41 and SEQ ID NOs: 57-82) were generated with amino acid variations at positions 13, 14, and 26. The VH3 binding polypeptides (SEQ ID NOs: 16-41 and SEQ ID NOs: 57-82) were evaluated for trastuzumab Fc binding, trastuzumab Fab binding, trastuzumab binding, and alkaline wash stability ( Example 10 ).

[0413] Example 1

[0414] Biacore evaluation of VH3 binding peptides

[0415] summary

[0416] The effects of mutations were studied to identify amino acid positions that allowed reduced binding to the Fc region while retaining alkaline wash stability. As described in Table 1, a class of VH3 binding polypeptides derived from SEQ ID NO: 88 (Fr1-4, SEQ ID NOs: 1 to 4) were identified. The polypeptides were evaluated in terms of: trastuzumab Fc binding, trastuzumab Fab binding, and alkaline wash stability.

[0417] Table 1. Summary of mutations (SEQ ID NO: 1 to 4)

[0418]

[0419] The polypeptide variants (SEQ ID NOs: 1-4) were evaluated along with an alkaline wash stable positive control that binds both the Fc and Fab fragments of trastuzumab (SEQ ID NO: 88), a control that does not bind Fc (SEQ ID NO: 180), and an alkaline wash unstable control that does not bind Fc (negative CTRL).

[0420] The following aspects were evaluated:

[0421] (1) Affinity assessment of Fc interactions (tested by high concentration injection of Fc fragments generated from trastuzumab).

[0422] (2) Affinity assessment of Fab interactions (tested by high concentration injection of Fab fragments generated from trastuzumab).

[0423] (3) Alkaline cleaning stability (tested by the reduction in trastuzumab binding after increasing numbers of treatments with 0.5 M NaOH).

[0424] The inventors surprisingly discovered a novel class of VH3 binding SpA derived polypeptides (SEQ ID NOs: 1-4) having diversified amino acids at positions 9, 10, 11, 13, 14 and optionally at positions 17 and 18, which exhibit no affinity or significantly reduced affinity for the Fc region of trastuzumab without loss of alkaline washing stability.

[0425] Materials and methods

[0426] Generation of His-Purification Candidate Peptides

[0427] The materials and equipment used are as follows: glycerol stocks of SEQ ID NOs: 1 to 4; LB medium, 2YT medium, carbenicillin, IPTG 1M, 125 ml and 250 ml baffled glass shake flasks, Infors HT shaking incubator; His-GraviTrap TM and kits (Cytiva TM )、PD10 GraviTraps(Cytiva TM ).

[0428] 5 μl of glycerol stock of each variant was inoculated into 4 ml LB supplemented with 200 μg / ml carbenicillin in a 125 ml flask and incubated overnight at 37°C and 200 rpm.

[0429] Protein expression medium (2YT medium supplemented with 100ug / ml carbenicillin) was prepared and added to filled baffled shake flasks (50ml per flask, 20 flasks in total). Each flask was inoculated with approximately 500μl of the above overnight culture to obtain a starting OD600 of 0.05. The flasks were incubated in an Infors HT shaking incubator at 37°C and 130rpm for approximately 2.5 hours until the OD600 reached 0.7. Thereafter, 25μl IPTG (1M) was added and the flasks were incubated overnight in an Infors HT shaking incubator at 27°C and 130rpm, and then the cultures were pelleted (8000g, 5 minutes) and resuspended in 10ml PBS + 20mM imidazole in a Falcon tube. To generate crude variant lysates, Falcon tubes were incubated in a 80-85°C water bath for 10 minutes, followed by centrifugation at 10000 g for 10 minutes to pellet cell debris and filter the supernatant with a 0.2 μm filter.

[0430] Samples were purified using His GraviTraps and the kit according to the kit instructions (PBS + 20 mM imidazole was used as binding / washing buffer). Buffer exchange into PBS was performed using PD10 Gravitraps and the kit instructions.

[0431] The concentration of the buffer exchange samples was measured using a NanoDrop (Thermo Scientific) according to the manufacturer's instructions. After purification, the samples were kept in the refrigerator until all measurements were completed, and then they were transferred to eppendorf tubes and kept in the refrigerator.

[0432] Biacore analysis of binding affinity of Fc and Fab fragments of trastuzumab

[0433] To assess binding to Fc (SEQ ID NO: 184) and Fab (SEQ ID NO: 182 and 183), VH3 binding polypeptides (SEQ ID NO: 1 to 4) were immobilized on a Biacore CM5 chip. Trastuzumab Fc (5000 nM) and trastuzumab Fab (5000 nM) fragments were used as analytes.

[0434] pH detection under fixed conditions:

[0435] The materials and equipment used are as follows: VH3 binding polypeptide variants (SEQ ID NO: 1 to 4); Biacore TM CM5 chip (Cytiva TM ); Biacore with different pH TM Acetate buffer (Cytiva TM); Biacore TM 8K+ Instrument (Cytiva TM ).

[0436] The Biacore DNA was analyzed at different pH values ​​(pH 4.5, 5, 5.5) using the standard method defined in the software. TM pH scouting was performed at 8K+ and it was found that the pH corresponding to a pH one unit below the pI of the target ligand gave the best surface attraction.

[0437] Biacore binding analysis:

[0438] The materials and equipment used are as follows: CM5 sensor chip (Cytiva TM ), Biacore TM NHS conjugation kit (Cytiva TM ), VH3 binding polypeptide (SEQ ID NO: 1 to 4); Biacore TM 8K+(Cytiva TM ), Fab (prepared in-house from trastuzumab), Fc from trastuzumab.

[0439] Immobilization was performed using standard methods in the Biacore software, with VH3 binding polypeptide variants coupled in flow cell 2 (FC2) and activated / inactivated in flow cell 1 (FC1). VH3 binding polypeptide variants were diluted in acetate buffer at an appropriate pH (based on pH-scouting) in a concentration range of 10-30 μg / ml. The level of immobilization did vary between different polypeptide variants (approximately 600-1300 Ru).

[0440] In each run, peptides were immobilized in FC2 and multiple chips were used until all candidates were tested.

[0441] Biacore binding analysis TM method:

[0442] Running buffer: PBS-P+

[0443] Flow rate: 10 μl / min

[0444] Sample injection: 600 s / 10 min on both flow cells (FC1 and FC2)

[0445] Dissociation time: 600s / 10min

[0446] Regeneration: 10 mM glycine-HCl pH 1.5, 30 μl / min, 2x30 s

[0447] The analyte (Fab or Fc fragment of trastuzumab) was injected per channel (cycle) as follows: buffer, 156 nM, 313 nM, 625 nM, 1250 nM, 2500 nM, 5000 nM.

[0448] All sensorgrams were generated with reference subtraction, and the response was the difference between the pre-injection baseline and the signal immediately before the end of the injection.

[0449] Biacore analysis of alkaline cleaning stability

[0450] Alkaline cleaning stability was assessed by immobilizing the VH3 binding polypeptides (SEQ ID NOs: 1 to 4) on a CM5 Biacore chip followed by 100 repeated cycles of binding to trastuzumab (1 μM) followed by injection of NaOH (0.5 M).

[0451] The materials and equipment used are as follows: CM5 sensor chip (Cytiva TM ), Biacore TM NHS conjugation kit (Cytiva TM ), VH3 binding polypeptide (SEQ ID NO: 1 to 4); Biacore TM 8K+(Cytiva TM ); trastuzumab; 0.5MNaOH.

[0452] Immobilization was performed using standard methods in the Biacore software, with VH3 binding polypeptide variants coupled in FC2 and activated / inactivated in FC1. VH3 binding polypeptide variants were diluted in acetate buffer at the appropriate pH (based on pH scouting) in a concentration range of 10-30 μg / ml. The level of immobilization did vary between different polypeptide variants (approximately 600-1300 Ru).

[0453] Biacore method for alkaline stability (per cycle):

[0454] Running buffer: PBS-P+

[0455] Flow rate: 10 μl / min

[0456] Sample injection 1 (Trastuzumab 1 μM): 300 s on both flow cells

[0457] Dissociation time 1: 60s

[0458] Sample injection 2 (0.5M NaOH): 600 s on both flow cells

[0459] Regeneration: 10 mM glycine-HCl pH 1.5, 30 μl / min, 2x30 s

[0460] This cycle was repeated more than 100 times to track the stability of the trastuzumab response values.

[0461] All sensorgrams were generated with reference subtraction, and the response was the difference between the pre-injection baseline and the signal immediately before the end of the injection.

[0462] result

[0463] Biacore analysis of binding affinity of Fc and Fab fragments of trastuzumab

[0464] Figure 1A and Figure 1B The response levels of the trastuzumab Fc and Fab interactions of the VH3 binding polypeptide variants are depicted in Figure 1. The data show that the VH3 binding polypeptide variants SEQ ID NO: 1-4 exhibit significantly reduced or eliminated binding affinity to the Fc fragment of trastuzumab while retaining binding to the Fab fragment of trastuzumab. The positive reference SEQ ID NO: 88 shows binding to the Fc fragment of trastuzumab, which is 2000RU when injected. The control (SEQ ID NO: 180) that does not bind to Fc does not show interaction with Fc (0RU when injected) and weak binding to Fab, which is ~100RU when injected.

[0465] Biacore analysis of alkaline cleaning stability

[0466] The alkaline cleaning stability was visualized by plotting the normalized trastuzumab response values ​​(expressed as % of the response in cycle 2) from the second cycle to the last cycle run as described above. A positive control (SEQ ID NO: 88) that binds both Fc and Fab fragments and a control (negative CTRL) that is not unstable in alkaline cleaning and does not bind Fc were present as controls in each individual stability run. The trastuzumab response values ​​after 100 washing cycles are summarized in Table 2. Figure 1C Alkaline wash stability plots are shown for the tested VH3 binding polypeptide variants (SEQ ID NOs: 1 to 4) compared to SEQ ID NO: 88 and an alkaline wash unstable, non-Fc binding control (negative CTRL). In each cycle, 0.5 M NaOH was injected at 10 μl / min with a contact time of 10 minutes.

[0467] Table 2. Trastuzumab response values ​​after 100 cycles (expressed as % of the response in cycle 2)

[0468]

[0469] in conclusion

[0470] Novel VH3 binding polypeptides SEQ ID NOs: 1 to 4 were identified which did not show binding to the Fc region of trastuzumab but showed binding to the Fab fragment of trastuzumab.

[0471] SEQ ID NOs: 1 to 4 are alkaline wash stable, retaining at least 21.5% of their trastuzumab response (% bound) in cycle 2 after 100 wash cycles of 0.5 M NaOH at 10 μl / min with a contact time of 10 minutes.

[0472] It was concluded that at least the amino acid combinations at positions 9, 10, 11, 13, 14 and optionally 17 and 18 together as set out in Table 1 result in the advantageous properties of the VH3 binding polypeptides according to the invention: alkaline washing stability, at least the binding to the Fab fragment of trastuzumab is retained, and reduced or abolished binding to the Fc fragment of trastuzumab is exhibited.

[0473] Example 2

[0474] Biacore evaluation of VH3 binding peptides with improved alkaline wash stability

[0475] summary

[0476] Based on the results from the Biacore evaluation of the VH3 binding polypeptides (SEQ ID NOs: 1-4) as described in Example 1, eight additional VH3 binding polypeptides (Fr7-14; SEQ ID NOs: 5-12) were identified with diversified amino acids at seven positions (9, 10, 11, 13, 14, 17 and 18), as described in Table 3. The polypeptides were evaluated for: trastuzumab Fc binding, trastuzumab binding and alkaline wash stability.

[0477] Table 3. Summary of mutations (SEQ ID NO: 5 to 12)

[0478]

[0479] The polypeptide variants (SEQ ID NOs: 5-12) were evaluated along with an alkaline wash stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab and an alkaline wash unstable control that does not bind Fc (negative CTRL).

[0480] The following aspects were evaluated:

[0481] (1) Affinity assessment of Fc interactions (tested by high concentration injection of Fc fragments generated from trastuzumab).

[0482] (2) Affinity assessment of the trastuzumab interaction (tested by injecting high concentrations of trastuzumab).

[0483] (3) Alkaline cleaning stability (tested by the reduction in trastuzumab binding after increasing numbers of treatments with 0.5 M NaOH).

[0484] The inventors have surprisingly discovered additional novel VH3 binding polypeptides (SEQ ID NOs: 5-12) having diversified amino acids at positions 9, 10, 11, 13, 14 and optionally at 17 and 18 that exhibit binding to trastuzumab, exhibit significantly reduced or abolished affinity for the Fc region of trastuzumab, and are alkaline washing stable.

[0485] Materials and methods

[0486] Generation of His-Purification Candidate Peptides

[0487] The materials and equipment used are as follows: glycerol stock solutions of SEQ ID NOs: 5 to 12; LB medium, 2YT medium, carbenicillin, IPTG 1M, 125 ml and 250 ml baffled glass shake flasks, Infors HT shaking incubator; His-GraviTrap TM and kits (Cytiva TM )、PD10 GraviTraps(Cytiva TM ).

[0488] 5 μl of glycerol stock of each variant was inoculated into 4 ml LB supplemented with 200 μg / ml carbenicillin in a 125 ml flask and incubated overnight at 37°C and 200 rpm.

[0489] Protein expression medium (2YT medium supplemented with 100ug / ml carbenicillin) was prepared and added to filled baffled shake flasks (50ml per flask, 20 flasks in total). Each flask was inoculated with approximately 500μl of the above overnight culture to obtain a starting OD600 of 0.05. The flasks were incubated in an Infors HT shaking incubator at 37°C and 130rpm for approximately 2.5 hours until the OD600 reached 0.7. Thereafter, 25μl IPTG (1M) was added and the flasks were incubated overnight in an Infors HT shaking incubator at 27°C and 130rpm, and then the cultures were pelleted (8000g, 5 minutes) and resuspended in 10ml PBS + 20mM imidazole in a Falcon tube. To generate crude variant lysates, Falcon tubes were incubated in a 80-85°C water bath for 10 minutes, followed by centrifugation at 10000 g for 10 minutes to pellet cell debris and filter the supernatant with a 0.2 μm filter.

[0490] Samples were purified using His GraviTraps and the kit according to the kit instructions (PBS + 20 mM imidazole was used as binding / washing buffer). Buffer exchange into PBS was performed using PD10 Gravitraps and the kit instructions.

[0491] The concentration of the buffer exchange samples was measured using a NanoDrop (Thermo Scientific) according to the manufacturer's instructions. After purification, the samples were kept in the refrigerator until all measurements were completed, and then they were transferred to eppendorf tubes and kept in the refrigerator.

[0492] Biacore analysis of the Fc fragment of trastuzumab and the binding affinity to trastuzumab

[0493] To assess binding to the Fc fragment of trastuzumab and to trastuzumab, the VH3 binding polypeptides were immobilized on a Biacore CM5 chip. Trastuzumab Fc fragment (5000 nM) and trastuzumab (625 nM) were used as analytes.

[0494] pH detection under fixed conditions:

[0495] The materials and equipment used are as follows: VH3 binding polypeptide variants (SEQ ID NO: 5-12); Biacore CM5 chip (Cytiva TM ); Biacore acetate buffer with different pH (Cytiva TM ); Biacore TM 8K+ Instrument (Cytiva TM ).

[0496] The Biacore DNA was analyzed at different pH values ​​(pH 4.5, 5, 5.5) using the standard method defined in the software. TM pH scouting was performed at 8K+ and it was found that the pH corresponding to a pH one unit below the pI of the target ligand gave the best surface attraction.

[0497] Biacore binding analysis:

[0498] The materials and equipment used are as follows: CM5 sensor chip (Cytiva TM ), Biacore TM NHS conjugation kit (Cytiva TM ), VH3 binding polypeptide (SEQ ID NO: 5 to 12); Biacore TM 8K+(Cytiva TM ); Fc from trastuzumab (SEQ ID NO: 184); trastuzumab (SEQ ID NOs: 178 and 179).

[0499] Immobilization was performed using standard methods in the Biacore software, with VH3 binding polypeptide variants coupled in FC2 and activated / inactivated in FC1. VH3 binding polypeptide variants were diluted in acetate buffer at an appropriate pH (based on pH-scouting) in a concentration range of 10-30 μg / ml. The level of immobilization did vary between different polypeptide variants (approximately 600-1300 Ru).

[0500] In each run, peptides were immobilized in FC2 and multiple chips were used until all candidates were tested.

[0501] Biacore method for binding analysis:

[0502] Running buffer: PBS-P+

[0503] Flow rate: 10 μl / min

[0504] Sample injection: 600 s / 10 min on both flow cells (FC1 and FC2)

[0505] Dissociation time: 600s / 10min

[0506] Regeneration: 10 mM glycine-HCl pH 1.5, 30 μl / min, 2x30 s

[0507] The analyte (Trastuzumab or Fc fragment of Trastuzumab) was injected per channel (cycle) as follows: buffer, 156 nM, 313 nM, 625 nM, 1250 nM, 2500 nM, 5000 nM.

[0508] All sensorgrams were generated with reference subtraction, and the response was the difference between the pre-injection baseline and the signal immediately before the end of the injection.

[0509] Biacore analysis of alkaline cleaning stability

[0510] By immobilizing VH3 binding polypeptides (SEQ ID NO: 5-12) on CM5 Biacore TM The alkaline cleaning stability was evaluated by repeated cycles of 100 bindings with trastuzumab (1 μM) followed by injection of NaOH (0.5 M) on the chip.

[0511] The materials and equipment used are as follows: CM5 sensor chip (Cytiva TM ), Biacore TM NHS conjugation kit (Cytiva TM ), VH3 binding polypeptide (SEQ ID NO: 5-12); Biacore TM 8K+(Cytiva TM ); trastuzumab; 0.5MNaOH.

[0512] Immobilization was performed using standard methods in the Biacore software, with VH3 binding polypeptide variants coupled in FC2 and activated / inactivated in FC1. VH3 binding polypeptide variants were diluted in acetate buffer at the appropriate pH (based on pH scouting) in a concentration range of 10-30 μg / ml. The level of immobilization did vary between different polypeptide variants (approximately 600-1300 Ru).

[0513] Biacore method for alkaline stability (per cycle):

[0514] Running buffer: PBS-P+

[0515] Flow rate: 10 μl / min

[0516] Sample injection 1 (Trastuzumab 1 μM): 300 s on both flow cells

[0517] Dissociation time 1: 60s

[0518] Sample injection 2 (0.5M NaOH): 600 s on both flow cells

[0519] Regeneration: 10 mM glycine-HCl pH 1.5, 30 μl / min, 2x30 s

[0520] This cycle was repeated more than 100 times to track the stability of the trastuzumab response values.

[0521] All sensorgrams were generated with reference subtraction, and the response was the difference between the pre-injection baseline and the signal immediately before the end of the injection.

[0522] result

[0523] Biacore analysis of the Fc fragment of trastuzumab and the binding affinity to trastuzumab

[0524] Figure 2A and Figure 2B The response levels of the interaction of the Fc fragment of trastuzumab and trastuzumab with VH3 binding polypeptide variants (SEQ ID NOs: 5 to 12) are depicted in Figure 1. The data show that the novel VH3 binding polypeptide variants (SEQ ID NOs: 5 to 12) exhibit significantly reduced or eliminated binding affinity to the Fc fragment of trastuzumab while retaining binding to trastuzumab. The positive reference (SEQ ID NO: 88) exhibits binding to both Fc and trastuzumab, at >2000RU and >6000RU, respectively, when injected.

[0525] Biacore analysis of alkaline cleaning stability

[0526] The alkaline cleaning stability was visualized by plotting the normalized trastuzumab response values ​​(expressed as % of the response in cycle 2) from the second cycle to the last cycle run as described above. A positive control (SEQ ID NO: 88) that binds both Fc and Fab fragments and a control (negative CTRL) that is not unstable in alkaline cleaning and does not bind Fc were present as controls in each individual stability run. The trastuzumab response values ​​after 100 washing cycles are summarized in Table 4. Figure 2C Shown is a graph of the alkaline wash stability of the tested VH3 binding polypeptide variants (SEQ ID NOs: 5 to 12) compared to an alkaline wash stable positive control (SEQ ID NO: 88) that binds both Fc and Fab fragments and an alkaline wash unstable control that does not bind Fc (negative CTRL). In each cycle, 0.5 M NaOH was injected at 10 μl / min with a contact time of 10 minutes.

[0527] Table 4. Trastuzumab response values ​​after 100 cycles (expressed as % of the response in cycle 2)

[0528]

[0529] in conclusion

[0530] Additional novel VH3 binding polypeptides (SEQ ID NOs: 5-12) were identified that did not show binding to the Fc fragment of trastuzumab, but did show binding to trastuzumab.

[0531] SEQ ID NO: 5-12 is alkaline wash stable, retaining at least 26% of its trastuzumab response (% bound) in cycle 2 after 100 wash cycles of 0.5 M NaOH at 10 μl / min with a contact time of 10 minutes.

[0532] It was concluded that at least the amino acid combination at positions 9, 10, 11, 13, 14 and optionally 17 and 18 as set out in Table 3 results in the advantageous properties of the VH3 binding polypeptides according to the invention herein: SEQ ID NO: 5-12 are alkaline washing stable, retain binding to trastuzumab but do not exhibit binding to the Fc fragment of trastuzumab.

[0533] Using information from the alkaline wash stability assay as well as the amino acid sequence information, it was concluded that at position X9X 10 X 11 –X 13 X 14 Scaffolds with the motif AQR-LA and at position X9X 10 X 11 –X 13 X 14 ––X 17 X 18 Scaffolds with the motif AYR-LA--AR in the scaffolds exhibited particularly desirable alkaline cleaning stability. 10 X 11 –X 13 X 14 ––X 17 X 18 VH3 binding polypeptides having a scaffold with the motif AYR-LA--AR in the peptides have the additional advantageous property that the presence of a tyrosine (Y in position 10) within the sequence allows the concentration of the VH3 binding polypeptide to be measured in a spectrophotometer.

[0534] Example 3

[0535] Biacore evaluation of VH3 binding peptides with enhanced binding affinity to trastuzumab Fab

[0536] summary

[0537] Based on the results from the Biacore evaluation of additional VH3 binding polypeptides (SEQ ID NOs: 5-12) as described in Example 2, three additional VH3 binding polypeptide variants (Fr31-33; SEQ ID NOs: 13 to 15) were identified with diversified amino acids at nine positions (9, 10, 11, 13, 14, 17, 18, 28 and 29), as described in Table 5. The polypeptides were evaluated for trastuzumab Fc binding, trastuzumab Fab binding, trastuzumab binding and alkaline wash stability.

[0538] Table 5. Summary of mutations (SEQ ID NO: 13 to 15)

[0539]

[0540] Polypeptide variants SEQ ID NOs: 13-15 were evaluated together with an alkaline wash stable positive control (SEQ ID NO: 88) that binds both Fc and Fab fragments and an alkaline wash unstable control that does not bind Fc (negative CTRL).

[0541] The following aspects were evaluated:

[0542] (1) Affinity assessment of Fc interactions (tested by high concentration injection of Fc fragments generated from trastuzumab).

[0543] (2) Affinity assessment of Fab interactions (tested by high-concentration injection of Fab fragments generated from trastuzumab)

[0544] (3) Affinity assessment of trastuzumab interaction (tested by high concentration injection of trastuzumab)

[0545] (4) Alkaline cleaning stability (tested by the reduction in trastuzumab binding after increasing numbers of treatments with 0.5 M NaOH).

[0546] The inventors surprisingly discovered additional novel VH3 binding polypeptides (SEQ ID NOs: 13 to 15) having diversified amino acids at nine positions (positions 9, 10, 11, 13, 14, 17, 18, 28 and 29) that exhibit even more desirable properties: are alkaline-wash stable, show binding to trastuzumab and to the Fab fragment of trastuzumab but do not exhibit affinity for the Fc region of trastuzumab.

[0547] Materials and methods

[0548] Generation of His-Purification Candidate Peptides

[0549] The materials and equipment used are as follows: glycerol stock solutions of SEQ ID NOs: 13 to 15; LB medium, 2YT medium, carbenicillin, IPTG 1M, 125 ml and 250 ml baffled glass shake flasks, Infors HT shaking incubator; His-GraviTrap TM and kits (Cytiva TM )、PD10 GraviTraps(Cytiva TM ).

[0550] 5 μl of glycerol stock of each variant was inoculated into 4 ml LB supplemented with 200 μg / ml carbenicillin in a 125 ml flask and incubated overnight at 37°C and 200 rpm.

[0551] Protein expression medium (2YT medium supplemented with 100ug / ml carbenicillin) was prepared and added to filled baffled shake flasks (50ml per flask, 20 flasks in total). Each flask was inoculated with approximately 500μl of the above overnight culture to obtain a starting OD600 of 0.05. The flasks were incubated in an Infors HT shaking incubator at 37°C and 130rpm for approximately 2.5 hours until the OD600 reached 0.7. Thereafter, 25μl IPTG (1M) was added and the flasks were incubated overnight in an Infors HT shaking incubator at 27°C and 130rpm, and then the cultures were pelleted (8000g, 5 minutes) and resuspended in 10ml PBS + 20mM imidazole in a Falcon tube. To generate crude variant lysates, Falcon tubes were incubated in a 80-85°C water bath for 10 minutes, followed by centrifugation at 10000 g for 10 minutes to pellet cell debris and filter the supernatant with a 0.2 μm filter.

[0552] Samples were purified using His GraviTraps and the kit according to the kit instructions (PBS + 20 mM imidazole was used as binding / washing buffer). Buffer exchange into PBS was performed using PD10 Gravitraps and the kit instructions.

[0553] The concentration of the buffer exchange samples was measured using a NanoDrop (Thermo Scientific) according to the manufacturer's instructions. After purification, the samples were kept in the refrigerator until all measurements were completed, and then they were transferred to eppendorf tubes and kept in the refrigerator.

[0554] Biacore analysis of the Fc and Fab fragments of trastuzumab and the binding affinity to trastuzumab

[0555] To assess binding to trastuzumab and to the Fc and Fab fragments of trastuzumab, VH3 binding polypeptides (SEQ ID NOs: 13 to 15) were immobilized on a Biacore TM On a CM5 chip, trastuzumab Fc fragment (5000 nM), trastuzumab Fab fragment (2500 nM) and trastuzumab (625 nM) were used as analytes.

[0556] pH detection under fixed conditions:

[0557] The materials and equipment used are as follows: VH3 binding polypeptide variants (SEQ ID NO: 13 to 15); Biacore TM CM5 chip (Cytiva TM ); Biacore acetate buffer with different pH (Cytiva TM ); Biacore TM 8K+ Instrument (Cytiva TM ).

[0558] The Biacore DNA was analyzed at different pH values ​​(pH 4.5, 5, 5.5) using the standard method defined in the software. TM pH scouting was performed at 8K+ and it was found that the pH corresponding to a pH one unit below the pI of the target ligand gave the best surface attraction.

[0559] Biacore binding analysis:

[0560] The materials and equipment used are as follows: CM5 sensor chip (Cytiva TM ), Biacore TM NHS conjugation kit (Cytiva TM ), VH3 binding polypeptide (SEQ ID NO: 13 to 15); Biacore TM 8K+(Cytiva TM ); Fab (made in-house from trastuzumab), Fc from trastuzumab, trastuzumab.

[0561] Immobilization was performed using standard methods in the Biacore software, with VH3 binding polypeptide variants coupled in FC2 and activated / inactivated in FC1. VH3 binding polypeptide variants were diluted in acetate buffer at an appropriate pH (based on pH-scouting) in a concentration range of 10-30 μg / ml. The level of immobilization did vary between different polypeptide variants (approximately 600-1300 Ru).

[0562] In each run, peptides were immobilized in FC2 and multiple chips were used until all candidates were tested.

[0563] Biacore method for binding analysis:

[0564] Running buffer: PBS-P+

[0565] Flow rate: 10 μl / min

[0566] Sample injection: 600 s / 10 min on both flow cells (FC1 and FC2)

[0567] Dissociation time: 600s / 10min

[0568] Regeneration: 10 mM glycine-HCl pH 1.5, 30 μl / min, 2x30 s

[0569] The analytes (Fab or Fc fragment of trastuzumab or trastuzumab) were injected per channel (cycle) as follows: buffer, 156 nM, 313 nM, 625 nM, 1250 nM, 2500 nM, 5000 nM.

[0570] All sensorgrams were generated with reference subtraction, and the response was the difference between the pre-injection baseline and the signal immediately before the end of the injection.

[0571] Biacore analysis of alkaline cleaning stability

[0572] Alkaline cleaning stability was assessed by immobilizing the VH3 binding polypeptides (SEQ ID NOs: 13 to 15) on a CM5 Biacore chip followed by 100 repeated cycles of binding to trastuzumab (1 μM) followed by injection of NaOH (0.5 M).

[0573] The materials and equipment used are as follows: CM5 sensor chip (Cytiva TM ), Biacore TM NHS conjugation kit (Cytiva TM ), VH3 binding polypeptide (SEQ ID NO: 13 to 15); Biacore TM 8K+(Cytiva TM ); trastuzumab; 0.5MNaOH.

[0574] Immobilization was performed using standard methods in the Biacore software, with VH3 binding polypeptide variants coupled in FC2 and activated / inactivated in FC1. VH3 binding polypeptide variants were diluted in acetate buffer at the appropriate pH (based on pH scouting) in a concentration range of 10-30 μg / ml. The level of immobilization did vary between different polypeptide variants (approximately 600-1300 Ru).

[0575] Biacore method for alkaline stability (per cycle):

[0576] Running buffer: PBS-P+

[0577] Flow rate: 10 μl / min

[0578] Sample injection 1 (Trastuzumab 1 μM): 300 s on both flow cells

[0579] Dissociation time 1: 60s

[0580] Sample injection 2 (0.5M NaOH): 600 s on both flow cells

[0581] Regeneration: 10 mM glycine-HCl pH 1.5, 30 μl / min, 2x30 s

[0582] This cycle was repeated more than 100 times to track the stability of the trastuzumab response values.

[0583] All sensorgrams were generated with reference subtraction, and the response was the difference between the pre-injection baseline and the signal immediately before the end of the injection.

[0584] result

[0585] Biacore analysis of the Fc and Fab fragments of trastuzumab and the binding affinity to trastuzumab

[0586] Figure 3A , Figure 3B and Figure 3C The response levels of the interaction of trastuzumab Fc, trastuzumab Fab and trastuzumab with VH3 binding polypeptide variants (SEQ ID NOs: 13 to 15) are depicted in FIG. The results show that the VH3 binding polypeptide variants (SEQ ID NOs: 13-15) exhibit significantly reduced or eliminated binding affinity to the Fc fragment of trastuzumab while retaining binding to trastuzumab and to the Fab fragment of trastuzumab. The alkaline-washed stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab shows binding to trastuzumab Fc, trastuzumab Fab and trastuzumab, respectively, at injection of >2000RU, >300RU and >6000RU.

[0587] Compared to the VH3 binding polypeptide tested in Example 2 (SEQ ID NO: 10), three additional VH3 binding polypeptides SEQ ID NO: 13 to 15 showed improved binding to trastuzumab and to trastuzumab Fab. Compared to the alkaline wash unstable control that does not bind to Fc (negative CTRL), SEQ ID NO: 13 and SEQ ID NO: 15 showed improved binding to both Fab and trastuzumab. Compared to the alkaline wash stable positive control SEQ ID NO: 88 that binds both Fc and Fab fragments, SEQ ID NO: 13 and SEQ ID NO: 15 showed improved binding to Fab. SEQ ID NO: 13 and SEQ ID NO: 15 showed trastuzumab response values ​​comparable to the positive control SEQ ID NO: 88.

[0588] Biacore analysis of alkaline cleaning stability

[0589] The stability was visualized by plotting the normalized trastuzumab response values ​​(expressed as % of the response in cycle 2) from the second to the last cycle run as described above. A base-cleaned stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab and a base-cleaned unstable control that does not bind Fc (negative CTRL) were present as controls in each individual stability run. The trastuzumab response values ​​after 100 wash cycles are summarized in Table 6. Figure 3D Alkaline wash stability plots of the tested VH3 binding polypeptide variants (SEQ ID NOs: 13-15) compared to an alkaline wash stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab and an alkaline wash unstable control that does not bind Fc (negative CTRL) are shown. In each cycle, 0.5 M NaOH was injected at 10 μl / min with a contact time of 10 minutes.

[0590] SEQ ID NO: 14 has an alkaline washing stability comparable to that of the VH3 binding polypeptide SEQ ID NO: 10 tested in Example 2. SEQ ID NO: 13 and SEQ ID NO: 15 have improved alkaline washing stability compared to the VH3 binding polypeptide SEQ ID NO: 10. SEQ ID NO: 13 and SEQ ID NO: 15 have an alkaline washing stability comparable to that of the alkaline washing stable positive control (SEQ ID NO: 88) that binds both Fc and Fab fragments. The VH3 binding polypeptides (SEQ ID NOs: 13 to 15) have higher alkaline washing stability than the alkaline washing unstable control (negative CTRL) that does not bind Fc.

[0591] Table 6. Trastuzumab response values ​​after 100 cycles (expressed as % relative to the response in cycle 2)

[0592] Peptides SEQ ID NO Binding % after 100 cycles Cycle 2 RU 88 52.6 3597 Fr33 15 50.7 3633 Fr31 13 48.3 3513 Fr32 14 31 1820 Negative CTRL 2 3322

[0593] in conclusion

[0594] Additional novel VH3 binding polypeptides (SEQ ID NOs: 13 to 15) did not show binding to trastuzumab Fc. Additional novel VH3 binding polypeptides (SEQ ID NOs: 13 to 15) showed improved binding to both Fab and trastuzumab compared to the VH3 binding polypeptide tested in Example 2 (SEQ ID NO: 10).

[0595] Additional VH3 binding polypeptides (SEQ ID NOs: 13 to 15) were alkaline wash stable, retaining at least 31% of their trastuzumab response in cycle 2 after 100 wash cycles of 0.5 M NaOH at 10 μl / min with a contact time of 10 minutes. SEQ ID NO: 14 had an alkaline wash stability comparable to that of the VH3 binding polypeptide SEQ ID NO: 10. SEQ ID NOs: 13 and 15 had improved alkaline wash stability compared to the VH3 binding polypeptide SEQ ID NO: 10. SEQ ID NOs: 13 and 15 showed improved binding to trastuzumab Fab compared to an alkaline wash stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab.

[0596] In conclusion, the presence of at least the amino acids at positions 9, 10, 11, 13, 14, 17, 18, 28 and 29 as set out in Table 5 leads to the advantageous properties of the VH3 binding polypeptides according to the invention herein: said VH3 binding polypeptides SEQ ID NOs: 13-15 showing even more improved alkaline washing stability properties show binding to the Fab fragment of Trastuzumab but do not show binding to the Fc fragment.

[0597] Based on the sequence information shown in Table 5 and the results presented in Example 3, it was concluded that the VH3 binding polypeptides comprising glycine (G) at position 29 (SEQ ID NO: 13 and 15) showed surprisingly high binding affinity to trastuzumab and to the Fab fragment of trastuzumab compared to the VH3 binding polypeptide comprising alanine (A) at position 29 (SEQ ID NO: 14) and compared to the alkaline washing stable positive control (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab. It was also concluded that the VH3 binding polypeptide comprising alanine (A) at position 28 and glycine (G) at position 29 (SEQ ID NO: 15) had surprisingly superior properties in terms of alkaline washing stability compared to the VH3 binding polypeptide comprising asparagine (N) at position 28 and glycine (G) at position 29.

[0598] Example 4

[0599] Evaluation of VH3 binding polypeptide multimeric variants by chromatography

[0600] summary

[0601] A subset of alkaline wash stable VH3 binding polypeptides with abolished Fc binding (Fr32 and Fr33; SEQ ID NOs: 14 and 15) were selected for further studies on the column. The further studies included multimerization of the polypeptides into tetramers and hexamers and expression of the multimers in E. coli. These multimeric VH3 binding polypeptides (SEQ ID NOs: 175 to 177) were initially characterized, where the dynamic binding capacity (DBC), pH elution and alkaline wash stability of the ligands were evaluated.

[0602] The effect of the A29G mutation on the DBC and elution pH of VH3 binding polypeptide tetramers (SEQ ID NOs: 175 and 176) was studied using trastuzumab in a pH gradient. The DBC and elution pH of a VH3 binding polypeptide hexamer (SEQ ID NO: 177) were tested using trastuzumab and different target molecules in a pH gradient. In addition, the alkaline cleaning stability of SEQ ID NO: 177 was tested by incubation with 0.5M NaOH for 4 hours followed by DBC measurement. A hexamer (SEQ ID NO: 181) of an alkaline cleaning stable polypeptide (SEQ ID NO: 88) bound to both the Fc and Fab fragments of trastuzumab was used as a control.

[0603] Materials and methods

[0604] Plasmid and cell banks

[0605] A subset of H6C-tagged polymer candidate variants were prepared according to the general recipe. In particular, tetramers of SEQ ID NO: 14 and tetramers and hexamers of SEQ ID NO: 15, respectively constituting sequences according to SEQ ID NO: 175 to 177, were ordered from ATUM (Newark, CA, USA) as DNA synthetic plasmids. The plasmids were transformed into chemically competent E. coli K12-017 cells and a research cell bank was prepared according to standard procedures.

[0606] Fermentation

[0607] Fermentations were performed using the above multimeric candidates with a continuous midstream step.

[0608] Seed culture was prepared in a 500 mL baffled shake flask containing 100 mL Terrific Broth (TB), 100 μL kanamycin (50 mg / mL) and 100 μL SEQ ID NO: 175-177 research cell bank (RCB). The seed culture was incubated for 15 hours at 37 ° C and 180 rpm agitation until a final OD600 value of about 20. The fermentation medium was prepared and sterilized at 121 ° C for 20 minutes in the reactor, followed by the addition of additives. The reactor was inoculated with an OD600 of 0.2. The initial conditions for the culture were 37 ° C, pH 7.1, 300 RPM stirring, 1 L / min aeration, and DO was kept constant at 30%. When the glucose level in the reactor was less than 1 g / L, a glucose feed of 0.3 / h specific growth rate was started. Protein expression was induced using isopropyl bD-thiogalactopyranoside (IPTG) at a final concentration of 1 mM. The cultivation was stopped after 25 hours and the reactor was heat treated.

[0609] Clarification of heat-treated fermentation media

[0610] Use a connection to 3600cm with a cutoff of 0.2 μM 2 Hollow fiber filter cartridge (Cytiva TM , Uppsala, Sweden The flux system clarifies the heat-treated fermentation medium. The fermentation broth is concentrated 3 times and then diafiltered with water. The retentate is concentrated until a pressure of 2 bar is reached. Sodium azide is added to the harvest to a final concentration of about 0.02% and then stored in a cold room. The clarified feed material is loaded on the first chromatography step.

[0611] Chromatographic purification

[0612] The construct was synthesized with hexa-histag and stained with Ni-agarose 6FF (Cytiva TM, Uppsala, Sweden) purification. The clarified feed was loaded onto Ni-agarose 6FF resin loaded in HiScale26 / 40 column. The column was balanced with 50mM phosphate, 500mM NaCl, pH 7.5, and then 300mL of clarified feed was loaded. The purified protein was eluted with a step gradient using 50mM phosphate, 500mM NaCl, pH 7.5 and 2M imidazole (Merck, Darmstadt, Germany). After being captured on the His-tag, the protein was further purified on Source 15Q. The eluate of the capture step was reduced for 60 minutes at room temperature by adding a final concentration of 50mM DTT. After reduction, Sephadex G50 (Cytiva TM The samples were desalted to 25 mM Tris pH 8 and then loaded onto Source 15Q (Cytiva TM The protein was eluted from the resin using a salt gradient of 25 mM Tris pH 8, 500 mM NaCl. The final protein was cleared from E. coli HCPs, aggregates and truncated forms by a polishing step. The protein was purified using Vivaspin 20 (Cytiva TM The eluted protein was concentrated to a high concentration of about 50 g / L using a 5 kDa (5 kDa molecular weight cut-off) spin column. The concentrated protein was used for coupling to the base matrix.

[0613] Coupling

[0614] Use epoxide chemical method to carry out coupling on 60 μ m and 50 μ m agarose beads.Protein ligand is reduced in 50 ml Falcon tube.In 20 mL ligand solution (50 mg / mL), add 169 mg NaHCO 3 , 21 mg Na 2 CO 3 , 175 mg NaCl and 7 mg EDTA.Falcon tube is placed on roller stage for 5-10 minutes, then 77 mg DTT is added.Reduction is carried out>45 minutes.Then use the PD10 post that is filled with Sephadex G-25 (Cytiva, Uppsala, Sweden) to desalinate ligand solution.Determine the ligand content in desalted solution by measuring 276 nm UV absorption.Wash epoxy activated gel with 0.1 M phosphate, 1 mM EDTA pH 8.6 of 3-5 gel volume (GV), and then according to the method coupling ligand described in US6399750.After fixing, use distilled water (3xGV) washing resin. The resin was mixed with 1 GV of 0.1 M phosphate, 1 mM EDTA, 10% thioglycerol pH 8.6 and the tube was left in a shaker overnight at room temperature. The resin was then washed alternately with 3 x GV of 0.1 M TRIS, 0.15 M NaCl pH 8.6 and 0.5 M HAc, followed by 8-10 x 1 GV of distilled water. The resin sample was sent for amino acid analysis and the ligand density (LD) was calculated based on the total amino acid content (mg / mL) in the resin.

[0615] Column packing and sampling with 1 mL cubes

[0616] To load the same volume of resin each time, a 50% resin slurry was prepared and loaded in 1 mL cubes using a set vacuum. A 1 ml cube of resin sample was transferred to a Tricorn column (Cytiva TM , Uppsala, Sweden).

[0617] Control of column packing

[0618] Check the packing of the column by injecting 0.8M NaCl solution into the column and calculating the asymmetry of the resulting peak. Equilibrate the column with 2CV 0.4M NaCl at a flow rate of 1mL / min. Inject 10μl of 0.8M NaCl solution at a flow rate of 20cm / h. Then use System (Cytiva TM , Uppsala, Sweden) to evaluate plate height and peak asymmetry factor.

[0619] Preparation of trastuzumab

[0620] The purified mAb solution was diluted in PBS (Medicago, Uppsala, Sweden) and filtered through a 0.2 μm syringe filter. Pure25 System (Cytiva TM The concentration was determined by measuring the UV maximum at 280 nm on a ELISA kit (University of Uppsala, Sweden).

[0621] DBC measurement

[0622] DBC measurement is carried out in Tricorn 5 / 50 post. Balance the post with PBS buffer. Trastuzumab, trastuzumab Fab fragment or nano antibody are loaded to the post via a sample pump to realize the required flow rate (usually 0.166mL / min) of 6 minutes of residence time (depending on the bed height of the post), until the UV signal reaches about 20% of the maximum value. The post is then washed with PBS buffer with a flow rate of 1mL / min. Eluted protein with elution buffer (50mM sodium citrate, pH 2.5) with a flow rate of 1mL / min. Clean the post with 0.1M NaOH with a flow rate of 0.166mL / min, continue for 15 minutes, then rebalance with PBS buffer.

[0623] pH-elution using a gradient

[0624] pH elution measurement is carried out in Tricorn 5 / 50 post.Use PBS buffer balance post.About 10mg trastuzumab, trastuzumab Fab fragment or nano antibody is loaded to post with the required flow rate (usually 0.166mL / min) of realizing 6 minutes residence time via sample pump.Then wash post with PBS buffer with the flow velocity of 1mL / min.Elute protein with the elution gradient of 50mM sodium citrate pH6.5 to 50mM sodium citrate pH 2.5 with the flow velocity of 1mL / min.Clean post with 0.1M NaOH with the flow velocity of 0.166mL / min, continue 15 minutes, rebalance with PBS buffer subsequently.Elution pH is determined as the top of elution peak.

[0625] Accelerating NaOH research

[0626] The accelerated NaOH study was performed by running an initial DBC test to measure the resin capacity at a set residence time, followed by filling the column with 0.5 M NaOH. When the column was completely filled, the flow was stopped, the column was incubated in NaOH for 4 hours, then re-equilibrated with PBS and a new DBC measurement was performed. This iteration was continued until the column had been incubated in 0.5 M NaOH for a total of 24 hours.

[0627] result

[0628] Evaluation of VH3 binding peptide tetramers by chromatography

[0629] The tetramer variants (SEQ ID NO: 175 and SEQ ID NO: 176) were evaluated using DBC measurement and pH elution. The results are summarized in Table 7.

[0630] Table 7. The reference resin was SEQ ID NO: 181. The two test resins SEQ ID NO: 175 and SEQ ID NO: 176 showed only VH3 interactions. DBC was measured with trastuzumab at a residence time (RT) of 6 minutes and 10% breakthrough. pH elution was measured using approximately 10 mg of trastuzumab. Ligand density (LD) is shown.

[0631]

[0632] Evaluation of VH3 binding peptide hexamer by chromatography

[0633] The hexameric variant (SEQ ID NO: 177) coupled resin was loaded into the column and preliminarily tested for dynamic binding capacity (DBC) for trastuzumab, trastuzumab Fab and variable heavy chain fragment (VHH). The results are summarized in Table 8.

[0634] Table 8. Dynamic binding capacity results for SEQ ID NO: 177 compared to SEQ ID NO: 181 on 60 μm agarose beads. Ligand density (LD) and DBC are shown.

[0635]

[0636] Analysis of the stability of on-column alkaline cleaning

[0637] An accelerated NaOH study was performed to test the alkaline cleaning stability of Fr33-6 (SEQ ID NO: 177) on beads. SEQ ID NO: 181 was used as a reference. In this study, DBC was measured at 6 minutes at room temperature, followed by a 4-hour incubation in 0.5 M NaOH with DBC measurements between each incubation. The resin was incubated for a total of 24 hours. The results from the alkaline cleaning stability study are shown in Table 9.

[0638] Table 9. Summary of DBC values ​​for SEQ ID NO: 177 compared to SEQ ID NO: 181 at the beginning and after 4 hours incubation with 0.5 M NaOH

[0639]

[0640]

[0641] in conclusion

[0642] Column studies showed that the single A29G mutation of SEQ ID NO: 175 to SEQ ID NO: 176 resulted in a decrease in elution pH, thereby indicating a higher affinity. This higher affinity was also shown in Example 3 using Biacore. In addition, the increased affinity of SEQ No: 177 compared to the reference resulted in an increased capacity for single 1: 1 interactions such as Fab, VHH or bispecific antibodies (Table 8). Surprisingly, these mutations can be made on the backbone without significantly reducing the alkaline wash stability of the protein (Table 9).

[0643] Example 5

[0644] Evaluation of Selective VH Interactions of VH3 Binding Peptides on Biacore summary

[0645] Antibodies are composed of heavy chains (HC) and light chains (LC), wherein HC is composed of three constant domains (CH1-CH3) and one variable domain (VH), and LC is composed of one constant domain (CL) and one variable domain (VL). Most of the changes in the IgG1 antibody framework are in VH and VL. Trastuzumab and adalimumab are both IgG1 antibodies with VH class 3 and VLκI. Although both trastuzumab and adalimumab have VH3 frameworks, trastuzumab and adalimumab differ in some amino acid positions, including two positions 57 and 64 (according to the Kabat numbering system) for VH3 interactions of the protein A domain (Table 10).

[0646] Table 10. Shows the amino acid residues at the Kabat positions as indicated for antibodies of the VH3 class including trastuzumab and adalimumab. Common and trade names of the antibodies are indicated.

[0647]

[0648] Even though there is a high degree of similarity between trastuzumab and adalimumab, the selective binding of the VH3 binding polypeptide or its multimer of the present invention to the VH3 domain is different for the antibodies. Adalimumab does not bind to the VH3 binding polypeptide multimer according to the present invention. Similarly, other non-VH3 antibodies such as brosuoyumab (IgG1, VH1, κI), vedolizumab (IgG1, VH1, κII) do not bind to the VH3 binding polypeptide of the present invention. On the other hand, antibodies (such as those described in Table 10) that have more sequence differences than trastuzumab but exhibit the same VH3 domain amino acid sequence as adalimumab show binding to the VH3 binding polypeptide and its multimer according to the present invention. Examples of such antibodies are avelumab (IgG1, VH3, λII) and dupilumab (IgG4, VH3, κII).

[0649] In the following example, a representative polypeptide according to the present disclosure (SEQ ID NO: 177) was immobilized on a Biacore TM The VH3 domain of the mAb from Table 10 was selected from the surface of the chip and studied for its binding selectivity compared to other non-binding mAbs. It is expected that the VH3 binding polypeptide multimer (SEQ ID NO: 177) does not show binding affinity to adalimumab, brosuzumab and vedolizumab, but binds to trastuzumab, avelumab and dupilumab, indicating that the VH3 binding polypeptide multimer binds to the VH3 region of the mAb of trastuzumab, which is also present in avelumab and dupilumab.

[0650] Materials and methods

[0651] To assess binding to VH3, VH3 binding peptides were immobilized on a Biacore TM On a CM5 chip. Different mAbs (5000 μM) were used as analytes at a flow rate of 10 μl / min for 10 min followed by a 10 min dissociation. After the run, the surface was regenerated by 2 injections of 10 mM glycine pH 1.5.

[0652] result

[0653] It is expected that the present data show that the VH3 binding polypeptide multimer (SEQ ID NO: 177) binds to trastuzumab, avelumab and dupilumab. However, it is expected that the VH3 binding polypeptide multimer does not bind to adalimumab, brosuzumab or vedolizumab.

[0654] in conclusion

[0655] Based on the expected results, it is concluded that the VH3 binding polypeptides and multimers thereof according to the present invention (as exemplified by SEQ ID NO: 177) specifically bind to the VH3 domain of trastuzumab. Trastuzumab and adalimumab are highly similar outside the VH3 domain and the VH3 binding polypeptides and multimers thereof do not bind to adalimumab, so it is concluded that the VH3 binding polypeptides and multimers specifically bind to the VH3 domain of trastuzumab.

[0656] VH3-class mAbs that differ greatly from trastuzumab outside the VH3 domain but have the same VH3 domain as trastuzumab (as presented in Table 10), such as avelumab and dupilumab, are expected to bind to the VH3 binding polypeptide multimer. The expected results show that the presence of residues I and E in Kabat positions 57 and 64, respectively, within the VH3 domain of adalimumab leads to the loss of its binding to the VH3 binding polypeptide multimer SEQ ID NO: 177. It is concluded that the VH3 binding polypeptide according to the present invention binds to the VH3 region of trastuzumab.

[0657] Example 6

[0658] Specificity testing of VH3-binding peptide multimers using VH1 and VH3 class targets

[0659] summary

[0660] Example 5 shows that certain mutations within the VH3 domain of trastuzumab are key to retaining trastuzumab VH3 binding. The specificity of VH3 binding polypeptide multimers can be tested by using targets with different sequences within the VH3 binding domain. In addition, the specificity of VH3 binding polypeptide multimers to VH3 targets can be tested by studying binding to both VH1 and VH3 targets and to VH1 / VH3 bispecific antibodies.

[0661] A panel of different commercial antibodies and one bispecific antibody were used to test whether the VH3 interaction of Fr33-6 (SEQ ID: 177) could be used to bind and elute the antibody from the column.

[0662] The following example shows that the VH3 binding polypeptide multimer (SEQ ID NO: 177) binds to a VH3 target having the same amino acids as trastuzumab in positions 15, 17, 19, 57, 59, 64, 65, 66, 68, 70, 81, 82a and 82b (according to the Kabat numbering system) of the VH3 domain. In addition, the results show that the VH3 binding polypeptide multimer does not bind to any tested target containing VH1, but retains the binding of the VH1 / VH3 bispecific antibody.

[0663] Materials and methods

[0664] Antibodies with different sequences in the VH3 binding domain (Table 11) and a panel of VH1 class antibodies were tested for binding to SEQ ID NO: 177 (trade names and suppliers are indicated in parentheses): Avelumab (Bavencio, Merck KGaA), Erenumab (Aimovig, Novartis), Dupilumab (Dupixent, Sanofi Genzyme), Denosumab (Xgeva, Amgen), Bevacizumab (Avastin, Roche), Adalimumab (Humira, AbbVie), Emicizumab (Hemlibra, Roche), Belimumab (Benlysta, GSK), Guselkumab (Tremfya, Jansen), Rituximab (Mabthera, Roche), Pembrolizumab (Keytruda, MSD).

[0665] Table 11. Shows the amino acid residues of eight antibodies at the Kabat positions as indicated. Common and trade names of the antibodies are indicated.

[0666]

[0667] Binding / elution (B / E) experiments were performed in a Tricorn 5 / 50 column. The column was balanced with PBS buffer. Afterwards, approximately 10 mg of mAb diluted to 1 mg / ml in PBS was loaded onto the column via a sample pump. The column was then washed with PBS buffer at a flow rate of 1 mL / min. The protein was eluted with 50 mM sodium citrate pH 2.5 at a flow rate of 1 mL / min. The column was cleaned with 0.1 M NaOH and then rebalanced with PBS buffer. Binding was defined as protein coming out of the elution pool, while non-binding was defined as protein entering the loaded flow-through (FT).

[0668] result

[0669] Antibodies with different sequences in the VH3 binding domain and a panel of VH1 class antibodies were tested for binding to SEQ ID NO: 177.

[0670] The results are summarized in Table 12. Four of the tested VH3 antibodies bind to SEQ ID NO: 177, namely, avelumab, efavirumab, dupilumab and denosumab. VH3-like targets (avelumab, dupilumab and denosumab) having the same amino acids as trastuzumab in positions 15, 17, 19, 57, 59, 64, 65, 66, 68, 70, 81, 82a and 82b (according to the Kabat numbering system) bind to the VH3 binding polypeptide multimer (SEQ ID NO: 177). The VH3-like target efavirumab having K in position 57 and S in position 59 also binds to the VH3 binding polypeptide multimer (SEQ ID NO: 177). Two of the VH3 class antibodies: avastin (which has a P in position 57 and an R in position 65) and humira (which has an I in position 57 and an E in position 64) did not bind to the VH3 binding polypeptide multimer (SEQ ID NO: 177).

[0671] The bispecific antibody hemlibra has a VH1 and a VH3 domain, which binds to a VH3 binding polypeptide multimer (SEQ ID NO: 177).

[0672] None of the four VH1 antibodies tested bound to the VH3 binding polypeptide multimer (SEQ ID NO: 177).

[0673] Table 12. Test binding specificity (binding / no binding) with several different commercial antibodies.

[0674]

[0675]

[0676] in conclusion

[0677] A representative VH3 binding polypeptide according to the present invention was tested. The VH3 binding polypeptide multimer (SEQ ID NO: 177) binds to VH3 class antibodies having the same amino acids as trastuzumab in positions 15, 17, 19, 57, 59, 64, 65, 66, 68, 70, 81, 82a and 82b (according to the Kabat numbering system) of the VH3 domain. It was confirmed that SEQ ID NO: 177 does not bind to VH1 class antibodies, but it binds to bispecific antibodies having at least one VH3 domain. It is concluded that the VH3 binding polypeptide according to the present invention binds to a VH3 region such as that present in trastuzumab.

[0678] It was also concluded that the VH3 interaction of the VH3 binding polypeptides according to the invention or multimers thereof (as exemplified herein by SEQ ID NO: 177) can be used to purify antibodies even if the Fc interaction is eliminated. This interaction is effective for some VH3 class antibodies, but not for all VH3 class antibodies. Furthermore, none of the VH1 class antibodies bound to the resin comprising SEQ NO: 177. Interestingly, bispecific antibodies with one binding arm can be purified in B / E mode, indicating that only one interaction is sufficient to be used as a purification tool.

[0679] Example 7

[0680] Separation of VH1 / VH3 bispecific antibodies from VH3 / VH3 homodimers using VH3 binding polypeptide multimers

[0681] summary

[0682] This example describes the separation of VH1 / VH1 and VH3 / VH3 homodimers and asymmetric bispecific antibody heterodimers composed of VH1 / VH3-like paired heavy chains. When producing asymmetric VH1 / VH3 bispecific antibodies, the two heavy chains must be correctly paired. The mispaired heavy chains are either VH1 / VH1 or VH3 / VH3 homodimers.

[0683] As shown in Example 6 and Table 12, the VH1 / VH1 homodimer does not show binding to SEQ ID NO: 177 and is therefore not bound by a resin coupled to an alkali-wash-stable VH3 binding polypeptide hexamer (SEQ ID NO: 177). In the following example, it is demonstrated that the VH3 / VH3 homodimer shows stronger binding to a resin coupled to an alkali-wash-stable VH3 binding polypeptide hexamer (SEQ ID NO: 177). Without being bound by theory, it is expected that this is due to the avidity effect resulting from the presence of two VH3 targets in the homodimer. Therefore, the VH3 / VH3 homodimer can be eluted at a lower pH in a gradient than the asymmetric VH1 / VH3 bispecific antibody.

[0684] It is concluded that the resin coupled to the alkali-wash-stable VH3-binding polypeptide or multimer thereof (e.g., hexamer SEQ ID NO: 177) has the advantageous property that it enables the simultaneous chromatographic separation of VH1 / VH1 and VH3 / VH3 homodimers from VH1 / VH3 heterodimers. By exploiting this effect of the resin, mismatched homodimers can be separated from correctly paired heterodimers. Thus, the resin comprising the alkali-wash-stable VH3-binding polypeptide or multimer thereof according to the present invention enables the purification of asymmetric VH1 / VH3 bispecific antibodies or fragments thereof in an advantageous manner using a single chromatographic step.

[0685] Emicizumab Separation of homodimers and heterodimers in the feed

[0686] Materials and methods

[0687] Emicizumab was ordered from Thermo Fisher (GeneArt, Regensburg, Germany) according to the published sequence (KEGG drug database). The bispecific antibody was produced in Expi293 cells and delivered in a 10-fold concentrated sterile filtered cell culture medium. The target protein concentration was about 1 g / L as measured by SDS-PAGE. The cell culture medium was loaded onto a control column containing a resin coupled to SEQ ID NO: 181 (as a reference for Fc and VH3 binding) or a column containing a resin coupled to SEQ ID NO: 177 that is bound only by VH3 interactions according to the present invention. The protein of SEQ ID NO: 177 was coupled to two agarose base matrices of 60 and 50 μm to see if the bead size would affect the resolution. Approximately 5 mL of feed was loaded onto a 1 mL column in a Tricorn 5 / 50 and eluted with a gradient from pH 6.5 to 2.5 using the following buffers: equilibration buffer, 20 mM sodium phosphate in 150 mM sodium chloride, pH 7.2; gradient from 50 mM sodium citrate pH 6.5 to 50 mM sodium citrate pH 2.5, followed by a wash with 0.5 M NaOH. After the cycle was complete, the column was regenerated again with the equilibration buffer. To separate homodimers from heterodimers, LC / MS was used to measure the mass of the protein in each elution fraction.

[0688] result

[0689] The Emicizumab feed contains VH1 / VH3 bispecific antibodies and in addition VH3 / VH3 mismatched homodimers. Using a control column containing a resin coupled to SEQ ID NO: 181, only one elution peak can be detected ( FIG. 4 ), SEQ ID NO: 181 being a hexamer of an alkali-cleaned stable polypeptide (SEQ ID NO: 88) that binds both the Fc and Fab fragments of trastuzumab. Therefore, in the control column containing a resin coupled to SEQ ID NO: 181, the VH1 / VH3 bispecific antibodies and the VH3 / VH3 mismatched homodimers in the Emicizumab feed cannot be separated from each other. In contrast, using a column containing a resin according to the invention coupled to SEQ ID NO: 177, two elution peaks can be detected ( FIG. 4 ). Figure 4B and 4C), SEQ ID NO: 177 is a hexamer of the alkaline-wash stable VH3 binding polypeptide (SEQ ID NO: 15) that does not bind to the Fc fragment of trastuzumab. Therefore, in a column containing a resin according to the invention coupled to SEQ ID NO: 177, the VH1 / VH3 bispecific antibody and the VH3 / VH3 mismatched homodimers in the emicizumab feed can be easily separated from each other. For the smaller 50 μm bead size, the resolution is optimal ( Figure 4C ). The eluate fractions from the 60 μm beads were analyzed by LC / MS. Based on the amino acid sequence, the homodimer is theoretically 485 Da larger than the heterodimer and can be detected in fractions 7 and 8 (Table 13). The results indicate that the homodimer is eluted at a slightly lower pH due to the dual interaction.

[0690] Table 13. LC / MS analysis of eluate fractions from SEQ ID NO: 177 on 60 μm agarose beads.

[0691]

[0692] The mismatched VH3 / VH3 homodimers bind more strongly to the SEQ ID NO: 177 resin than the VH1 / VH3 heterodimers of the bispecific antibody. This is expected to be due to the presence of multiple binding sites and avidity effects. Thus, in a column containing a resin coupled to SEQ ID NO: 177 according to the present invention, the VH3 / VH3 homodimers elute at a lower pH. Figure 4B and 4C In the chromatogram in , there is a clear peak corresponding to the elution of VH3 / VH3 homodimer eluted at pH ~2.9 and a clear peak corresponding to the elution of VH1 / VH3 bispecific antibody at a higher pH.

[0693] in conclusion

[0694] In conclusion, the separation of mismatched homodimers from heterodimers can be achieved using any VH3 binding polypeptide or multimer thereof according to the invention (as shown here for Fr33-6 (SEQ ID No: 177)). This separation is based on binding to the antibody VH3 interaction. When the antibody is mismatched and therefore has two VH3 domains that can interact with the polypeptide of the invention, it will bind more firmly to the column and elute at a slightly more acidic pH. This separation can be performed due to the removal of the Fc interaction of protein A.

[0695] It is concluded that the resin composed of the alkaline-washing stable VH3 binding polypeptide or multimer thereof (such as the hexamer SEQ ID NO: 177) has an advantageous property, namely that it enables the chromatographic separation of mismatched VH1 / VH1 and VH3 / VH3 homodimers from VH1 / VH3 bispecific antibodies. The advantageous properties of the alkaline-washing stable VH3 binding polypeptide or multimer thereof enable the separation of VH1 / VH1 and VH3 / VH3 homodimers from VH1 / VH3 bispecific antibodies. As shown herein, the alkaline-washing stable VH3 binding polypeptide hexamer SEQ ID NO: 177 and the alkaline-washing stable VH3 binding polypeptide SEQ ID NO: 15 that does not bind to the Fc fragment of trastuzumab do not bind to the Fc fragment and VH1 domain of the antibody, but exhibit high affinity binding to the VH3 domain of the antibody. The alkaline cleaning stability of the polypeptides and multimers thereof enables the use of the VH3 binding polypeptides and / or multimers in the chromatographic separation of VH1 / VH1 and VH3 / VH3 homodimers and VH1 / VH3 bispecific antibodies. In addition, the properties allow the repeated use of resins containing the polypeptides and / or multimers with intermittent washing steps while significantly retaining their binding properties.

[0696] By utilizing this superior effect of the resin composed of the alkaline-wash-stable VH3-binding polypeptide or multimer thereof according to the present invention, the production of bispecific antibodies can be revolutionized, making it more economical to produce bispecific antibodies and thus facilitating the production of therapeutic drugs containing bispecific antibodies. Simultaneous purification of correctly paired VH1 / VH3 bispecific antibodies from both VH1 / VH1 and VH3 / VH3 homodimers is beneficial for the production of highly pure VH1 / VH3 bispecific antibody therapeutics.

[0697] Example 8

[0698] Evaluation of VH3 binding peptides in different scaffolds

[0699] To evaluate the impact of mutations in positions 9, 10, 11, 13, 14, 17, 18, 28 and 29 in different scaffolds, SEQ ID NO: 89 was modified in these nine positions with amino acid residues according to Tables 1, 3 and 5. The resulting VH3 binding polypeptides are listed as SEQ ID NOs: 42-56.

[0700] VH3 binding polypeptides (SEQ ID NOs: 42-45) were generated essentially as described in the section entitled "Generation of His-purification candidate polypeptides" in Example 1. Evaluation and analysis were performed essentially as described in the sections entitled "Biacore analysis of binding affinity to Fc and Fab fragments of trastuzumab" and "Biacore analysis of alkaline wash stability" in Example 1.

[0701] VH3 binding polypeptides (SEQ ID NOs:42-45) were evaluated along with a control that binds both the trastuzumab Fc and Fab fragments (SEQ ID NO:89), a control that does not bind Fc (SEQ ID NO:180), and an alkaline-wash-labile control that does not bind Fc (negative CTRL).

[0702] The following aspects were evaluated:

[0703] (1) Affinity assessment of Fc interactions (tested by high concentration injection of Fc fragments generated from trastuzumab).

[0704] (2) Affinity assessment of Fab interactions (tested by high concentration injection of Fab fragments generated from trastuzumab).

[0705] (3) Alkaline cleaning stability (tested by the reduction in trastuzumab binding after increasing numbers of treatments with 0.5 M NaOH).

[0706] VH3 binding polypeptides (SEQ ID NOs: 46-53) were generated essentially as described in the section entitled "Generation of His-purification candidate polypeptides" in Example 2. Evaluation and analysis were performed essentially as described in the sections entitled "Biacore analysis of binding affinity to the Fc fragment of trastuzumab and to trastuzumab" and "Biacore analysis of alkaline wash stability" in Example 2.

[0707] VH3 binding polypeptides (SEQ ID NOs: 46-53) were evaluated along with a control that binds both the trastuzumab Fc and Fab fragments (SEQ ID NO: 89) and an alkaline wash labile control that does not bind Fc (negative CTRL).

[0708] The following aspects were evaluated:

[0709] (1) Affinity assessment of Fc interactions (tested by high concentration injection of Fc fragments generated from trastuzumab).

[0710] (2) Affinity assessment of the trastuzumab interaction (tested by injecting high concentrations of trastuzumab).

[0711] (3) Alkaline cleaning stability (tested by the reduction in trastuzumab binding after increasing numbers of treatments with 0.5 M NaOH).

[0712] VH3 binding polypeptides (SEQ ID NOs: 54-56) were generated essentially as described in the section entitled "Generation of His-purification candidate polypeptides" in Example 3. Evaluation and analysis were performed essentially as described in the sections entitled "Biacore analysis of binding affinity to Fc and Fab fragments of trastuzumab and to trastuzumab" and "Biacore analysis of alkaline wash stability" in Example 3.

[0713] VH3 binding polypeptides (SEQ ID NOs: 54-56) were evaluated along with a control that binds both the trastuzumab Fc and Fab fragments (SEQ ID NO: 89) and an alkaline wash labile control that does not bind Fc (negative CTRL).

[0714] The following aspects were evaluated:

[0715] (1) Affinity assessment of Fc interactions (tested by high concentration injection of Fc fragments generated from trastuzumab).

[0716] (2) Affinity assessment of Fab interactions (tested by high concentration injection of Fab fragments generated from trastuzumab).

[0717] (3) Affinity assessment of the trastuzumab interaction (tested by injecting high concentrations of trastuzumab).

[0718] (4) Alkaline cleaning stability (tested by the reduction in trastuzumab binding after increasing numbers of treatments with 0.5 M NaOH).

[0719] The VH3 binding polypeptides (SEQ ID NOs:42-56) are predicted to be alkaline wash stable or exhibit improved alkaline wash stability properties, exhibit VH3 binding affinity, and exhibit significantly reduced or abolished affinity for the Fc region of trastuzumab compared to SEQ ID NO:89.

[0720] Example 9

[0721] Evaluation of additional VH3 binding polypeptides in additional scaffolds

[0722] To evaluate the additional stent positions X9X 10 X 11 X 13 X 14 X 17 X 18 X 28 X 29The amino acid "AYRLAARAG" in the native domains of the SpA protein are modified with amino acid residues to have the same amino acids as described in Table 5 for the VH3 binding polypeptide Fr33 (SEQ ID NO: 15) at positions 9, 10, 11, 13, 14, 17, 18, 28 and 29. The resulting VH3 binding polypeptide (AFr33) on the background of SEQ ID NO:92 was listed as SEQ ID NO:85, the resulting VH3 binding polypeptide (BFr33) on the background of SEQ ID NO:91 was listed as SEQ ID NO:84, the resulting VH3 binding polypeptide (CFr33) on the background of SEQ ID NO:90 was listed as SEQ ID NO:83, the resulting VH3 binding polypeptide (DFr33) on the background of SEQ ID NO:93 was listed as SEQ ID NO:86, and the resulting VH3 binding polypeptide (EFr33) on the background of SEQ ID NO:94 was listed as SEQ ID NO:87.

[0723] VH3 binding polypeptides (SEQ ID NOs: 83-87) were generated essentially as described in the section entitled "Generation of His-purification candidate polypeptides" in Example 3. Evaluation and analysis were performed essentially as described in the sections entitled "Biacore analysis of binding affinity to Fc and Fab fragments of trastuzumab and to trastuzumab" and "Biacore analysis of alkaline wash stability" in Example 3.

[0724] The VH3 binding polypeptides (SEQ ID NOs: 83-87) were evaluated in pairs with their corresponding scaffold polypeptides (SEQ ID NOs: 90-94) that bind both trastuzumab Fc and Fab fragments as reference and together with an alkaline-washed destabilized non-Fc binding control (negative CTRL).

[0725] The following aspects were evaluated:

[0726] (1) Affinity assessment of Fc interactions (tested by high concentration injection of Fc fragments generated from trastuzumab).

[0727] (2) Affinity assessment of Fab interactions (tested by high concentration injection of Fab fragments generated from trastuzumab).

[0728] (3) Affinity assessment of the trastuzumab interaction (tested by injecting high concentrations of trastuzumab).

[0729] (4) Alkaline cleaning stability (tested by the reduction in trastuzumab binding after increasing numbers of treatments with 0.5 M NaOH).

[0730] The VH3 binding polypeptides (SEQ ID NOs: 83-87) are predicted to be alkaline-wash stable or exhibit improved alkaline-wash stability properties, exhibit VH3 binding affinity, and exhibit significantly reduced or abolished affinity for the Fc region of trastuzumab compared to their corresponding scaffold polypeptides (SEQ ID NOs: 90-94).

[0731] Example 10

[0732] Evaluation of additional VH3 binding peptides in two different scaffolds

[0733] To evaluate the effect of mutations in positions 13 and 14 in two different scaffolds, alkaline wash stable VH3 binding polypeptides (Fr33) SEQ ID NO: 15 and SEQ ID NO: 56 were modified in these two positions with amino acid residues according to Table 14. The resulting VH3 binding polypeptides on the background of SEQ ID NO: 15 are listed as SEQ ID NOs: 16-40, and the resulting VH3 binding polypeptides on the background of SEQ ID NO: 56 are listed as SEQ ID NOs: 57-81. In addition, the effect of a glutamine (Q) to serine (S) mutation in position 26 was evaluated in two different scaffolds: alkaline wash stable VH3 binding polypeptides (Fr33) SEQ ID NO: 15 and SEQ ID NO: 56. The resulting VH3 binding polypeptide (VH3K2) on the background of SEQ ID NO: 15 is listed as SEQ ID NO: 41, and the resulting VH3 binding polypeptide (VH3K2) on the background of SEQ ID NO: 56 is listed as SEQ ID NO: 82.

[0734] Table 14. Summary of mutations (SEQ ID NO: 16-40 and SEQ ID NO: 57-81)

[0735]

[0736]

[0737] VH3 binding polypeptides (SEQ ID NOs: 16-41 and SEQ ID NOs: 57-82) were generated essentially as described in the section entitled "Generation of His-purification candidate polypeptides" in Example 3. Evaluation and analysis were performed essentially as described in the sections entitled "Biacore analysis of binding affinity to Fc and Fab fragments of trastuzumab and to trastuzumab" and "Biacore analysis of alkaline wash stability" in Example 3.

[0738] VH3 binding polypeptides (SEQ ID NOs: 16-41) were evaluated along with a control that binds both the trastuzumab Fc and Fab fragments (SEQ ID NO: 88) and an alkaline wash labile control that does not bind Fc (negative CTRL).

[0739] VH3 binding polypeptides (SEQ ID NOs: 57-82) were evaluated along with a control that binds both the trastuzumab Fc and Fab fragments (SEQ ID NO: 89) and an alkaline wash labile control that does not bind Fc (negative CTRL).

[0740] The following aspects were evaluated:

[0741] (1) Affinity assessment of Fc interactions (tested by high concentration injection of Fc fragments generated from trastuzumab).

[0742] (2) Affinity assessment of Fab interactions (tested by high concentration injection of Fab fragments generated from trastuzumab).

[0743] (3) Affinity assessment of the trastuzumab interaction (tested by injecting high concentrations of trastuzumab).

[0744] (4) Alkaline cleaning stability (tested by the reduction in trastuzumab binding after increasing numbers of treatments with 0.5 M NaOH).

[0745] The VH3 binding polypeptides (SEQ ID NOs: 16-41) are predicted to be alkaline wash stable or exhibit improved alkaline wash stability properties, exhibit VH3 binding affinity, and exhibit significantly reduced or abolished affinity for the Fc region of trastuzumab compared to SEQ ID NO:88.

[0746] The VH3 binding polypeptides (SEQ ID NOs:57-82) are predicted to be alkaline wash stable or exhibit improved alkaline wash stability properties, exhibit VH3 binding affinity, and exhibit significantly reduced or abolished affinity for the Fc region of trastuzumab compared to SEQ ID NO:89.

[0747] Embodiment 11

[0748] Biacore evaluation of IgG binding peptides after knockout mutation of Fc interactions

[0749] Biacore analysis of binding affinity of Fc and Fab fragments of trastuzumab

[0750] To evaluate binding to Fc (SEQ ID NO: 184) and VH3 / Fab (SEQ ID NO: 182 and 183), IgG binding polypeptides before mutation (Group 1; G1) and polypeptides after knockout mutation of Fc interaction (Groups 2-9) were immobilized on a Biacore CM5 chip, followed by trastuzumab Fc (500 nM) and trastuzumab Fab (500 nM) fragments as analytes.

[0751] Each Fc knockout group has mutations according to the following (at positions corresponding to the following positions in SEQ ID NO:89):

[0752] Group 2 (G2): 9A, 10Y, 11R, 13L, 14A, 17A, 18R, 28A, 29G

[0753] Group 3 (G3): 9A, 10Y, 11R, 13L, 14A, 17A, 18R, 26S, 28A, 29G

[0754] Group 4 (G4): 9A, 10Y, 11E, 13R, 14A, 17A, 18R, 28A, 29G Group 5 (G5): 9A, 10Y, 11E, 13R, 14A, 17A, 18L, 28A, 29G Group 6 (G6): 9A, 10Q, 11R, 13R, 14A, 17L, 18R, 28A, 29G Group 7 (G7): 9A , 10Y, 11E, 13L, 14R, 17A, 18R, 28A, 29G Group 8 (G8): 9A, 10Y, 11E, 13A, 14R, 17A, 18R, 28A, 29G Group 9 (G9): 9Y, 10Q, 11R, 13L, 14A, 17A, 18L, 28A, 29G The sequences contained in each group are described in the following Table 15 with reference to SEQ ID NO (SID).

[0755] Table 15: Summary of Fc knockouts of IgG polypeptides (SID = SEQ ID NO)

[0756]

[0757]

[0758] Therefore, each row in Table 15 refers to the same base sequence, namely the sequence indicated in the column labeled G1. The subsequent columns indicate which sequences belong to each group of that particular base sequence.

[0759] The constructs were expressed and purified as disclosed above.

[0760] Biacore binding analysis:

[0761] The materials and equipment used are as follows: CM5 sensor chip (Cytiva TM ), Biacore TM NHS conjugation kit (Cytiva TM ), polypeptides (SEQ ID NO:89-SEQ ID NO:94 and SEQ ID NO:185-SEQ ID NO:239); Biacore TM 8K+(Cytiva TM ); Fab-fragment and Fc-fragment (prepared in-house from trastuzumab as disclosed above).

[0762] Immobilization was performed using standard methods in the Biacore software, with peptide variants coupled in flow cell 2 (FC2) and activated / deactivated in flow cell 1 (FC1). The peptide variants for immobilization were mixed in acetate buffer (Cytiva TM ) with a pH lower than the pI of the peptide > 1 unit, with a concentration range of 10-50 μg / ml. The level of immobilization did vary between the different polypeptide variants (approximately 700-2000 Ru, see Table 16).

[0763] In each run, peptides were immobilized in FC2 and multiple chips were used until all candidates were tested.

[0764] Biacore binding analysis TM method:

[0765] Running buffer: PBS-P+

[0766] Flow rate: 10 μl / min

[0767] Sample injection: 600 s / 10 min on both flow cells (FC1 and FC2)

[0768] Dissociation time: 600s / 10min

[0769] Regeneration: 10 mM glycine-HCl pH 1.5, 30 μl / min, 2x30 s

[0770] The analytes, Fab and Fc fragments of trastuzumab, were injected at a concentration of 500 nM in running buffer.

[0771] All sensorgrams were generated with reference subtraction, and the response was the difference between the pre-injection baseline and the signal immediately before the end of the injection.

[0772] result

[0773] Biacore analysis of binding of Fc and Fab fragments of trastuzumab

[0774] The response levels of the trastuzumab Fc and Fab interactions of the polypeptide variants are summarized in Table 16 (levels rounded to the nearest multiple of 50).

[0775] Table 16: Results of Fc binding and Fab binding

[0776]

[0777]

[0778]

[0779] In Group 1, polypeptide sequences SEQ ID NO 90-SEQ ID NO: 94) (non-mutated wt domain) and SEQ ID NO: 191 showed binding to the Fc fragment and Fab (VH3) of trastuzumab. Polypeptide sequences SEQ ID NO: 89, SEQ ID NO: 185-SEQ ID NO: 190 and SEQ ID NO: 192-SEQ ID NO: 193 did not show binding to the Fab (VH3) fragment of trastuzumab.

[0780] The data show that the IgG binding polypeptide variants subjected to Fc knockout mutations according to Group 2 (SEQ ID NOs: 194-208) have abolished or significantly reduced binding affinity to the Fc fragment of trastuzumab compared to their corresponding sequences in the original / parent polypeptide (Group 1).

[0781] Different mutations that knock out Fc interactions can have different effects on VH3 interactions (Fab-interactions) on different IgG polypeptides, manifesting as stronger or weaker VH3 / Fab interactions, see Table 16.

[0782] Interestingly, it can be observed that in some cases, such as with respect to SEQ ID NO:89, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187 and SEQ ID NO:192, mutations in both Group 2 and Group 3 (see SEQ ID NO:199-SEQ ID NO:202 and SEQ ID NO:207, SEQ ID NO:212-SEQ ID NO:215 and SEQ ID NO:220) provide Fab binding activity that is not present in the same domain in Group 1, while Fc binding activity is eliminated.

[0783] SEQ ID NO: 188-SEQ ID NO: 190 in Group 1 had no Fab binding, and mutations according to the present disclosure did not provide Fab binding. However, Fc binding was efficiently knocked out by mutations in the tested groups (Groups 2 and 3).

[0784] Thus, mutations according to the present disclosure have been shown to enhance or retain pre-existing Fab binding activity in a variety of Protein A domains or Protein A domain variants while also knocking out pre-existing Fc binding activity. In some cases, Fab binding activity can also be introduced when the domain did not previously have Fab binding activity, but this was not the case for all domains that initially lacked Fab binding activity. However, all domains that initially had Fab / VH3 binding activity showed retention or enhancement of Fab / VH3 binding activity while Fc binding activity was substantially abolished.

[0785] Therefore, polypeptides according to the scope of the claims have been demonstrated to be VH3 binding polypeptides having weak or no Fc binding activity.

[0786] Itemized list of implementation options

[0787] 1. A VH3 binding polypeptide derived from Staphylococcal protein A (SpA) or any domain thereof, wherein the polypeptide has binding affinity for the VH3 region of trastuzumab and has a lower binding affinity for the Fc region of trastuzumab than the binding affinity of SEQ ID NO: 88 or SEQ ID NO: 89 for the same Fc region of trastuzumab, and wherein the VH3 binding polypeptide is alkaline-wash stable.

[0788] 2. A VH3 binding polypeptide comprising a sequence A consisting of an amino acid sequence selected from the group consisting of i), ii) and iii),

[0789] Where i), ii) and iii) are defined as follows:

[0790] i)X8X9X 10X 11 AX 13 X 14 X 15 X 16 X 17 X 18 X 19 PNLX 23 X 24 X 25 X 26 RX 28 X 29 FIQSLX 35 X 36 (SEQ ID NO:95)

[0791] Among them, independently of each other,

[0792] X8 is selected from E, D and A;

[0793] X 15 Selected from E and Q;

[0794] X 16 Selected from I and V;

[0795] X 19 Select from L and M;

[0796] X 23 Selected from N and T;

[0797] X 24 is selected from A and E, if it is E;

[0798] X 25 is selected from D and E, if it is E;

[0799] X 35 Selected from K, R and H;

[0800] X 36 Selected from D and H;

[0801] ii) an amino acid sequence having at least 83% identity to the sequence defined in i)

[0802] iii) an amino acid sequence that is at least 70% identical to any sequence selected from residues 8-36 of SEQ ID NO:88, residues 8-36 of SEQ ID NO:89, residues 8-36 of SEQ ID NO:90, residues 8-36 of SEQ ID NO:91, residues 8-36 of SEQ ID NO:92, residues 11-39 of SEQ ID NO:93, and residues 1-29 of SEQ ID NO:94,

[0803] wherein, in addition, in each of i), ii) and iii), independently of one another,

[0804] X9 is selected from Q, Y and A;

[0805] X 10 Selected from Q and Y;

[0806] X 11 Selected from T, E and R;

[0807] X 13 Selected from L, E, R, A and Q;

[0808] X 14 Selected from L, E, R, A, Q and W;

[0809] X 17 Selected from A, H and L;

[0810] X 18 Selected from R, L and H;

[0811] X 26 Selected from Q and S;

[0812] X 28 is selected from N and A; and

[0813] X 29 Select from A and G.

[0814] 3. A VH3 binding polypeptide according to item 2, wherein the VH3 binding polypeptide has binding affinity for the VH3 region of trastuzumab and has a lower binding affinity for the Fc region of trastuzumab than SEQ ID NO: 88 or SEQ ID NO: 89.

[0815] 4. A VH3 binding polypeptide according to any one of items 1 to 3, wherein the trastuzumab is defined by a heavy chain amino acid sequence according to SEQ ID NO: 183 and a light chain amino acid sequence according to SEQ ID NO: 184.

[0816] 5. A VH3 binding polypeptide according to any one of items 2-4, wherein X9 is selected from Q and Y.

[0817] 6. A VH3 binding polypeptide according to any one of items 2-4, wherein X9 is selected from Q and A.

[0818] 7. A VH3 binding polypeptide according to any one of items 2 to 4, wherein X9 is selected from A and Y.

[0819] 8. A VH3 binding polypeptide according to any one of items 2-4, 6 and 7, wherein X9 is A.

[0820] 9. A VH3 binding polypeptide according to any one of items 2-4, 5 and 7, wherein X9 is Y.

[0821] 10. A VH3 binding polypeptide according to any one of items 2-6, wherein X9 is Q.

[0822] 11. A VH3 binding polypeptide according to any one of items 2 to 10, wherein X 10 For Q.

[0823] 12. A VH3 binding polypeptide according to any one of items 2 to 10, wherein X 10 is Y.

[0824] 13. A VH3 binding polypeptide according to any one of items 2 to 12, wherein X 11 Selected from T and E.

[0825] 14. A VH3 binding polypeptide according to any one of items 2 to 12, wherein X 11 Selected from T and R.

[0826] 15. A VH3 binding polypeptide according to any one of items 2 to 12, wherein X 11 Selected from R and E.

[0827] 16. A VH3 binding polypeptide according to any one of items 2 to 14, wherein X 11 is T.

[0828] 17. A VH3 binding polypeptide according to any one of items 2 to 13 and 15, wherein X 11 For E.

[0829] 18. A VH3 binding polypeptide according to any one of items 2-12, 14 and 15, wherein X 11 For R.

[0830] 19. A VH3 binding polypeptide according to any one of items 2 to 18, wherein X 13 Selected from L, E, R and A; or selected from L, E, R and Q; or selected from L, E, A and Q; or selected from L, R, A and Q; or selected from E, R, A and Q; in particular, selected from L, E, R and A; or selected from L, E, R and Q; or selected from L, E, A and Q; or selected from L, R, A and Q.

[0831] 20. A VH3 binding polypeptide according to any one of items 2 to 18, wherein X 13Selected from L, E and R; or selected from L, E and A; or selected from L, E and Q; or selected from L, R and A; or selected from L, R and Q; or selected from L, A and Q; or selected from E, R and A; or selected from E, R and Q; or selected from E, A and Q; or selected from R, A and Q; in particular, selected from L, E and R; or selected from L, E and A; or selected from L, E and Q; or selected from L, R and A; or selected from L, R and Q.

[0832] 21. A VH3 binding polypeptide according to any one of items 2 to 18, wherein X 13 Selected from L and E; or selected from L and R; or selected from L and A; or selected from L and Q; or selected from E and R; or selected from E and A; or selected from E and Q; or selected from R and A; or selected from R and Q; or selected from A and Q; in particular, selected from L and E; or selected from L and R; or selected from L and A; or selected from L and Q.

[0833] 22. A VH3 binding polypeptide according to any one of items 2 to 21, wherein X 13 For L.

[0834] 23. A VH3 binding polypeptide according to any one of items 2 to 21, wherein X 13 is A.

[0835] 24. A VH3 binding polypeptide according to any one of items 2 to 21, wherein X 13 For E.

[0836] 25. A VH3 binding polypeptide according to any one of items 2 to 21, wherein X 13 For Q.

[0837] 26. A VH3 binding polypeptide according to any one of items 2 to 21, wherein X 13 For R.

[0838] 27. A VH3 binding polypeptide according to any one of items 2 to 26, wherein X 14 Selected from A, W, E, L and Q; or selected from A, W, E, L and R; or selected from A, W, E, Q and R; or selected from A, W, L, Q and R; or selected from A, E, L, Q and R; or selected from W, E, L, Q and R.

[0839] 28. A VH3 binding polypeptide according to any one of items 2 to 26, wherein X 14Selected from A, W, E and L; or selected from A, W, E and Q; or selected from A, W, E and R; or selected from A, W, L and Q; or selected from A, W, L and R; or selected from A, W, Q and R; or selected from A, E, L and Q; or selected from A, E, L and R; or selected from A, E, Q and R; or selected from A, L, Q and R; or selected from W, E, L and Q; or selected from W, E, L and R; or selected from W, E, Q and R; or selected from W, L, Q and R; or selected from E, L, Q and R.

[0840] 29. A VH3 binding polypeptide according to any one of items 2 to 26, wherein X 14 is selected from A, W and E; or from A, W and L; or from A, W and Q; or from A, W and R; or from A, E and L; or from A, E and Q; or from A, E and R; or from A, L and Q; or from A, L and R; or from A, Q and R; or from W, E and L; or from W, E and Q; or from W, E and R; or from W, L and Q; or from W, L and R; or from W, Q and R; or from E, L and Q; or from E, L and R; or from E, Q and R; or from L, Q and R.

[0841] 30. A VH3 binding polypeptide according to any one of items 2 to 26, wherein X 14 is selected from A and W; or from A and E; or from A and L; or from A and Q; or from A and R; or from W and E; or from W and L; or from W and Q; or from W and R; or from E and L; or from E and Q; or from E and R; or from L and Q; or from L and R; or from Q and R.

[0842] 31. A VH3 binding polypeptide according to any one of items 2 to 30, wherein X 14 is A.

[0843] 32. A VH3 binding polypeptide according to any one of items 2 to 30, wherein X 14 For W.

[0844] 33. A VH3 binding polypeptide according to any one of items 2 to 30, wherein X 14 For E.

[0845] 34. A VH3 binding polypeptide according to any one of items 2 to 30, wherein X 14 For L.

[0846] 35. A VH3 binding polypeptide according to any one of items 2 to 30, wherein X 14 For Q.

[0847] 36. A VH3 binding polypeptide according to any one of items 2 to 30, wherein X 14 For R.

[0848] 37. A VH3 binding polypeptide according to any one of items 2 to 36, wherein X 17 Selected from A and H.

[0849] 38. A VH3 binding polypeptide according to any one of items 2 to 36, wherein X 17 Selected from A and L.

[0850] 39. A VH3 binding polypeptide according to any one of items 2 to 36, wherein X 17 Selected from H and L.

[0851] 40. A VH3 binding polypeptide according to any one of items 2 to 38, wherein X 17 is A.

[0852] 41. A VH3 binding polypeptide according to any one of items 2-37 and 39, wherein X 17 For H.

[0853] 42. A VH3 binding polypeptide according to any one of items 2-36, 38 and 39, wherein X 17 For L.

[0854] 43. A VH3 binding polypeptide according to any one of items 2 to 42, wherein X 18 Selected from R and L.

[0855] 44. A VH3 binding polypeptide according to any one of items 2 to 42, wherein X 18 Selected from R and H.

[0856] 45. A VH3 binding polypeptide according to any one of items 2 to 42, wherein X 18 Selected from H and L.

[0857] 46. ​​A VH3 binding polypeptide according to any one of items 2 to 44, wherein X 18 For R.

[0858] 47. A VH3 binding polypeptide according to any one of items 2 to 43 and 45, wherein X 18 For L.

[0859] 48. A VH3 binding polypeptide according to any one of items 2-42, 44 and 45, wherein X 18 For H.

[0860] 49. A VH3 binding polypeptide according to any one of items 2 to 48, wherein X 26 For Q.

[0861] 50. A VH3 binding polypeptide according to any one of items 2 to 48, wherein X 26 For S.

[0862] 51. A VH3 binding polypeptide according to any one of items 2 to 50, wherein X 28 is N.

[0863] 52. A VH3 binding polypeptide according to any one of items 2 to 50, wherein X 28 is A.

[0864] 53. A VH3 binding polypeptide according to any one of items 2 to 52, wherein X 29 Select from A and G.

[0865] 54. A VH3 binding polypeptide according to any one of items 2 to 53, wherein X 29 is A.

[0866] 55. A VH3 binding polypeptide according to any one of items 2 to 53, wherein X 29 For G.

[0867] 56. A VH3 binding polypeptide according to any one of items 2 to 55, wherein X 14 A and X 10 Y or X9X 10 Selected from AY.

[0868] 57. A VH3 binding polypeptide according to any one of items 2 to 56, wherein X9X 10 X 11 Selected from QQT, QYT, YQT, AQE, AQR and AYR; such as selected from QQT, QYT, AQE, AQR and AYR; such as selected from AQE, AQR and AYR; such as selected from AQR and AYR, such as wherein X9X 10 X 11 For AYR.

[0869] 58. A VH3 binding polypeptide according to any one of items 2 to 57, wherein X 17 X 18 is selected from AR, HL and LH; such as selected from AR and HL; such as wherein X 17 X 18 For AR.

[0870] 59. A VH3 binding polypeptide according to any one of items 2 to 58, wherein X 24 X 25 For EE.

[0871] 60. A VH3 binding polypeptide according to any one of items 2 to 59, wherein X 28 X 29 Selected from NA, NG, AA and AG; such as selected from NA, NG and AG or selected from NG, AA and AS; such as selected from NG and AG or selected from AG and NA or selected from AG and AA.

[0872] 61. A VH3 binding polypeptide according to any one of items 2 to 60, wherein X 28 X 29 NA or AG or AA or NG.

[0873] 62. A VH3 binding polypeptide according to any one of items 2 to 61, wherein independently of each other, X9X 10 X 11 is selected from AQE, AQR and AYR; and X 13 X 14 Selected from LA, LW, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ and RR;

[0874] As independently of each other, X9X 10 X 11 is selected from AQE, AQR and AYR; and X 13 X 14 Selected from LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ and RR;

[0875] As independently of each other, X9X 10 X 11 is selected from AQR and AYR; and X 13 X 14 Selected from LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ and RR; such as where X9X 10 X 11 For AYR and X 13 X 14 Selected from LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ and RR.

[0876] 63. A VH3 binding polypeptide according to any one of items 2 to 62, wherein X9X 10 X 11 X 13 X 14selected from QQTLA, QYTLA, YQTLA, AQELA, AQRLA, AYRLA and AYRLW; such as selected from QQTLA, QYTLA, AQELA, AQRLA, AYRLA and AYRLW; such as selected from AQELA, AQRLA, AYRLA and AYRLW; such as selected from AQRLA and AYRLA; such as wherein X9X 10 X 11 X 13 X 14 For AYRLA.

[0877] 64. A VH3 binding polypeptide according to any one of items 2 to 63, wherein independently of each other, X9X 10 X 11 is selected from AQE, AQR and AYR; and X 13 X 14 Selected from LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ, RR and LW; and X 17 X 18 Selected from LH and AR;

[0878] As independently of each other, X9X 10 X 11 is selected from AQR and AYR; and X 13 X 14 Selected from LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ, RR and LW; and 17 X 18 Selected from LH and AR;

[0879] As independently of each other, X9X 10 X 11 is AYR; and X 13 X 14 Selected from LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ, RR and LW; and 17 X 18 Selected from LH and AR;

[0880] As independently of each other, X9X 10 X 11 is AYR; and X 13 X 14Selected from LA, AA, AE, AL, AQ, AR, EA, EE, EL, EQ, ER, LA, LE, LL, LQ, LR, QA, QE, QL, QQ, QR, RA, RE, RL, RQ, RR and LW; and 17 X 18 For AR.

[0881] 65. A VH3 binding polypeptide according to any one of items 2 to 64, wherein X9X 10 X 11 X 13 X 14 X 17 X 18 Selected from

[0882] QQTLALH, QYTLALH, YQTLALH, QQTLAAR, AQELALH, AQRLALH, AYRLALH, AYRLWLH, AYRLWAR, AYRLAAR, AYRLAHL and AYRLWHL; if selected from QQTLALH, QYTLALH, QQTLAAR, AQELALH, AQRLALH, AYR LALH, AYRLWLH, AYRLWAR, AYRLAAR, AYRLAHL and AYRLWHL; if selected from AQELALH, AQRLALH, AYRLALH, AYRLWAR, AYRLAAR and AYRLAHL; if selected from AQRLALH, AYRLALH and AYRLAAR; if selected from AQRLALH and AYRLAAR.

[0883] 66. A VH3 binding polypeptide according to any one of items 2 to 65, wherein X9X 10 X 11 X 13 X 14 X 17 X 18 For AYRLAAR.

[0884] 67. A VH3 binding polypeptide according to any one of items 2 to 65, wherein X 24 X 25 X 28 X 29 is selected from EENA, EENG, EEAA and EEAG; such as selected from EENA, EENG and EEAG; such as selected from EENG and EEAG; such as wherein X 24 X 25 X 28 X 29 For EEAG.

[0885] 68. A VH3 binding polypeptide according to any one of items 2 to 67, wherein X 26X 28 X 29 is selected from QNG, QAA, QAG, QNA and SAG; such as selected from QNG, QAG, QNA and SAG; such as selected from QNG, QAG and SAG and / or selected from QNG, QAG, QNA or selected from QNG, QNA and SAG; such as selected from QAG and SAG; such as wherein X 26 X 28 X 29 It is QAG or SAG.

[0886] 69. A VH3 binding polypeptide according to any one of items 2 to 68, wherein X 26 X 28 X 29 is selected from QAG and SAG; such as wherein X 26 X 28 X 29 For QAG.

[0887] 70. A VH3 binding polypeptide according to any one of items 2 to 69, wherein sequence i) corresponds to the sequence from position 8 to position 36 of a sequence selected from SEQ ID NO: 1-82, such as selected from SEQ ID NO: 1-40 and 42-81, such as selected from SEQ ID NO: 1-15 and 42-56.

[0888] 71. A VH3 binding polypeptide according to item 70, wherein sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from SEQ ID NO: 1-41, such as selected from SEQ ID NO: 1-40, such as selected from 1-15.

[0889] 72. A VH3 binding polypeptide according to item 70, wherein sequence i) corresponds to a sequence from position 8 to position 36 in a sequence selected from the group consisting of: SEQ ID NOs: 1, 2, 4-43 and 45-82; such as selected from the group consisting of: SEQ ID NOs: 5-7, 9-11, 13-41, 46-48, 50-52 and 54-82; such as selected from the group consisting of: SEQ ID NOs: 6-7, 10, 13-41, 47-48, 51 and 54-82; such as selected from the group consisting of: SEQ ID NOs: 6-7, 10, 13, 15-41, 47-48, 51, 54 and 56-82; such as selected from the group consisting of: SEQ ID NOs: 6, 10, 13, 15-41, 47, 51, 54 and 56-82; such as selected from the group consisting of: SEQ ID NOs: 13, 15-41, 54 and 56-82; NO:13, 15-40, 54 and 56-81; such as selected from SEQ ID NO:13, 15, 54 and 56.

[0890] 73. A VH3 binding polypeptide according to item 70, wherein sequence i) corresponds to a sequence from position 8 to position 36 in a sequence selected from SEQ ID NOs: 15-41 and 56-82, such as selected from SEQ ID NOs: 15-40 and 56-81 or selected from SEQ ID NOs: 15, 41, 56 and 82.

[0891] 74. A VH3 binding polypeptide according to item 70, wherein sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from SEQ ID NO: 14, 15, 55 and 56.

[0892] 75. A VH3 binding polypeptide according to item 70, wherein sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the following: SEQ ID NO: 1, 2, 4-41; such as selected from SEQ ID NO: 5-7, 9-11, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13, 15-41; such as selected from SEQ ID NO: 6, 10, 13, 15-41; such as selected from SEQ ID NO: 13, 15-41; such as selected from SEQ ID NO: 13, 15-40; such as selected from SEQ ID NO: 13 and 15.

[0893] 76. A VH3 binding polypeptide according to item 70, wherein sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from SEQ ID NOs: 15-41, such as selected from SEQ ID NOs: 15-40 or selected from SEQ ID NOs: 15 and 41.

[0894] 77. A VH3 binding polypeptide according to item 70, wherein sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from SEQ ID NO: 14 and 15.

[0895] 78. A VH3 binding polypeptide according to item 70, wherein sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from the following: SEQ ID NO:42-43 and 45-82; such as selected from SEQ ID NO:46-48, 50-52 and 54-82; such as selected from SEQ ID NO:47-48, 51 and 54-82; such as selected from SEQ ID NO:47-48, 51, 54 and 56-82; such as selected from SEQ ID NO:47, 51, 54 and 56-82; such as selected from SEQ ID NO:54 and 56-82; such as selected from SEQ ID NO:54 and 56-81; such as selected from SEQ ID NO:54 and 56.

[0896] 79. A VH3 binding polypeptide according to item 70, wherein sequence i) corresponds to a sequence from position 8 to position 36 in a sequence selected from SEQ ID NOs: 56-82, such as selected from SEQ ID NOs: 56-81 or selected from SEQ ID NOs: 56 and 82.

[0897] 80. A VH3 binding polypeptide according to item 70, wherein sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from SEQ ID NO: 55 and 56.

[0898] 81. A VH3 binding polypeptide according to item 70, wherein sequence i) corresponds to the sequence from position 8 to position 36 in SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15.

[0899] 82. A VH3 binding polypeptide according to item 70, wherein sequence i) corresponds to the sequence from position 8 to position 36 in SEQ ID NO:54, SEQ ID NO:55 or SEQ ID NO:56.

[0900] 83. A VH3 binding polypeptide according to any one of items 2-4, which has a sequence iii) selected from the following: a sequence corresponding to residues 8-36 in SEQ ID NO:83; a sequence corresponding to residues 8-36 in SEQ ID NO:84; a sequence corresponding to residues 8-36 in SEQ ID NO:85; a sequence corresponding to residues 11-39 in SEQ ID NO:86; and a sequence corresponding to residues 1-29 in SEQ ID NO:87.

[0901] 84. A VH3 binding polypeptide according to any one of items 1 to 83, wherein said polypeptide derived from SpA or said sequence A forms part of a three-helix bundle protein domain.

[0902] 85. A VH3 binding polypeptide according to item 84, wherein said polypeptide derived from SpA or said sequence A forms part of two helices having interconnected loops within said three-helix bundle protein domain.

[0903] 86. A VH3 binding polypeptide according to any one of items 84-85, wherein the three-helix bundle protein domain is selected from a bacterial receptor domain.

[0904] 87. A VH3 binding polypeptide according to any one of items 84 to 86, wherein the three-helix bundle protein domain is selected from the domain of Staphylococcus aureus protein A or a derivative thereof.

[0905] 88. The VH3 binding polypeptide according to any one of items 2 to 87, further comprising a sequence B arranged at the C-terminus of said sequence A, said sequence B consisting of an amino acid sequence selected from iv) and v), wherein iv) and v) are defined as follows:

[0906] iv)DPSX 40 SX 42 X 43 X 44 LX 46 EAX 49 X 50 LNX 53 X 54 (SEQ ID NO:96)

[0907] Among them, independently of each other,

[0908] X 40 Select from Q, T and V;

[0909] X 42 Selected from A, K, L and T;

[0910] X 43 Selected from N, E, A and S;

[0911] X 44 Selected from L, I and V;

[0912] X 46 is selected from A, G, S and K, such as selected from A, S and K;

[0913] X 49 is selected from K and Q, if it is K;

[0914] X 50 Selected from K and R;

[0915] X 53 is selected from D, E, and K; and

[0916] X 54 Selected from A and S;

[0917] v) an amino acid sequence that is at least 75% identical to a sequence as defined in iv).

[0918] 89. A VH3 binding polypeptide according to any one of items 2 to 88, comprising a binding module sequence C, which sequence C consists of the following: sequence A according to any one of items 2 to 87 and sequence B according to item 88, in the following order from N-terminus to C-terminus

[0919] [Sequence A]-[Sequence B]

[0920] Or an amino acid sequence that is at least 70% identical to any sequence selected from the group consisting of residues 8-54 of SEQ ID NO:88, residues 8-54 of SEQ ID NO:89, residues 8-54 of SEQ ID NO:90, residues 8-54 of SEQ ID NO:91, residues 8-54 of SEQ ID NO:92, residues 11-57 of SEQ ID NO:93, and residues 1-47 of SEQ ID NO:94.

[0921] 90. A VH3 binding polypeptide according to any one of items 2 to 89, comprising a binding module sequence C consisting of the sequences [sequence A], [L2] and [H3], in the following order from N-terminus to C-terminus

[0922] [Sequence A]-[L2]-[H3]

[0923] wherein [Sequence A] is as defined in any one of items 2-87,

[0924] and wherein, independently of each other, [L2] is selected from:

[0925] DPSV (SEQ ID NO:97);

[0926] DPSQ (SEQ ID NO: 98);

[0927] EPSQ (SEQ ID NO: 99);

[0928] DPST (SEQ ID NO: 100);

[0929] EPSV (SEQ ID NO: 101); and

[0930] DPSL (SEQ ID NO: 102);

[0931] and [H3] is selected from:

[0932] SANLLAEAKKLNDA(SEQ ID NO:103);

[0933] SKEILAEAKKLNDA(SEQ ID NO:104);

[0934] SKAILAEAKKLNDA(SEQ ID NO:105);

[0935] SANLLAEAKKLNDA(SEQ ID NO:106);

[0936] SANLLAEAKKLNES(SEQ ID NO:107);

[0937] STNVLGEAKKLNES(SEQ ID NO:108);

[0938] SANVLGEAQKLNDS(SEQ ID NO:109);

[0939] SLEILCEAKKLNDA(SEQ ID NO:110);

[0940] SLEILAEAKKLNDA (SEQ ID NO: 111); and

[0941] SKKILKEAKKLNKA (SEQ ID NO: 112).

[0942] 91. A VH3 binding polypeptide according to any one of items 89 to 90, comprising a binding module sequence C selected from the group consisting of

[0943] [Sequence A]-DPSQSANLLAEAKKLNDA (SEQ ID NO: 113);

[0944] [Sequence A]-DPSVSKEILAEAKKLNDA (SEQ ID NO: 114);

[0945] [Sequence A]-DPSVSKAILAEAKKLNDA (SEQ ID NO: 115);

[0946] [Sequence A]-DPSQSANLLAEAKKLNES (SEQ ID NO: 116);

[0947] [Sequence A]-DPSVSLEILGEAKKLNDA (SEQ ID NO: 117);

[0948] [Sequence A]-DPSVSLEILCEAKKLNDA (SEQ ID NO: 118);

[0949] [Sequence A]-DPSVSLEILAEAKKLNDA (SEQ ID NO: 119);

[0950] [Sequence A]-DPSVSLALLAEAKKLNDA (SEQ ID NO: 120);

[0951] [Sequence A]-DPSQSANLLSEAKKLNES (SEQ ID NO: 121);

[0952] [Sequence A] -DPSQSTNVLGEAKKLNES (SEQ ID NO: 122); and

[0953] [Sequence A]-DPSQSANVLGEAQKLNDS (SEQ ID NO: 123);

[0954] wherein [Sequence A] is as defined in any one of items 2-87.

[0955] 92. A VH3 binding polypeptide according to any one of items 88 to 91, comprising a binding module sequence C selected from:

[0956] vi) [Sequence A]-DPSQSANLLAEAKKLNDA (SEQ ID NO: 113);

[0957] wherein [Sequence A] is as defined in any one of items 2-87; and

[0958] vii) an amino acid sequence that is at least 85% identical to the sequence defined in vi).

[0959] 93. A VH3 binding polypeptide according to any one of items 88 to 91, comprising a binding module sequence C selected from:

[0960] viii) [Sequence A]-DPSVSKAILAEAKKLNDA (SEQ ID NO: 115)

[0961] wherein [Sequence A] is as defined in any one of items 2-87; and

[0962] ix) an amino acid sequence that is at least 85% identical to a sequence as defined in viii).

[0963] 94. A VH3 binding polypeptide according to any one of items 88 to 91, comprising a binding module sequence C selected from:

[0964] x) [Sequence A]-DPSVSKEILAEAKKLNDA (SEQ ID NO: 114)

[0965] wherein [Sequence A] is as defined in any one of items 2-87; and

[0966] xi) an amino acid sequence that is at least 85% identical to the sequence defined in x).

[0967] 95. A VH3 binding polypeptide according to any one of items 2-95, wherein sequence vi) or viii) corresponds to the sequence from position 8 to position 54 in a sequence selected from SEQ ID NO: 1-82, such as selected from SEQ ID NO: 1-40 and 42-81, such as selected from SEQ ID NO: 1-15 and 42-56.

[0968] 96. A VH3 binding polypeptide according to item 95, wherein sequence viii) corresponds to the sequence from position 8 to position 54 in a sequence selected from SEQ ID NO: 1-41, such as selected from SEQ ID NO: 1-40, such as selected from SEQ ID NO: 1-15.

[0969] 97. A VH3 binding polypeptide according to item 95, wherein sequence vi) or viii) corresponds to a sequence from position 8 to position 54 in a sequence selected from the group consisting of: SEQ ID NO: 1, 2, 4-43 and 45-82; such as selected from the group consisting of SEQ ID NO: 5-7, 9-11, 13-41, 46-48, 50-52 and 54-82; such as selected from the group consisting of SEQ ID NO: 6-7, 10, 13-41, 47-48, 51 and 54-82; such as selected from the group consisting of SEQ ID NO: 6-7, 10, 13, 15-41, 47-48, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NO: 6, 10, 13, 15-41, 47, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NO: 13, 15-41, 54 and 56-82; NO:13, 15-40, 54 and 56-81; such as selected from SEQ ID NO:13, 15, 54 and 56.

[0970] 98. A VH3 binding polypeptide according to item 95, wherein sequence vi) or viii) corresponds to a sequence from position 8 to position 54 in a sequence selected from SEQ ID NOs: 15-41 and 56-82, such as selected from SEQ ID NOs: 15-40 and 56-81, such as selected from SEQ ID NOs: 15, 41, 56 and 82.

[0971] 99. A VH3 binding polypeptide according to item 95, wherein sequence vi) or viii) corresponds to the sequence from position 8 to position 54 in a sequence selected from SEQ ID NO: 14, 15, 55 and 56.

[0972] 100. A VH3 binding polypeptide according to item 95, wherein sequence viii) corresponds to the sequence from position 8 to position 54 in a sequence selected from the following: SEQ ID NO: 1, 2, 4-41; such as selected from SEQ ID NO: 5-7, 9-11, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13, 15-41; such as selected from SEQ ID NO: 6, 10, 13, 15-41; such as selected from SEQ ID NO: 13, 15-41; such as selected from SEQ ID NO: 13, 15-40; such as selected from SEQ ID NO: 13 and 15.

[0973] 101. A VH3 binding polypeptide according to item 95, wherein sequence viii) corresponds to a sequence from position 8 to position 54 in a sequence selected from SEQ ID NOs: 15-41, such as selected from SEQ ID NOs: 15-40 or selected from SEQ ID NOs: 15 and 41.

[0974] 102. A VH3 binding polypeptide according to item 95, wherein sequence viii) corresponds to the sequence from position 8 to position 54 in a sequence selected from SEQ ID NO: 14 and 15.

[0975] 103. A VH3 binding polypeptide according to item 95, wherein sequence vi) corresponds to the sequence from position 8 to position 54 in a sequence selected from the following: SEQ ID NO:42-43 and 45-82; such as selected from SEQ ID NO:46-48, 50-52 and 54-82; such as selected from SEQ ID NO:47-48, 51 and 54-82; such as selected from SEQ ID NO:47-48, 51, 54 and 56-82; such as selected from SEQ ID NO:47, 51, 54 and 56-82; such as selected from SEQ ID NO:54 and 56-82; such as selected from SEQ ID NO:54 and 56-81; such as selected from SEQ ID NO:54 and 56.

[0976] 104. A VH3 binding polypeptide according to item 95, wherein sequence vi) corresponds to a sequence from position 8 to position 54 in a sequence selected from SEQ ID NO: 56-82, such as selected from SEQ ID NO: 56-81 or selected from SEQ ID NO: 56 and 82.

[0977] 105. A VH3 binding polypeptide according to item 95, wherein sequence vi) corresponds to the sequence from position 8 to position 54 in a sequence selected from SEQ ID NO:55 and 56.

[0978] 106. A VH3 binding polypeptide according to item 95, wherein sequence viii) corresponds to the sequence from position 8 to position 54 in SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15.

[0979] 107. A VH3 binding polypeptide according to item 95, wherein sequence vi) corresponds to the sequence from position 8 to position 54 in SEQ ID NO:54, SEQ ID NO:55 or SEQ ID NO:56.

[0980] 108. A VH3 binding polypeptide according to item 83, which comprises a sequence selected from the following: a sequence corresponding to residues 8-54 in SEQ ID NO:83; a sequence corresponding to residues 8-54 in SEQ ID NO:84; a sequence corresponding to residues 8-54 in SEQ ID NO:85; a sequence corresponding to residues 11-57 in SEQ ID NO:86 and a sequence corresponding to residues 1-47 in SEQ ID NO:87.

[0981] 109. A VH3 binding polypeptide according to any one of items 2-82 and 84-107, comprising sequences [S1], [binding module sequence C] and [S2], in the order from N-terminus to C-terminus as follows

[0982] [S1]-[binding module sequence C]-[S2],

[0983] wherein [S1] or [S2] may be present or absent, [Binding Module Sequence C] is as defined in any one of items 88 to 107, and

[0984] Among them, independently of each other,

[0985] [S1] Selected from

[0986] ADNKFNK (SEQ ID NO: 124);

[0987] VDAKFDK (SEQ ID NO: 125);

[0988] VDNKFNK (SEQ ID NO: 126);

[0989] ADAQQNKFNK (SEQ ID NO: 127);

[0990] IAAKHDK (SEQ ID NO: 128);

[0991] IAAQHDK (SEQ ID NO: 129);

[0992] ADNNFNK (SEQ ID NO: 130);

[0993] IAAKFDE (SEQ ID NO:131);

[0994] PAAKHDK (SEQ ID NO:132);

[0995] ADNAFNT (SEQ ID NO:133);

[0996] FNK;

[0997] ADNRFNE (SEQ ID NO:134);

[0998] IDSKFDE (SEQ ID NO:135);

[0999] ADNRFNR (SEQ ID NO:136);

[1000] ADNKHNK (SEQ ID NO:137);

[1001] ADSKFDE (SEQ ID NO:138);

[1002] IDAKHDE (SEQ ID NO:139);

[1003] QQNKFNK (SEQ ID NO:140);

[1004] ADNKFHK (SEQ ID NO:141);

[1005] KFNK (SEQ ID NO:142);

[1006] ADNNFNR (SEQ ID NO:143);

[1007] AAAKHDK (SEQ ID NO:144);

[1008] IDNKFNK (SEQ ID NO:145);

[1009] IDAKFDE (SEQ ID NO:146);

[1010] DNNFNK (SEQ ID NO:147);

[1011] ADNKFNE (SEQ ID NO:148);

[1012] AAAQHDK (SEQ ID NO:149); and

[1013] AAAKFDE (SEQ ID NO: 150);

[1014] [S2] Selected from

[1015] QAPK (SEQ ID NO: 151);

[1016] QAPP (SEQ ID NO: 152);

[1017] QAP;

[1018] QAPR (SEQ ID NO: 153);

[1019] QAPE (SEQ ID NO: 154);

[1020] APK;

[1021] QAPG (SEQ ID NO: 155);

[1022] QAIK (SEQ ID NO: 156); and

[1023] QA.

[1024] 110. A VH3 binding polypeptide according to any one of items 2 to 109, comprising a sequence selected from the group consisting of:

[1025] ADNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 157);

[1026] VDNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 158);

[1027] ADNKFNK-[Sequence A]-DPSVSKEILAEAKKLNDAQAPK (SEQ ID NO: 159);

[1028] VDAKFDK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 160);

[1029] VDNKFNK-[Sequence A]-DPSVSKEILAEAKKLNDAQAPK (SEQ ID NO: 161);

[1030] VDAKFDK-[sequence A]-DPSVSKAILAEAKKLNDAQAPK (SEQ ID NO: 162);

[1031] ADNNFNK-[Sequence A]-DPSQSANLLAEAKKLNESQAPK (SEQ ID NO: 163);

[1032] ADNKHNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 164);

[1033] ADNKFNK-[Sequence A]-DPSQSANLLAEAAPK (SEQ ID NO: 165);

[1034] IAAQHDK-[Sequence A]-DPSVSLEILAEAKKLNDAQAPK (SEQ ID NO: 166);

[1035] ADNKFHK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 167);

[1036] FNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 168);

[1037] IAAQHDK-[Sequence A]-DPSVSLEILCEAKKLNDAQAPK (SEQ ID NO: 169);

[1038] IDAKFDE-[Sequence A]-DPSVSLALLAEAKKLNDAQAPP (SEQ ID NO: 170);

[1039] DNNFNK-[Sequence A]-DPSQSANLLAEAKKLNESQAPK (SEQ ID NO: 171);

[1040] VDAKFDK-[Sequence A]-DPSQSANLLAEAKKLNDAQAIK (SEQ ID NO: 172);

[1041] ADNRFNE-[Sequence A]-DPSVSKEILAEAKKLNDAQAPE (SEQ ID NO: 173);

[1042] and

[1043] IDAKFDE-[Sequence A]-DPSVSLSLLAEAKKLNDAQAPP (SEQ ID NO: 174);

[1044] wherein [Sequence A] is as defined in any one of items 2-87.

[1045] 111. A VH3 binding polypeptide according to any one of items 2 to 110, comprising a sequence selected from the group consisting of:

[1046] xii) VDNKFNK-[Sequence A]-DPSQSANLLAEAKKLNDAQAPK (SEQ ID NO: 158)

[1047] wherein [Sequence A] is as defined in any one of items 2-87;

[1048] xiii) an amino acid sequence that is at least 86% identical to the sequence defined in xii).

[1049] 112. A VH3 binding polypeptide according to any one of items 2 to 110, comprising a sequence selected from the group consisting of:

[1050] xiv) VDAKFDK-[Sequence A]-DPSVSKAILAEAKKLNDAQAPK (SEQ ID NO: 162)

[1051] wherein [Sequence A] is as defined in any one of items 2-87; and

[1052] xv) An amino acid sequence that is at least 86% identical to a sequence as defined in xiv).

[1053] 113. A VH3 binding polypeptide according to any one of items 2 to 112, wherein sequence xii) or xiv) corresponds to a sequence selected from SEQ ID NO: 1-82, such as selected from SEQ ID NO: 1-40 and 42-81, such as selected from SEQ ID NO: 1-15 and 42-56.

[1054] 114. A VH3 binding polypeptide according to item 113, wherein sequence xiv) corresponds to a sequence selected from SEQ ID NO: 1-41, such as selected from SEQ ID NO: 1-40, such as selected from SEQ ID NO: 1-15.

[1055] 115. A VH3 binding polypeptide according to item 113, wherein sequence xii) or xiv) corresponds to a sequence selected from the group consisting of: SEQ ID NO: 1, 2, 4-43 and 45-82; such as selected from the group consisting of SEQ ID NO: 5-7, 9-11, 13-41, 46-48, 50-52 and 54-82; such as selected from the group consisting of SEQ ID NO: 6-7, 10, 13-41, 47-48, 51 and 54-82; such as selected from the group consisting of SEQ ID NO: 6-7, 10, 13, 15-41, 47-48, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NO: 6, 10, 13, 15-41, 47, 51, 54 and 56-82; such as selected from the group consisting of SEQ ID NO: 13, 15-41, 54 and 56-82; NO:13, 15-40, 54 and 56-81; such as selected from SEQ ID NO:13, 15, 54 and 56.

[1056] 116. A VH3 binding polypeptide according to item 113, wherein sequence xii) or xiv) corresponds to a sequence selected from SEQ ID NOs: 15-41 and 56-82, such as selected from SEQ ID NOs: 15-40 and 56-81 or selected from SEQ ID NOs: 15, 41, 56 and 82.

[1057] 117. A VH3 binding polypeptide according to item 113, wherein sequence xii) or xiv) corresponds to a sequence selected from SEQ ID NO: 14, 15, 55 and 56.

[1058] 118. A VH3 binding polypeptide according to item 113, wherein sequence xiv) corresponds to a sequence selected from the following: SEQ ID NO: 1, 2, 4-41; such as selected from SEQ ID NO: 5-7, 9-11, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13, 15-41; such as selected from SEQ ID NO: 6, 10, 13, 15-41; such as selected from SEQ ID NO: 13, 15-41; such as selected from SEQ ID NO: 13, 15-40; such as selected from SEQ ID NO: 13 and 15.

[1059] 119. A VH3 binding polypeptide according to item 113, wherein sequence xiv) corresponds to a sequence selected from SEQ ID NO: 15-41, such as selected from SEQ ID NO: 15-40 or selected from SEQ ID NO: 15 and 41.

[1060] 120. A VH3 binding polypeptide according to item 113, wherein sequence xiv) corresponds to a sequence selected from SEQ ID NO: 14 and 15.

[1061] 121. A VH3 binding polypeptide according to item 113, wherein sequence xii) corresponds to a sequence selected from the following: SEQ ID NO:42-43 and 45-82; such as selected from SEQ ID NO:46-48, 50-52 and 54-82; such as selected from SEQ ID NO:47-48, 51 and 54-82; such as selected from SEQ ID NO:47-48, 51, 54 and 56-82; such as selected from SEQ ID NO:47, 51, 54 and 56-82; such as selected from SEQ ID NO:54 and 56-82; such as selected from SEQ ID NO:54 and 56-81; such as selected from SEQ ID NO:54 and 56.

[1062] 122. A VH3 binding polypeptide according to item 113, wherein sequence xii) corresponds to a sequence selected from SEQ ID NO: 56-82, such as selected from SEQ ID NO: 56-81 or selected from SEQ ID NO: 56 and 82.

[1063] 123. A VH3 binding polypeptide according to item 113, wherein sequence xii) corresponds to a sequence selected from SEQ ID NO:55 and 56.

[1064] 124. A VH3 binding polypeptide according to item 113, wherein sequence xiv) corresponds to SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15.

[1065] 125. A VH3 binding polypeptide according to item 113, wherein sequence xii) corresponds to a sequence in SEQ ID NO:54, SEQ ID NO:55 or SEQ ID NO:56.

[1066] 126. A VH3 binding polypeptide according to item 108, which comprises a sequence selected from the following: a sequence corresponding to residues 1-58 in SEQ ID NO:83; a sequence corresponding to residues 1-58 in SEQ ID NO:84; a sequence corresponding to residues 1-58 in SEQ ID NO:85; a sequence corresponding to residues 3-60 in SEQ ID NO:86; and a sequence corresponding to residues 1-51 in SEQ ID NO:87, or a sequence selected from the following: a sequence corresponding to residues 1-58 in SEQ ID NO:83; a sequence corresponding to residues 1-58 in SEQ ID NO:84; a sequence corresponding to residues 1-58 in SEQ ID NO:85; a sequence corresponding to residues 1-63 in SEQ ID NO:86 and a sequence corresponding to residues 1-51 in SEQ ID NO:87.

[1067] 127. A VH3 binding polypeptide multimer, wherein each monomer of the multimer comprises a VH3 binding polypeptide, which VH3 binding polypeptide is independently selected from any VH3 binding polypeptide defined in any one of items 1-126.

[1068] 128. A VH3 binding polypeptide multimer, wherein each monomer of the multimer comprises a sequence A, which is independently selected from any sequence A defined in any one of items 2-87.

[1069] 129. A VH3 binding polypeptide multimer according to item 127 or 128, wherein the multimer is selected from a dimer, a trimer, a tetramer, a pentamer, a hexamer, a heptamer, an octamer, a nonamer and a decamer.

[1070] 130. A VH3 binding polypeptide multimer according to any one of items 127-129, wherein the multimer is selected from a dimer, a tetramer, a pentamer, a hexamer, a heptamer and an octamer; such as selected from a dimer, a tetramer and a hexamer.

[1071] 131. A VH3 binding polypeptide multimer according to any one of items 127-130, wherein the multimer is a tetramer or a hexamer.

[1072] 132. A VH3 binding polypeptide multimer according to any one of items 127-131, wherein the multimer is a homomer.

[1073] 133. A VH3 binding polypeptide multimer according to any one of items 127-132, wherein the multimer comprises a sequence selected from SEQ ID NO: 175, SEQ ID NO: 176 and SEQ ID NO: 177, such as wherein the sequence is SEQ ID NO: 177.

[1074] 134. A VH3 binding polypeptide multimer according to any one of items 127-132, wherein the multimer is a heteromer comprising at least two or at least three different VH3 binding polypeptides, each of which is as defined in any one of items 1-126.

[1075] 135. A VH3 binding polypeptide multimer according to any one of items 127-131 and 134, wherein the multimer is a heteromer comprising at least two or at least three different sequences A, each of which is as defined in any one of items 2-87.

[1076] 136. A VH3 binding polypeptide multimer according to any one of items 127-135, further comprising at least one linker.

[1077] 137. A VH3 binding polypeptide multimer according to item 136, wherein the linker comprises at most 15 amino acid residues.

[1078] 138. A VH3 binding polypeptide according to any one of items 1-126 or a VH3 binding polypeptide multimer according to any one of items 127-137, comprising additional amino acids at the C-terminus and / or N-terminus.

[1079] 139. A VH3 binding polypeptide or VH3 binding polypeptide multimer according to item 138, wherein the additional amino acids improve the production, purification, in vitro stabilization or coupling of the polypeptide.

[1080] 140. A VH3 binding polypeptide or a VH3 binding polypeptide multimer according to item 138 or 139, wherein the additional amino acids improve the coupling of the polypeptide and are selected from one or more cysteine ​​residues, multiple lysine residues and multiple histidine residues.

[1081] 141. A VH3 binding polypeptide multimer according to any one of items 127-140, wherein the VH3 binding polypeptide monomer is expressed as a fusion protein.

[1082] 142. A VH3 binding polypeptide multimer according to any one of items 127-140, wherein the VH3 binding polypeptide monomer units are covalently coupled together.

[1083] 143. A VH3 binding polypeptide according to any one of items 1-126 and 138-140 or a VH3 binding polypeptide multimer according to any one of items 127-142, which is capable of binding to VH3 such that the K of the interaction is D Value is at most 1x10 -7 M, such as up to 1x10 -8 M, such as up to 1x10 -9 M, such as up to 1x10 -10 M, such as up to 1x10 -11 M.

[1084] 144. A VH3 binding polypeptide according to any one of items 1-126, 138-140 and 143 or a VH3 binding polypeptide multimer according to any one of items 127-143, which is capable of binding to VH3 such that the K of the interaction is D The value is the interaction of SEQ ID NO: 88 and / or SEQ ID NO: 89 with VH3, such as the K of the interaction of SEQ ID NO: 88 with VH3 D At least 25%, such as at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80%, such as at least 90% of the value.

[1085] 145. A VH3 binding polypeptide according to any one of items 1-126, 138-140 and 143-144 or a VH3 binding polypeptide multimer according to any one of items 127-144, which is not capable of being transported at a rate of less than 1 x 10 -4 M, if less than 1x10 -3 The interaction K of M D The value is bound to the Fc region.

[1086] 146. The VH3 binding polypeptide according to any one of items 1-126, 138-140 and 143-144 or the VH3 binding polypeptide multimer according to any one of items 127-145 retains at least 19%, such as at least 20%, such as at least 21%, such as at least 23%, such as at least 25%, such as at least 27%, such as at least 29%, such as at least 31%, such as at least 33%, such as at least 35%, such as at least 37%, such as at least 39%, such as at least 41%, such as at least 43%, such as at least 45%, such as at least 47%, such as at least 48%, such as at least 50% of its original VH3 binding ability after 100 repeated binding cycles followed by washing with 0.5M NaOH.

[1087] 147. The VH3 binding polypeptide according to any one of items 1-126, 138-140 and 143-146, or the VH3 binding polypeptide multimer according to any one of items 127-146, after incubation in 0.5 M NaOH, such as after repeated incubation with 0.5 M NaOH, exhibits an alkaline cleaning stability of at least 35%, such as at least 40%, such as at least 40%, such as at least 45%, such as at least 50%, such as at least 55%, such as at least 60%, such as at least 65%, such as at least 70%, such as at least 75%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95% of the alkaline cleaning stability of SEQ ID NO:88 or SEQ ID NO:89.

[1088] 148. The VH3 binding polypeptide according to any one of items 1-126, 138-140 and 143-147 or the VH3 binding polypeptide multimer according to any one of items 127-147, after incubation in 0.5M NaOH, such as after repeated incubation with 0.5M NaOH, exhibits alkaline cleaning stability within the range of ±25%, such as within the range of ±20%, such as within the range of ±15%, such as within the range of ±10%, such as within the range of ±5% of the alkaline cleaning stability of SEQ ID NO:88 or SEQ ID NO:89.

[1089] 149. A polynucleotide encoding a VH3 binding polypeptide according to any one of items 1-126, 138-140 and 143-148 or a VH3 binding polypeptide multimer according to any one of items 127-141 and 143-148.

[1090] 150. An expression vector comprising a polynucleotide according to item 149.

[1091] 151. A host cell comprising an expression vector according to item 150.

[1092] 152. A method for producing a VH3 binding polypeptide according to any one of items 1-126, 138-140 and 143-148 or a VH3 binding polypeptide multimer according to any one of items 127-141 and 143-148, comprising

[1093] - culturing the host cell according to item 151 under conditions allowing expression of said polypeptide or multimer from said expression vector, and

[1094] - isolating said polypeptide or multimer.

[1095] 153. A separation matrix comprising a VH3 binding polypeptide according to any one of items 1-126, 138-140 and 143-148 or a VH3 binding polypeptide multimer according to any one of items 127-148 coupled to a solid support.

[1096] 154. A separation matrix according to item 153, wherein the VH3 binding polypeptide multimer is a multimer according to any one of items 127-148.

[1097] 155. A separation matrix according to item 153 or 154, wherein the VH3 binding polypeptide multimer is a tetramer or a hexamer.

[1098] 156. A separation matrix according to any one of items 153 to 155, wherein the VH3 binding polypeptide comprises a sequence selected from the group consisting of: SEQ ID NO: 1-87, such as selected from SEQ ID NO: 1-82; such as selected from SEQ ID NO: 1, 2, 4-43 and 45-82; such as selected from SEQ ID NO: 5-7, 9-11, 13-41, 46-48, 50-52 and 54-82; such as selected from SEQ ID NO: 6-7, 10, 13-41, 47-48, 51 and 54-82; such as selected from SEQ ID NO: 6-7, 10, 13, 15-41, 47-48, 51, 54 and 56-82; such as selected from SEQ ID NO: 6, 10, 13, 15-41, 47, 51, 54 and 56-82; NO:13, 15-41, 54 and 56-82; such as selected from SEQ ID NO:13, 15-40, 54 and 56-81; such as selected from SEQ ID NO:13, 15, 54 and 56.

[1099] 157. A separation matrix according to any one of items 153-156, wherein the VH3 binding polypeptide comprises a sequence selected from the following: SEQ ID NO: 1-41; such as selected from SEQ ID NO: 1, 2, 4-41; such as selected from SEQ ID NO: 5-7, 9-11, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13-41; such as selected from SEQ ID NO: 6-7, 10, 13, 15-41; such as selected from SEQ ID NO: 6, 10, 13, 15-41; such as selected from SEQ ID NO: 13, 15-41; such as selected from SEQ ID NO: 13, 15-40; such as selected from SEQ ID NO: 13 and 15.

[1100] 158. A separation matrix according to any one of items 153-156, wherein the VH3 binding polypeptide comprises a sequence selected from the following: SEQ ID NO:42-82; such as selected from SEQ ID NO:42-43 and 45-82; such as selected from SEQ ID NO:46-48, 50-52 and 54-82; such as selected from SEQ ID NO:47-48, 51 and 54-82; such as selected from SEQ ID NO:47-48, 51, 54 and 56-82; such as selected from SEQ ID NO:47, 51, 54 and 56-82; such as selected from SEQ ID NO:54 and 56-82; such as selected from SEQ ID NO:54 and 56-81; such as selected from SEQ ID NO:54 and 56.

[1101] 159. A separation matrix according to any one of items 153-157, wherein the VH3 binding polypeptide comprises a sequence selected from SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15.

[1102] 160. A separation matrix according to any one of items 153-156 and 158, wherein the VH3 binding polypeptide comprises a sequence selected from SEQ ID NO:54, SEQ ID NO:55 or SEQ ID NO:56.

[1103] 161. A separation matrix according to any one of items 153-156, wherein the VH3 binding polypeptide comprises the sequence SEQ ID NO:41 or SEQ ID NO:82.

[1104] 162. A separation matrix according to any one of items 153-157 and 159, comprising a VH3 binding polymer selected from SEQ ID NO: 175, SEQ ID NO: 176 and SEQ ID NO: 177.

[1105] 163. A separation matrix according to any one of items 153-162, wherein the solid support comprises a polymer selected from the group consisting of: polyhydroxy polymers, such as polysaccharides; polyvinyl alcohol, polyhydroxyalkyl acrylates, polyhydroxyalkyl methacrylates, polyacrylamide and polymethacrylamide.

[1106] 164. A separation matrix according to item 163, wherein the polymer is a polysaccharide, preferably a polysaccharide selected from dextran, starch, cellulose, pullulan, agar and agarose.

[1107] 165. A separation matrix according to any one of items 153-164, wherein the solid support is in the form of fibers, beads or particles.

[1108] 166. A separation matrix according to any one of items 153-165, wherein the VH3 binding polypeptide is coupled to a solid support by covalent or non-covalent bonding.

[1109] 167. A method for separating an immunoglobulin or a fragment thereof, comprising

[1110] a) contacting a liquid sample comprising said immunoglobulin or fragment thereof with a separation matrix according to any one of items 153-166.

[1111] 168. The method according to item 167, further comprising:

[1112] b) washing the separation matrix with a washing solution, and

[1113] c) eluting the immunoglobulin or fragment thereof from the separation matrix with an eluent, and optionally

[1114] d) washing the separation matrix with a washing solution.

[1115] 169. A method according to any one of items 167-168, wherein the fragment is selected from a Fab fragment, a Fab' fragment, F(ab')2, a scFab fragment, a Fv fragment, a scFv fragment, a diabody, a triabody and a minibody.

[1116] 170. The method according to any one of items 167-169, wherein the immunoglobulin or fragment thereof is an asymmetric immunoglobulin or fragment thereof.

[1117] 171. A method according to item 170, wherein the asymmetric immunoglobulin or fragment thereof is a multispecific immunoglobulin or fragment thereof, such as at least a bispecific or trispecific immunoglobulin or fragment thereof.

[1118] 172. A method according to any one of items 167-171, wherein the separation matrix comprises a VH3 binding polypeptide according to SEQ ID NO: 14 or a multimer comprising SEQ ID NO: 14, and the pH level during elution is higher than 4, such as approximately in the range of 4.10-4.20, such as approximately 4.15.

[1119] 173. A method according to any one of items 167-171, wherein the separation matrix comprises a VH3 binding polypeptide according to SEQ ID NO: 15 or a multimer comprising SEQ ID NO: 15, and the pH level during elution is lower than 4, such as approximately in the range of 3.7-3.80, such as approximately 3.75.

[1120] 174. A method for isolating an asymmetric immunoglobulin or a fragment thereof, comprising the steps of:

[1121] a) providing a liquid sample comprising a mixture of at least one symmetric immunoglobulin or a fragment thereof and at least one asymmetric immunoglobulin or a fragment thereof;

[1122] b) contacting the liquid sample with a separation matrix to which the symmetric immunoglobulin or fragment thereof and the asymmetric immunoglobulin or fragment thereof bind with different affinities, wherein the separation matrix is ​​as defined in claim 14;

[1123] c) eluting the immunoglobulin or fragment thereof from a separation matrix, whereby the symmetric immunoglobulin or fragment thereof and the asymmetric immunoglobulin or fragment thereof are at least partially eluted separately from each other, and optionally

[1124] d) washing the separation matrix with a washing solution.

[1125] 175. The method according to item 174, wherein step c) involves:

[1126] c) eluting the immunoglobulin or fragment thereof from the separation matrix with a pH gradient or a step elution with at least two different pH levels, whereby the symmetric immunoglobulin or fragment thereof and the asymmetric immunoglobulin or fragment thereof are at least partially eluted at different pH levels.

[1127] 176. A method for isolating an asymmetric immunoglobulin or a fragment thereof according to item 174 or 175, wherein the asymmetric immunoglobulin or a fragment thereof comprises only one VH3 region and the symmetric immunoglobulin or a fragment thereof comprises at least two VH3 regions or no VH3 region.

[1128] 177. A method for separating asymmetric immunoglobulins or fragments thereof according to any one of items 174-176, wherein the separation matrix is ​​as defined in any one of items 153-166.

[1129] 178. A method for separating asymmetric immunoglobulins or fragments thereof according to any one of items 174-177, wherein no more than 25%, such as no more than 20%, such as no more than 15%, such as no more than 10% of the asymmetric immunoglobulins or fragments thereof are present in the same eluate as the symmetric immunoglobulins or fragments thereof.

[1130] 179. A method for isolating an asymmetric immunoglobulin or a fragment thereof according to any one of items 174-178, wherein the asymmetric immunoglobulin or a fragment thereof is a multispecific immunoglobulin or a fragment thereof, such as at least a bispecific or trispecific immunoglobulin or a fragment thereof.

[1131] 180. A VH3 binding polypeptide derived from Staphylococcus protein A (SpA) or any domain thereof, wherein in alignment with SEQ ID NO: 89, corresponding to positions X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X29 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26 The positions are independent of each other as follows:

[1132] X9 is selected from Q, Y and A;

[1133] X 10 Selected from Q and Y;

[1134] X 11 Selected from T, E and R;

[1135] X 13Selected from L, E, R, A and Q;

[1136] X 14 Selected from L, E, R, A, Q and W;

[1137] X 17 Selected from A, H and L;

[1138] X 18 Selected from R, L and H;

[1139] X 26 Selected from Q and S;

[1140] X 28 is selected from N and A; and

[1141] X 29 Select from A and G.

[1142] 181. A VH3 binding polypeptide derived from Staphylococcus protein A (SpA) or any domain thereof, wherein in alignment with SEQ ID NO: 88, corresponding to positions X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X29 10 , X 11 , X 13 , X 14 , X 17 , X 18 and X 26 The positions are independent of each other as follows:

[1143] X9 is selected from Q, Y and A;

[1144] X 10 Selected from Q and Y;

[1145] X 11 Selected from T, E and R;

[1146] X 13 Selected from L, E, R, A and Q;

[1147] X 14 Selected from L, E, R, A, Q and W;

[1148] X 17 Selected from A, H and L;

[1149] X 18 Selected from R, L and H;

[1150] X 26 Selected from Q and S;

[1151] X 28 is selected from N and A; and

[1152] X 29 Select from A and G.

Claims

1. A VH3 binding polypeptide derived from Staphylococcal protein A (SpA) or any domain thereof, wherein the polypeptide has binding affinity for the VH3 region of trastuzumab and has a lower binding affinity for the Fc region of trastuzumab than the binding affinity of SEQ ID NO: 88 for the same Fc region of trastuzumab, and wherein the VH3 binding polypeptide is alkaline-wash stable.

2. The VH3 binding polypeptide according to claim 1, comprising a sequence A consisting of an amino acid sequence selected from i), ii) and iii), Where i), ii) and iii) are defined as follows: i)X8X9X 10 X 11 AX 13 X 14 X 15 X 16 X 17 X 18 X 19 PNLX 23 X 24 X 25 X 26 R X 28 X 29 FIQSLX 35 X 36 (SEQ ID NO:95) in, Independently of each other, X8 is selected from E, D and A; X 15 Selected from E and Q; X 16 Selected from I and V; X 19 Select from L and M; X 23 Selected from N and T; X 24 is selected from A and E, if it is E; X 25 is selected from D and E, if it is E; X 35 Selected from K, R and H; X 36 Selected from D and H; ii) an amino acid sequence having at least 83% identity to the sequence defined in i) iii) an amino acid sequence that is at least 70% identical to any sequence selected from residues 8-36 of SEQ ID NO:88, residues 8-36 of SEQ ID NO:89, residues 8-36 of SEQ ID NO:90, residues 8-36 of SEQ ID NO:91, residues 8-36 of SEQ ID NO:92, residues 11-39 of SEQ ID NO:93, and residues 1-29 of SEQ ID NO:94, wherein, in addition, in each of i), ii) and iii), independently of one another, X9 is selected from Q, Y and A; X 10 Selected from Q and Y; X 11 Selected from T, E and R; X 13 Selected from L, E, R, A and Q; X 14 Selected from L, E, R, A, Q and W; X 17 Selected from A, H and L; X 18 Selected from R, L and H; X 26 Selected from Q and S; X 28 is selected from N and A; and X 29 Select from A and G.

3. The VH3 binding polypeptide of claim 2, wherein X9 is A and X 11 For R.

4. The VH3 binding polypeptide according to claim 2 or 3, wherein X9X 10 X 11 X 13 X 14 Selected from AQRLA and AYRLA; such as X9X 10 X 11 X 13 X 14 For AYRLA.

5. The VH3 binding polypeptide according to any one of claims 2 to 4, wherein X 17 X 18 For AR.

6. The VH3 binding polypeptide according to any one of claims 2 to 5, wherein sequence i) corresponds to the sequence from position 8 to position 36 in a sequence selected from SEQ ID NOs: 1 to 82.

7. The VH3 binding polypeptide according to any one of claims 2 to 6, further comprising a sequence B arranged at the C-terminus of the sequence A, the sequence B consisting of an amino acid sequence selected from iv) and v), and wherein iv) and v) are defined as follows: iv)DPSX 40 SX 42 X 43 X 44 LX 46 EAX 49 X 50 LNX 53 X 54 (SEQ ID NO:96) wherein, independently of each other, X 40 Select from Q, T and V; X 42 Selected from A, K, L and T; X 43 Selected from N, E, A and S; X 44 Selected from L, I and V; X 46 is selected from A, G, S and K, such as selected from A, S and K; X 49 is selected from K and Q, if it is K; X 50 Selected from K and R; X 53 is selected from D, E, and K; and X 54 Selected from A and S; v) an amino acid sequence that is at least 75% identical to a sequence as defined in iv).

8. The VH3 binding polypeptide according to any one of claims 2 to 7, comprising a binding module sequence C consisting of: Sequence A according to any one of claims 2 to 6 and sequence B according to claim 7, the order from N-terminus to C-terminus is as follows [Sequence A]-[Sequence B] Or any amino acid sequence that is at least 70% identical to any sequence selected from the group consisting of residues 8-54 of SEQ ID NO:88, residues 8-54 of SEQ ID NO:89, residues 8-54 of SEQ ID NO:90, residues 8-54 of SEQ ID NO:91, residues 8-54 of SEQ ID NO:92, residues 11-57 of SEQ ID NO:93, and residues 1-47 of SEQ ID NO:

94.

9. The VH3 binding polypeptide according to any one of claims 2 to 8, comprising a binding module sequence C selected from: vi) [Sequence A]-DPSQSANLLAEAKKLNDA (SEQ ID NO: 113); wherein [Sequence A] is as defined in any one of claims 2 to 6; vii) an amino acid sequence that is at least 85% identical to the sequence defined in vi); viii) [Sequence A]-DPSVSKAILAEAKKLNDA (SEQ ID NO: 115) wherein [Sequence A] is as defined in any one of claims 2 to 6; ix) an amino acid sequence that is at least 85% identical to the sequence defined in viii); x) [Sequence A]-DPSVSKEILAEAKKLNDA (SEQ ID NO: 114) wherein [Sequence A] is as defined in any one of claims 2 to 6; and xi) an amino acid sequence that is at least 85% identical to the sequence defined in x).

10. The VH3 binding polypeptide according to any one of claims 2 to 9, wherein sequence vi) or viii) corresponds to the sequence from position 8 to position 54 of a sequence selected from SEQ ID NO: 1-82, such as selected from SEQ ID NO: 1-41, such as selected from SEQ ID NO: 1-40, selected from SEQ ID NO: 1-15, such as selected from SEQ ID NO: 13-15, such as SEQ ID NO:

15.

11. A VH3 binding polypeptide multimer, wherein each monomer of the multimer comprises a VH3 binding polypeptide independently selected from any VH3 binding polypeptide as defined in any one of claims 1 to 10 and wherein the multimer is preferably a tetramer or a hexamer.

12. The VH3 binding polypeptide multimer of claim 11, wherein the multimer comprises a sequence selected from the group consisting of SEQ ID NO: 175, SEQ ID NO: 176 and SEQ ID NO: 177, such as wherein the sequence is SEQ ID NO:

177.

13. The VH3 binding polypeptide according to any one of claims 1-10 or the VH3 binding polypeptide multimer according to any one of claims 11-12, which exhibits an alkaline cleaning stability of at least 35%, such as at least 40%, such as at least 40%, such as at least 45%, such as at least 50%, such as at least 55%, such as at least 60%, such as at least 65%, such as at least 70%, such as at least 75%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95% of the alkaline cleaning stability of SEQ ID NO: 88 after incubation in 0.5 M NaOH.

14. A separation matrix comprising a VH3 binding polypeptide according to any one of claims 1 to 10 and 13 or a VH3 binding polypeptide multimer according to any one of claims 11 to 13 coupled to a solid support, preferably in the form of fibers, beads or particles.

15. A method for separating an immunoglobulin or a fragment thereof, the method comprising a) contacting a liquid sample containing the immunoglobulin or a fragment thereof with the separation matrix according to claim 14.

16. A method for isolating an asymmetric immunoglobulin or a fragment thereof, the method comprising the steps of: a) providing a liquid sample comprising a mixture of at least one symmetric immunoglobulin or a fragment thereof and at least one asymmetric immunoglobulin or a fragment thereof; b) contacting the liquid sample with a separation matrix to which the symmetric immunoglobulin or fragment thereof and the asymmetric immunoglobulin or fragment thereof bind with different affinities, wherein the separation matrix is ​​as defined in claim 14; c) eluting the immunoglobulins or fragments thereof from the separation matrix, whereby the symmetric immunoglobulins or fragments thereof and the asymmetric immunoglobulins or fragments thereof are at least partially eluted separately from each other, and optionally d) washing the separation matrix with a washing solution.